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Introduction 6 
 
1 Introduction 
1.1 General background 
Cancer has become more and more prevalent over the last few years, reaching its 
highest ever levels per capita in the Western world in 2008. Cancer is a group of 
diseases characterized by the uncontrolled growth and spreading of abnormal cells. 
This is related to dynamic changes in the genome. Mutations that produce dominant 
gain of function oncogenes and loss of function tumor suppressor genes have been 
discovered due to their alteration in human and animal cancer cells, and by their ability 
to elicit cancer phenotypes in experimental models [1]. 
Typical treatments for cancer include surgery, radiation therapy and chemotherapy. 
When cancer is diagnosed, surgery is used to remove solid tumors from normal tissue 
if an operation is possible, and chemotherapy is used very often to eliminate residual 
cancer cells [2]. Because cancer cells are immortalized and proliferate without control, 
they are very sensitive to chemotherapeutic agents. However, chemotherapy also kills 
normal cells because tumor cells are not specifically targeted, resulting in significant 
side effects [2]. Radiation is a third approach, which has improved in the last few years. 
Using advanced lasers it is possible to determine the exact location of the diseased 
tissue and focus the treatment there, but like surgery, radiation therapy must be 
complemented by chemotherapy to eliminate residual cells [3]. 
In the last 10 years, the problem of resistance against chemotherapeutic agents has 
become more common, and further investigation revealed that the resistant tumor cells 
contained mutations that allowed them to regulate drug cytotoxicity [4-6]. 
Novel approaches have therefore been tested, including hormone therapy, biological 
therapy and targeted therapy [2, 7-10].These strategies are more specific to cancer 
cells and their metabolism. In clinic, they achieve promising levels of cytotoxicity 
towards cancer cells and reduce unwanted side effects.  
Targeted therapy is based on the specific elimination of cancer cells without damaging 
the surrounding, healthy tissues [11-13]. For this approach to work, two major 
components are needed: first, a specific binding moiety that only targets cancer cells, 
and second, a toxic moiety that is taken up by endocytosis and induces cell death. 
These two components are often functionally combined as fusion proteins, also called 
immunotoxins. Such reagents can be administered intravenously and will find their way 
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through the blood stream to the target tissue. Therefore, they must be very stable in 
serum and their size should be adjusted to ensure they are not eliminated by the 
kidneys. Another important issue is the potential immune response of the patient, since 
the binding moieties of immunotoxins often comprise antibodies (full-length, single 
chain or Fab-fragment) generated in murine cells, and the cytotoxic domain is often a 
toxin from plants (e.g. ricin) or bacteria (e.g. endotoxin A or diphtheria toxin) [14-17]. 
The patient’s immune system recognizes both components as foreign and attempts to 
clear them from the body, thus reducing their efficacy [18]. The effects of targeted 
therapeutics could be improved if the fusion proteins were not recognized as foreign, 
which could be achieved by using fully human components. An additional challenge is 
the production of such therapeutics in bacteria (Escherichia coli) since small amounts 
of bacterial endotoxins can persist, and can induce a strong inflammatory response in 
the patient. 
The past two decades has witnessed a dramatic increase in our understanding of the 
molecular basis of cancer, following the identification and functional characterization of 
many oncogenes and tumor suppressor genes [19-22]. Oncogenes encode proteins 
that strongly promote cell proliferation, increasing the chance that a normal cell will 
develop into a tumor cell. Since the 1970s, dozens of oncogenes have been identified, 
most requiring an additional step, such as mutations in another gene, or environmental 
factors such as viral infection, to cause cancer [23-26]. Many cells normally undergo 
apoptosis when the genome is damaged but the presence of an activated oncogene 
can prevent cell death and result in continued, disorderly proliferation [27]. A tumor 
suppressor gene (anti-oncogene) normally functions to limit cell proliferation, so in this 
case the loss of function takes away the control and facilitates cancer development, 
usually in combination with other genetic changes [23]. Tumor suppressor genes, or 
more precisely, the proteins they encode, either have a dampening or repressive effect 
on the regulation of the cell cycle or promote apoptosis, and sometimes both [28]. The 
products of oncogenes and tumor suppressor genes have therefore become an 
important target for new anti-cancer drugs. 
In colon, breast and lung cancer the TP53 gene plays an important role as a tumor 
suppressor [29]. The product (p53) regulates several key steps in the control of cell 
proliferation and apoptosis, and its loss is a major key in cancer progression. The 
activity of mutated p53 can be restored by a small molecule called RITA, resulting in 
the apoptosis of the cancer cells. In 2004, Shin et al. published data showing that wild 
type p53 activity could also be restored by ribozymes [30]. Mutant p53 RNA was 
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repaired, wild-type p53 protein again expressed and this induced apoptosis in human 
cancer cells. There is a growing realization that many eukaryotic regulatory proteins 
play important roles in cancer progression. 
Oncogenes and their products can clearly serve as classically defined drug targets 
whose inactivation by small molecules or microRNAs could place a brake on cancer 
cell proliferation [31]. Oncogenes are highly upregulated in many cancer cells and 
could serve as a potent therapeutic target. 
Taking everything into consideration a therapeutic approach is needed that is highly 
effective in targeting and eliminating cancer cells. From the beginning of the 
development process the main focus should be the compatibility and efficacy of such 
therapeutic approaches in vivo, applying at all stages: construction, production and 
application. Ideally, there should be no risk to healthy cells and the patient’s immune 
system should not be triggered. The products of oncogenes and tumor suppressor 
genes are promising targets for such novel immunotherapeutics.  
1.2 Cancer 
Cancer develops from healthy cells through a complex process. The first step is 
initiation, in which a change in the cell’s genetic material (the DNA sequence and 
sometimes the chromosome structure) primes the cell to undergo mutation [32]. The 
change in the cell’s genetic material may occur spontaneously or may be brought about 
by an agent that causes cancer (a carcinogen). Further development of cancer requires 
staging, which describes the extent or spread of the disease at the time of diagnosis. 
This is essential in the choice of therapy and in determining the prognosis.  
The most prevalent form of cancer is lung carcinoma, representing 10.4% of all cancer 
in both sexes. For woman, breast cancer is the second most prevalent, and the fifth 
most common cause of cancer-related deaths (in 2005, breast cancer caused 502,000 
deaths worldwide representing 7% of cancer-related deaths and almost 1% of all 
deaths). For men, prostate cancer is the second most prevalent. Even in a small 
country such as the UK, 35,000 men are diagnosed each year, and ~10,000 die of this 
disease (www.cancer.org).  
Hodgkin lymphoma (HL), also known as Hodgkin disease, is a less common form of 
cancer but it is very aggressive. It arises from an abnormal lymphocytes, and among 
the ~500,000 Americans with lymphoma, over 142,000 have HL. In 2006, ~7,800 new 
cases of HL were detected and 1,490 Americans died from the disease 
(www.uihealthcare.com, University of Iowa, Hospital and Clinics, USA). HL occurs 
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mainly in young adults, with a peak occurrence between ages 16 and 34. Older 
patients, especially those over age 55, may also develop HL. The diagnosis of HL 
depends on the detection of abnormal blood cells called Reed-Sternberg cells. HL has 
been studied more than any other type of lymphoma. With the many rapid advances in 
diagnosis and treatment, over 80% of patients with HL can be cured. 
The National Cancer Institute estimates that approximately 10.8 million Americans with 
a history of cancer were alive in January 2004. Some of these individuals were cancer-
free, while others still had evidence of cancer and may have been undergoing 
treatment. Approximately 1,437,180 new cancer cases are expected to be diagnosed in 
2008. 
 
Fig. 1-1    Age-Adjusted Cancer Death Rates,* Males by Sites, US, 1930-2004. US Moratlity Data 1960 to 
2004, US Mortality Volumes 1930 to 1959, National Center of Health Statistics, Centers of 
Disease Control and Prevention, 2006. American Cancer Society, Surveillance Research, 2008. 
(* Per 100,000, age-adjusted to the 2000 US standard population) 
1.3 Molecular carcinogenesis 
In 2000, Hanahan & Weinberg described six characteristic changes which convert a 
normal human cell into a cancer cell [33]. These are known as the “hallmarks of 
cancer”: 
1. Self-sufficiency in growth signals 
2. Insensitivity to growth-inhibitory signals 
3. Evasion of apoptosis 
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4. Limitless replicative potential 
5. Sustained angiogenesis 
6. Tissue invasion and metastasis 
Each of these physiological changes represents the successful breach of an anticancer 
defense mechanism, hardwired into cells and tissues.  
To achieve the first hallmark, normal cells have to overcome the need for external 
mitogenic growth signals, which are normally required before they can move from a 
quiescent (G0) state into an active proliferative state. These signals are transmitted into 
the cell via transmembrane receptors that bind to external signaling molecules. Tumor 
cells generate many of their own signaling molecules which make them independent 
from external stimulation.  
Multiple anti-proliferative signals work to maintain cellular quiescence and tissue 
homeostasis. These signals include soluble and immobilized growth inhibitors 
embedded in the extracelluar matrix and on the surfaces of nearby cells. These signals 
are also received by transmembrane receptors coupled to intracellular signaling 
circuits. Anti-growth signals can block proliferation by forcing cells in the G0 state or by 
inducing cells to permanently relinquish their proliferative potential by becoming 
postmitotic. All anti-growth signals are funneled through the retinoblastoma protein 
(pRb) and two related proteins, p107 and p130. These proteins interact with the 
transcription factor E2F which then controls the expression of other genes that are 
essential for progression from G1 into S phase [34]. For a cell to ignore these anti-
proliferative signals, the pRb pathway and the control of E2F must be disrupted to allow 
cell proliferation. TGFβ plays an important role by preventing the phosphorylation that 
TGFβ suppresses the expression of a gene that regulates the cell cycle machinery in a 
yet unknown way [35], but cell proliferation requires more than the avoidance of anti-
growth signals. Healthy tissues constrain cell proliferation by forcing cells to enter 
irreversibly into a postmitotic, differentiated state. In contrast, tumor cells manage to 
avoid this terminal differentiation. 
The third hallmark of cancer is the evasion of apoptosis, which allows tumor cells to 
prosper by increasing the rate of proliferation and reducing the rate of attrition. 
Apoptosis is a major source of this attrition. Apoptosis is triggered by two major 
components: sensors and effectors. The sensors are responsible for monitoring the 
extracellular and intracellular environments for conditions of normality or abnormality 
that determine whether a cell should live or die. The sensors are survival and death 
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signals that regulate the functions of the effectors. The longevity of cells is also 
maintained in part by cell-matrix and cell-cell adherence-based survival signals whose 
abrogation elicits apoptosis [36, 37]. Many signals that induce apoptosis converge on 
the mitochondria which respond to pro-apoptotic signals by releasing cytochrome C, an 
important catalyst of apoptosis [38]. Members of the Bcl-2 family of proteins can act in 
a pro-apoptotic manner (Bax, Bak, Bid, Bim) but also in an anti-apoptotic manner 
(oncogenes such as Bcl-2, Bcl-XL, Bcl-W) in part by governing mitochondrial death 
signaling through cytochrome C release [39, 40]. The tumor suppressor protein p53 
can induce apoptosis by upregulating the expression of a pro-apoptotic protein called 
BAX to induce DNA damage. BAX again stimulates the release of cytochrome C and 
acts in a pro-apoptoic way. 
The ultimate effectors of apoptosis are intracellular proteases celled caspases 8 and 9 
[41]. They are activated by the death receptor FAS or by cytochrome C. These 
caspases trigger the activation of many effector caspases, promoting apoptosis. 
Resistance to apoptosis can be acquired through a variety of mechanisms. The most 
frequent is the loss of a pro-apoptotic regulator, often caused by mutation of the p53 
tumor suppressor gene [29]. Another mechanism is the abrogation of the FAS death 
signal which has been discovered in a large proportion of lung and colon carcinoma 
cell lines. Another mechanism is hypermethylation of the promoter regions of the DAPK 
tumor suppressor genes, which are then silenced. New technologies and new drugs 
will enable cross-talk between the active components of parallel apoptotic signaling 
pathways in tumor cells resulting in the restoration of the apoptotic defense 
mechanism. 
The fourth hallmark of cancer is limitless replicative potential. The work of Hayflick and 
colleagues initially showed that cells in culture have a finite replicative potential [42]. 
When a cell population has progressed through a certain number of divisions, it stops 
proliferating. Tumor cells in culture appear to be immortalized, i.e. the cells can divide 
indefinitely. Telomeres are essential to facilitate this unlimited multiplication.  
Sustained angiogenesis is often observed in tumors because oxygen and nutrients 
supplied by the vasculature are crucial for cell function and survival. When a tissue is 
formed, the growth of new blood vessels (angiogenesis) is tightly regulated. Cells 
within aberrant proliferative lesions lack angiogenic activity and must develop this 
ability to survive. Angiogenesis is promoted and blocked by positive and negative 
signals conveyed by soluble factors that bind to receptors on the surface of endothelial 
cells. Selectins, integrins and adhesion molecules mediate cell-matrix and cell-cell 
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interactions and play an important role in this process. Two classes of integrins are 
expressed on quiescent and sprouting vessels, so their signaling contributes to the 
regulation of angiogenesis [43]. Extracellular proteases are connected with pro-
angiogenic integrins and determine the invasive capability of angiogenic endothelial 
cells [44].  
The ability to induce angiogenesis appears to be acquired in a discrete step during 
tumor development via an “angiogenic switch” from vascular quiescence, an early to 
mid-stage event in many human cancers. Tumors activate this switch by changing the 
balance between angiogenesis inducers and inhibitors [45]. One strategy to induce this 
shift involves the transcriptional regulation of pro-angiogenic growth factors and 
inhibitor genes. Another is the activation or inhibition of proteases that control the 
availability of angiogenesis regulators through complex proteolytic cascades. Tumor 
angiogenesis therefore offers many promising therapeutic targets [46].  
After primary tumor development, pioneer cells invade surrounding tissues in a process 
known as metastasis, the sixth hallmark of cancer. Metastasis causes 90% of human 
cancer deaths [33]. The ability to invade other tissues enables cancer cells to spread 
out in the whole body without any limits. The complex mechanism of invasion and 
metastasis is incompletely understood, although it is known to involve the activation of 
extracellular proteases, and the modification of cadherin, cell-cell adhesion molecule 
(CAM) and integrin binding specificities to facilitate the penetration and colonization of 
adjacent tissues. 
These six hallmarks of cancer represent new directions for cancer therapy. As the 
development of cancer is better understood, the more challenging it becomes to 
develop more effective and more specific therapeutic strategies that either encourage 
the activation of tumor suppressor genes or inhibit the activation of oncogenes.  
1.4 Targeted cancer therapy 
Surgery, radiation therapy and chemotherapy are the most prevalent current 
treatments for cancer, but each has drawbacks and often a combination of therapies is 
required for effective treatment. Chemotherapeutic agents (anti-cancer drugs such as 
FOLFOX, XELOX, Methotrexate) affect all dividing cells and block further proliferation 
[47]. Since cancer cells divide rapidly, the principle of chemotherapy is that cancer cells 
will be affected more potently than healthy cells. However, this is not targeted therapy, 
and healthy dividing cells such as hair follicles and gastric mucosa are also affected, as 
well as cells of the immune system. Furthermore, chemotherapy has a limited effect on 
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non-solid tumors. The localization and visualization of diseased cells is not possible 
with the abovementioned methods. Therefore, there is a high risk of relapse. Logically 
the next step in anticancer drug development is the specific targeting of cancer cells. 
One of the first targeted therapies used Gleevec (imatinib) from Novartis [48]. Gleevec 
inhibits BCR/ABL tyrosine kinase activity and is effective against chronic myelogenous 
leukemia (CML) [49]. This small molecule, called imatinib mesylate, is a tyrosine kinase 
inhibitor and is also used for the treatment of metastatic gastrointenstinal stromal 
tumors (GISTs) expressing KIT, the stem cell factor receptor. Although Gleevec 
represents a leap in the right direction, it can also inhibit proteins unrelated to Ph+ CML 
or KIT-positive GIST, and some patients rapidly develop resistance to the drug [50, 51]. 
Targeted therapies require a target that is expressed solely on malignant cells, so 
antibodies recognizing tumor-specific antigens represent a good starting point [13]. 
Several antibodies with such properties have been generated by phage display or 
hybridoma technology [52, 53]. In 1997, Neri et al. described antibodies generated 
against oncofetal fibronectin (B-FN) isoformin to detect the aggressive tumor grafted F9 
murine teratocarcinoma in nude mice [54]. Following the evaluation of mouse 
antibodies against cancer antigens, novel strategies for antibody humanization were 
developed [18]. Since the development of the hybridoma approach [52], a large 
number of rodent mAbs specific for therapeutically-relevant antigens have been 
generated and characterized. Unfortunately, the fact that rodent antibodies are 
immunogenic in humans limits their clinical potential, especially when repeated 
administration is required. Several strategies have therefore been developed to convert 
rodent antibody sequences into their human counterparts, which could be important in 
therapeutic regimens that call for long-term treatment since anti-idiotypic responses 
would be avoided [18]. The concept of fusion proteins has also been developed, in 
which a tumor-specific binding domain is fused to a cytotoxic domain. After antigen-
specific detection of the target cells, the protein complex should be internalized 
allowing the cytotoxic component to induce apoptosis. In 1999, Barth et al. described 
immunotoxins targeting the human CD30 and CD25 receptor by fusing a specific ligand 
to a modified Pseudomonas aeruginosa exotoxin A (ETA') lacking its cell-binding 
domain [55, 56]. As long as 35 years ago, immunotoxins were created by chemically 
conjugating an antibody to a whole protein toxin, or, for more selective activity, by using 
a protein toxin devoid of its natural binding domain (e.g. ricin A/anti-CD5, 
idarubizin/anti-CD3, diphtheria toxin/anti-IL2R). Immunotoxins combine selective 
targeting of cancer cells via a specific ligand with a potent cytotoxin. As mentioned 
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above, the immunogenic effects in patients play an important role in the efficacy of 
such therapeutic proteins [57]. The goal in developing therapeutic fusion proteins is the 
evaluation of fully human immunotoxins to eliminate side effects for the patient and to 
improve the efficacy of the drug.  
In this thesis, I will present a novel, fully human immunotoxin in which the human ligand 
for the receptor CD30 is fused to a truncated version of a human kinase serving as 
toxic component. These fusion proteins are called immunokinases. 
1.5 The lymphocyte activation marker CD30 
One of the most peculiar immunohistological characteristics of the tumour cells like 
Hodgkin's lymphoma (HL) cells, anaplastic large cell lymphoma (ALCL) and embryonal 
carcinomas is the expression of the antigen CD30 [58]. Physiologically, CD30 
expression is restricted to a few activated lymphocytes in normal lymphoid tissue and a 
small population of decidual cells [59]. CD30 is a member of the tumor necrosis factor 
(TNF) receptor superfamily whose members which regulate survival of cells. The 
structure of its extracellular domain consists of six characteristic cysteine-rich 
pseudorepeats. CD30 exists as 105- and 120-kDa membrane glycoproteins originating 
from a 90-kDa precursor, and as a 57-kDa intracellular form. CD30 molecules are 
phosphorylated at serine and/or tyrosine residues. The 57-kDa molecule has kinase 
activity [60]. The extracellular portion of CD30 is proteolytically cleaved to produce a 
soluble sCD30, which is often used as serum tumor marker. Its endogenious 
counterligand, CD30 ligand (CD30L, CD153), is a type II membrane-associated 
glycoprotein also belonging to the TNF family [61, 62]. CD30L is expressed 
predominantly on activated T cells, monocytes/macrophages and on several B cells 
[63]. Recent cloning of CD30L has enabled studies to explore its function and tissue 
contribution but the complete biological function and signaling pathways of CD30 and 
CD30L are still not fully understood. Recent data indicate that recombinant CD30L 
induced on one hand proliferative effects in some HD-derived cell lines but on the other 
hand growth inhibition in CD30+ lymphoma cells [64].  
The expression of CD30 by atypical T cells (LyP and ALCL cells) and B cells 
(Hodgkin’s diseases) but not found on most normal tissues affords a great opportunity 
to use CD30 as therapeutic target.  
Until now several studies demonstrated the selective and potent anti tumour activity of 
chemically- or genetically-linked antibodies or antibody-fragments targeting the CD30 
receptor in vitro as well as in mouse models [55, 59, 65-72]. 
Introduction 15 
1.6 Human death associated protein kinase 
Apoptosis (programmed cell death) is a genetically controlled cell death process, which 
is important at various developmental stages, as well as in the maintenance of tissue 
homeostasis. Over the past few years, many of the key players in this process have 
been identified, including receptors, adapter proteins, proteases and other positive and 
negative regulators. One of the positive mediators of apoptosis is DAPkinase (DAPk). 
DAPk was discovered via a functional gene cloning approach based on the transfection 
of mammalian cells with an antisense cDNA library and the subsequent isolation of 
death-protective cDNA fragments [73]. Antisense DAPk RNA expression protected 
HeLa cells from interferon-γ-induced cell death. DAPk is a pro-apoptotic Ser/Thr kinase 
that participates in a wide spectrum of apoptotic signals including IFN-γ, TNF-α, 
activated c-Myc, TGF-η and detachment from the extracellular matrix [74, 75]. This 
actin microfilament-associated Ca2+/calmodulin (CaM)-dependent kinase has a unique 
multidomain structure including modules that mediate protein–protein interactions such 
as ankyrin repeats and the death domain [76]. The death-promoting effects of DAPk 
depend on its catalytic activity, correct intracellular localization, and on the presence of 
the death domain. Four additional kinases that show a significant homology in their 
catalytic domain to DAPk have recently been identified. ZIP(Dlk)-kinase and DRP-1 are 
the closest family members, as their catalytic domains share approximately 80% 
identity to that of DAPk [77].  
 
Fig. 1-2    The DAP-kinase family of proteins. The following structural domains are boxed: catalytic domain 
(pink), CaM regulatory region (red), ankyrin repeats (blue), cytoskeleton-binding domain (cyan), 
death domain (green) and leucine zipper motif (brown). Numbers shown in the kinase boxes 
correspond to percentage of identity at the amino acid level to the catalytic domain of DAP-
kinase [77]. 
Two more-distant DAPk-related proteins are DRAK1 and DRAK2 [78]. Phylogenetic 
analysis, based on multiple sequence alignment of the catalytic domains of 16 proteins, 
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shows that DAPk, ZIP(Dlk)-kinase and DRP-1 may be grouped into a distinct clade with 
high bootstrap probabilities. DRAK1 and DRAK2 form another clade sharing a putative 
common ancestor to the other DAPk-related proteins. Interestingly, the extracatalytic 
domains of these five members differ considerably from each other. Additionally, ZIP-
kinase, DRAK1 and DRAK2 were shown to be localized exclusively to the nucleus and 
do not require Ca2+/CaM for activation. DRP-1, however, is a cytoplasmic kinase, 
containing a typical CaM-regulatory domain similar to that of DAPk and a short C-
terminal segment required for homodimerization. Interestingly, DRP-1 can promote cell 
death following ectopic expression and it shares with DAPk many of the induced 
subcellular events including membrane blebbing and the formation of autophagic 
vesicles [77]. 
 
Fig. 1-3    Apoptosis inducing signal cascade introduced by the phosphorylation of DAPK2. A mechanism 
for DAPK regulation consisting of autophosphorylation-based regulation which imposes a safety 
device on the catalytic activity of DAPK and consequently restrains its pro-apoptotic functions in 
growing cells. The functional autophosphorylation site is dephosphorylated upon the apoptotic 
stimulus leading to DAPK activation. The various domains are marked: KD (kinase domain); DD 
(death domain). The catalytic cleft is marked by a V-shaped structure in which the phosphate 
residue on serine 308 resides. [77].  
Death-associated protein kinase related protein-1 (DRP-1) is another member of the 
DAPk family, also known as Death-associated protein kinase 2 (DAPK2). DAPK2 and 
DAPK1 are soluble cytosolic proteins sharing a conserved N-terminal protein kinase 
domain and a Ca2+/calmodulin (CaM)-regulatory domain that controls their catalytic 
activity [77]. This unique regulatory mechanism is based on autophosphorylation, which 
is relieved when Ca2+-activated calmodulin binds to the CaM domain. Therefore, 
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deletion of this domain (∆CaM) generates a constitutively active mutant kinase that 
enhances the stimulation of apoptosis [76].  
Drugs that inhibit aberrant kinase activity have been developed to treat proliferative and 
inflammatory diseases [79]. Some of them have already reached the clinic e.g. small-
molecule monotarget inhibitors such as imatinib, gefitinib and erlotinib; multitarget 
inhibitors such as sorafenib and sunitinib; and monoclonal antibodies such as 
trastuzumab and cetuximab. There have been no reports of therapeutic agents based 
on the restoration of a missing kinase activity until now.  
1.7 Novel strategies for targeted cancer therapy 
In order to develop a novel, protein-based anticancer drug by fusing a constitutively 
active kinase domain to a tumor-specific ligand for the restoration of an active tumor 
suppressor protein, I constructed a constitutively-active fusion protein, DAPK2∆CaM-
CD30L. The basic idea was to target CD30+ L540 and L1236 cells (which do not 
express DAPK2). The receptor-specific replacement of DAPK2 catalytic activity should 
induce apoptosis in those cells and the immunokinase could therefore be used for 
novel targeted cancer treatments. This immunokinase should not be immunogenic due 
to its human origin and thus should have a long half life in the patient. 
An attractive alternative to protein-based therapeutics are oligonucleotides. Unlike 
proteins, oligonucleotides can be synthesized in a chemical process and offer 
significant advantages in terms of reduced production costs and simpler regulatory 
approval processes. Based on the potency of immunotoxins that on one hand possess 
a specific binding domain and on the other hand possess a toxic moiety, the idea 
developed to design full RNA-based immunotoxins, so called immuno-RNA-transcripts. 
For the development of a novel, RNA-based anticancer drug, high-affinity single-
stranded nucleic acid ligands could serve as the binding moiety. They exhibit specificity 
and avidity comparable to mAbs and can be generated against most targets. The toxic 
moiety in this case should be a small interfering RNA (siRNA). RNA interference 
(RNAi) became very popular because of the Nobel prize awarded to Fire and Mellow in 
2007 for its discovery [80]. The targets could be oncogenes or housekeeping genes 
that would be downregulated by RNAi to induce apoptosis. 
1.8 RNA interference 
The phenomenon of gene silencing was initially discovered in transgenic plants 
following the unexpected outcomes in experiments performed by Napoli and Jorgensen 
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in the early 1990s [81]. In an attempt to alter flower colors in petunia, Jorgensen 
transfected additional copies of a gene encoding chalcone synthase, a key enzyme for 
flower pigmentation into plants with a pink or violet flower color. Overexpression of the 
target gene should have generated darker flowers, but instead produced less 
pigmented, fully or partially white flowers. The activity of chalcone synthase seemed to 
have decreased. In fact, both the endogenous genes and the transgenes were 
downregulated in the white flowers.  
 
Fig. 1-4 Example of gene silencing in Petunia plants [81]. 
It was discovered that the introduction of the transgene could inhibit the expression of 
homologous sequences. This inhibition could take place either at the level of 
transcription (transcriptional gene silencing, TGS) or at the posttranscriptional level 
(posttranscriptional gene silencing, PTGS) [82]. Soon after, a related event termed 
quelling was also observed in the fungus Neurospora crassa [83]. However the exact 
mechanism of these phenomena remained unclear although it was evident that RNA 
played a key role in gene silencing.  
Plant virologists performed an experiment in which short sequences of plant genes 
were introduced into viruses and showed that the targeted gene was suppressed in an 
infected plant. This phenomenon was termed virus-induced gene silencing (VIGS), and 
the set of such phenomena were collectively called posttranscriptional gene silencing 
[84]. 
In 1998, Fire and Mello published in Nature their breakthrough study about the 
mechanism of RNA interference [85]. It was discovered earlier that antisense RNA, and 
also sense RNA, could silence genes but that the results were not clearly reproducible 
and the effects were usually modest. Furthermore only the injection of long double 
stranded RNA (dsRNA) into the nematode C. elegans induced potent silencing of 
target mRNA. They ended their paper by speculating about the possibility that “dsRNA 
could be used by the organism for physiological gene silencing”. In a follow up study in 
PNAS Fire presented results that mRNA is the target for dsRNA, this induced gene 
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silencing and that the mRNA is degraded prior to translation [86]. He also indicated that 
RNAi might be a specific “tactical” approach to viral defense in lower organisms. 
Later, it became clear that posttranscriptional gene silencing in plants and RNA 
interference are fundamentally related processes both mediated by double stranded 
RNA molecules [87].  
Soon after these studies the discovery of RNA interference (RNAi) was documented in 
various organisms [88]. Biochemical studies of RNAi were further elucidated in an in 
vitro model based on Drosophila embryo extracts. This showed that target mRNA 
degradation is guided by 21-23 nucleotide (nt) long double stranded RNAs that are 
fragments of long double stranded precursor RNAs. In accordance with these findings 
Elbashir et al. were able to elicit a potent and specific RNAi response in cultured 
mammalian cells by the application of short (21-23 nt) double stranded RNAs, also 
known as short interfering RNAs (siRNAs), without the induction of non-specific 
interferon-linked pathways [89, 90]. This was the starting point for the rapid 
development of RNA interference as a standard laboratory research tool. 
 
Fig. 1-5    Cellular mechanism of RNA interference. Long double-stranded RNA (dsRNA) is cleaved, by the 
enzyme Dicer, into small interfering RNA (siRNA). These siRNAs are incorporated into the 
RNA-induced silencing complex (RISC), where the strands are separated. The RISC containing 
the guide or antisense strand seeks out and binds to complementary mRNA sequences. These 
mRNA sequences are then cleaved by Argonaute, the enzyme within the RISC responsible for 
mRNA degradation, which leads to mRNA down-modulation [90]. 
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The initial step in the RNA interference pathway is the processing of long dsRNA by an 
RNase III-type enzyme called Dicer whose cleavage results in products of 21 to 23 nt 
long siRNAs containing 2 nt overhangs at their 3’ end and a 5’ phosphate group. After 
Dicer processing the siRNA molecules are unwound and the antisense strand of the 
siRNA is assembled into the RNA induced silencing complex (RISC) [91]. RISC 
assembly is not fully understood due to the multitude of different proteins that are 
associated in this complex. So far the only protein that is common to all RISC 
complexes that have been characterized are proteins of the ARGONAUTE (Ago) 
family. The activated RISC complex, called siRISC, then recognizes complementary 
mRNA sequences by antisense siRNA/mRNA base pairing and this is followed by the 
cleavage of the target mRNA strand [92, 93]. In other systems such as plants, worms 
and fungi, an RNA-dependent RNA polymerase (RdRP) plays an important role in 
generating and/or amplifying siRNAs. 
From the early RNAi experiments it was clear that the process was exceptional. Due to 
the studies of Fire and Mellow it became clear that the early findings of the PTGS 
phenomenon were comparable to RNAi. Today it is known that plants, worms and flies 
have an effective anti-viral mechanism where RNAi protects cells from virus replication 
(Fig. 1-6: Pathway 1). Pathway 2 presents the elimination of undesirable products due 
to RNAi. It was shown that a mutated RNAi machinery in C. elegans activates 
transposons and the function of the genome is disturbed [94]. Beside the discovery of 
RNAi a class of endogenous RNA molecules were studied: microRNAs (miRNAs) [95]. 
These microRNAs are processed from larger hairpin-like precursor RNAs. The miRNAs 
can regulate gene expression by base-pairing to mRNA, which often, although not 
always, results in the inhibition of translation (Fig. 1-6: Pathway 3). Additionally it was 
found in yeast that similar processes keep heterochromatic regions condensed and 
transcriptionally suppressed. RNAi-like mechanisms regulate the activity of genes in 
the immediate vicinity of condensed blocks of chromatin (Fig. 1-6: Pathway 4) [93]. 
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Fig. 1-6   Cellular processes dependent on the RNAi machinery. The Dicer and RISC complexes play a 
central role in the destruction of invading viral RNA (1), the elimination of transcripts from mobile 
elements (transposons) and repetitive DNA (2), the block of protein synthesis brought about by 
small RNAs generated within the cell (3), and the RNAi-mediated suppression of transcription 
(4). The machinery is also utilized when siRNA is introduced into the cell experimentally to 
inhibit the activity of specific genes (5). The figure is schematic, and the Dicer and RISC 
complexes can vary dependent on cellular process (Source: www.nobelprize.org, Advanced 
Information on The Nobel Prize in Physiology or Medicin 2006). 
Pathway 5 shows the technical approach of RNAi for functional gene silencing. Via 
transfection siRNAs are internalized into the cytosol to be further processed to achieve 
specific effects in gene regulation. RNAi is not only a powerful tool to study the function 
and interactions of genes it also raises expectations about novel, promising 
applications for RNAi-governed gene regulation in medicine.  
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1.9 RNA interference for cancer therapy  
RNA interference has been described as “one of the most exciting discoveries in 
biology in the last couple of decades”. As this mechanism appears to operate in all 
eukaryotes – including yeast, mammals and plants – RNAi seems to play a central role 
in controlling gene expression. RNAi, particularly siRNAs are now used routinely to 
analyze intracellular signaling, cancer, infections and the genetic basis of development. 
Like the fabled “magic bullets”, a siRNA is able to destroy its target mRNA without 
affecting other transcripts. Thus the potential for the use of RNAi in medicine appears 
limitless. Targets for RNAi could include oncogenes, viral genes and genes responsible 
for heart disease, Alzheimer’s disease and many more. 
One major advantage of siRNA-based techniques is their use in the high-throughput 
screening of cancer cells, rapidly providing information about gene expression profiles 
and thus facilitating the discovery of promising protein targets that are dysregulated in 
cancer [96]. Additionally RNAi offers the opportunity to silence the expression of any 
cancer-associated gene product that might generate anti-proliferative or pro-apoptotic 
effects. In this respect, proteins that cannot be targeted by conventional small molecule 
drugs are particularly attractive targets for siRNA-based therapy. Finally, the large-
scale production of siRNAs by chemical synthesis is relatively inexpensive. 
Most of the studies presented here demonstrated that siRNA-based gene silencing 
efficiently inhibited or reduced tumor cell growth. Therefore siRNA-based drugs will be 
particularly useful in combination with other therapies that help to eradicate neoplastic 
cells. For future applications it will be of important to identify target proteins whose 
silencing directly induces cell death without further stimuli. In addition, technologies that 
allow specific in vivo delivery are of crucial importance for siRNA based therapies. 
1.10    Aptamers  
Aptamers (from Latin aptus: to fit and Greek mere: to bind) are single stranded nucleic 
acid molecules (DNA or RNA) folding in a specific three-dimensional structure. 
Aptamers are engineered through repeated rounds of in vitro selection or equivalently, 
SELEX (systematic evolution of ligands by exponential enrichment) to bind to various 
molecular targets such as small molecules, proteins, nucleic acids, and even cells, 
tissues and organisms [97]. A library containing 40 random nucleotides flanked by 
primer-binding regions contains 420 individual sequences. An aptamer specifically 
binding to the target antigen is identified after several round of selection when all non-
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binding RNA sequences are washed away. The principle of the selection process is 
shown in Fig. 1-7. 
  
Fig. 1-7   The SELEX process. A random DNA or RNA library is initially incubated with the target of choice, 
allowing unbound sequences to be removed. DNA or RNA molecules bound to the target are 
recovered and amplified by polymerase chain reaction. This process is repeated several times 
until specific binding sequences are isolated (Source: http://www.ufz.de/index.php?de=14146).  
For further analysis when an aptamer sequence is selected and identified, a powerful 
computational structure prediction algorithm was developed to visualize the secondary 
structure of such an aptamer, allowing secondary structure-specific binding regions to 
be determined [98]. Thus it has become possible to add further nucleotides to the 
identified aptamer sequence without affecting functionality. This makes it possible to 
create aptamers with increased avidity, bispecific aptamers [99], or even complex 
molecules such as allosteric ribozymes that can be switched on and off by ligand 
binding. Aptamer sequences and target information are available in two different 
comprehensive aptamer databases: http://aptamer.icmb.utexas.edu and 
http://mfgn.usm.edu/ebl/riboapt/.  
Aptamers are highly useful in biotechnological and therapeutic applications as they 
offer molecular recognition properties that rival that of the commonly used biomolecule 
namely antibodies. In addition to their comparable recognition, aptamers offer 
advantages over antibodies as they can be readily produced by chemical synthesis, 
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possess desirable storage properties, and elicit little or no immunogenicity in 
therapeutic applications.  
Recent developments have been rewarded by the approval of the first aptamer-based 
drug, used for the treatment of age-related macular degeneration (AMD), and offered 
by OSI Pharmaceuticals. In addition, Archemix (Cambridge, MA; 
http://www.archemix.com) is leading the development of aptamers as a new 
class of directed therapeutics for the prevention and treatment of chronic 
and acute diseases. 
In this study two different aptamers should be used as binding moiety for a novel 
approach of anti-cancer durgs. 
1.11    Novel target gens for RNA interference  
The goal of siRNA-based cancer therapy is either to quash the expression of cancer-
causing genes, or force the cell into apoptosis after specific mRNA degradation. 
Eukaryotic elongation factor 2 (EEF2) is a member of the GTPase superfamily, and 
catalyzes the GTP-dependent translocation of aminoacyl tRNA from the A site to the P 
site of the ribosome during the peptide chain elongation step of protein biosynthesis 
[34]. The activity of EEF2 is tightly regulated by a specific calmodulin-dependent 
protein kinase. ADP ribosylation of EEF2 by diphtheria toxin or Pseudomonas A toxin 
was shown to inhibit protein biosynthesis efficiently and thus induce apoptosis [16, 55]. 
These toxins are effective in various cell types and have been used for the 
development of targeted anti-cancer agents, so-called immunotoxins. The silencing of 
EEF2 by RNAi should also provide a useful strategy for the elimination of cancerous 
cells.  
In cooperation with the Max Planck Institute for Infection Biology, Department of 
Molecular Biology, in Berlin, three other highly potent gens for RNAi targeting were 
identified by screening a library containing more than 1000 siRNAs. The first was 
SKIP1 interacting partner 5 (SKIP5). Sphingosine kinases (SKs) is a conserved lipid 
kinase that catalyzes formation Sphingosine-1-phosphate (S1P) from the precursor 
shphingolipid, sphingosine. Sphingolipid metabolites are lipid second messengers 
involved in diverse cellular processes [100, 101]. S1P is characterized as a signaling 
molecule with dual function. On one hand it binds to five different S1P receptors that 
are coupled to a variety of G-proteins to regulate diverse biological functions, one the 
other hand it appears to act as an intracellular second messenger but its binding 
partner are still unknown. By targeting SK1 interacting partner 5 we target a not well 
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characterized gene but surely influence the ceramide and sphingolipid metabolic 
pathways. The second was Polo-like kinase 1 (PLK1), which is essential for genome 
stability during mitosis and is overexpressed in certain human tumors, making it both a 
diagnostic marker and a potential therapeutic target [102]. PLK1 inhibitors can restore 
mitotic regulation and may be suitable for the suppression of tumor growth in vivo, 
particularly in the case of mammary carcinoma cells. RNAi-induced silencing of PLK1 
leads to the disruption of mitosis and ultimately the induction of apoptosis. Finally we 
identified G-protein coupled receptor kinase 4 (GRK4). GRKs regulate the activity of G-
protein coupled receptors (GPCRs) via the phosphorylation of their intracellular 
domains after the release and activation of their associated G-proteins [103]. GPCRs 
are a large family of transmembrane proteins that are activated by an external ligand or 
physical signal. After activation, the receptor conformation changes, in turn activating 
associated G-proteins [104]. GRKs regulate cell signaling by phosphorylating 
heptahelical receptors, thereby promoting GPCR interaction with β-arrestins. If GRK4 is 
silenced by RNAi this inhibits receptor internalization and β-arrestin-dependent 
signaling, ultimately inducing apoptosis.  
1.12    Selective systemic delivery of siRNAs 
The main challenge with therapeutic siRNAs is specific delivery to tumor cells following 
systemic administration, which is required to reduce or eliminate off-target effects 
(OFT) in vivo. Therapeutic siRNAs have been coupled to antibody fragments and 
aptamers or packaged into nanoparticles coated with receptor-targeting ligands. These 
cell type-specific delivery strategies facilitate siRNA uptake into cancer cells through 
endocytosis.  
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Fig. 1-8   Delivery of small interfering RNAs. (A) Non-selective approaches. Cholesterol groups can be 
linked to chemically modified small interfering RNAs (siRNAs) for systemic delivery (Aa). 
siRNAs can also be delivered systemically by stable nucleic acid–lipid particles (SNALPs) (Ab). 
(B) Selective approaches. Aptamer–siRNA chimeras allow siRNAs to be delivered to specific 
cell types that display receptors recognized by the aptamers (Ba and Bb). An all-RNA approach 
can be used to couple aptamers and siRNAs (Ba), or a biotin–streptavidin approach can be 
used to achieve coupling (Bb). Antibody fragments (Fabs) and siRNAs can be linked with 
protamine to deliver siRNAs to specific cell-surface receptors (Bc). Nanoparticles that display 
specific ligands on their surfaces can be used to target siRNAs to specific cell types (Bd). PEG, 
polyethylene glycol [105]. 
Heavy-chain antibody fragments (Fabs) specifc for the HIV-1 envelope glycoprotein 
gp120 have been used to achieve specific siRNA delivery to HIV-1 infected cells. This 
was achieved in vitro and in vivo [106]. The Fab fragments were conjugated to 
positively charged protamine (which interacts with negatively charged siRNA 
molecules) and to a fluorescent tag, allowing the specificity of targeting to be 
monitored. The Fab-siRNA (siRNA against group-specific antigen protein, Gag) 
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complexes selectively targeted HIV mRNA in cultured T-lymphocytes infected with HIV-
1. This experiment resulted in a >70% decrease in the levels of p24 Gag. The ERBB2 
growth factor receptor (erythroblastic leukemia viral oncogene homolog 2), expressed 
on mammary carcinoma cells, was also effectively targeted with a Fab-siRNA complex 
[106].  
RNA ligands (aptamers) are promising alternatives to Fab molecules. They can be 
designed to bind cell-surface receptors selectively and can be linked covalently to the 
siRNA sequence. After binding, the receptor/RNA complex is internalized wherein the 
siRNA is cleaved by DICER and released into the cytosol. For example, McNamarra et 
al. described an aptamer-siRNA that bound specifically to PSMA (Fig. 1-8 Ba) and 
caused a reduction of tumor growth in a mouse model after intratumoral injections 
every 2 days for 20 days [102].  
In another study where aptamer-based drugs were used to target PSMA-expressing 
cells, biotinylated siRNAs and biotinylated aptamers were conjugated non-covalently to 
the biotin-binding protein streptavidin [107]. The biotin-labeled 27-mer siRNAs were 
bound into these aptamer complexes to induce a more potent RNAi response due to 
recognition of siRNA by DICER, and subsequent incorporation into the active RISC.  
A more powerful approach involves the use of nanoparticles. These are designed to 
carry large, protected payloads of siRNAs that target cancer cells. Targeting is 
achieved by coating the surface of the nanoparticles with cell-specific ligands. For 
example, Erwing sarcoma tumors were targeted in vivo using nanoparticles coated with 
transferrin ligands [105]. The nanoparticles were composed of cyclodextrin-containing 
polycations (CDPs) engineered to interact with negatively charged siRNAs (siRNA 
against Ews-Fli1). PEG polymers were coupled to the outer surface through terminal 
adamantine groups on the polymers, conferring stability and preventing aggregation 
(which should be avoided in vivo). The adamantane-PEG chains were linked to 
transferring, and the chains and CDPs self-assembled into nanoparticles. Several 
injections of these coated nanoparticles resulted in the inhibition of tumor formation in a 
mouse xenograft model [108].  
In addition to the possible off-target effects of non-directed siRNA-based drugs, a 
general consideration for the therapeutic use of RNAi is the dosage. In non-selective 
systemic delivery systems, a large amount of siRNA needs to be administered to 
achieve efficient in vivo gene silencing. The cell type-specific delivery of siRNAs would 
reduce the necessary dose. 
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Fig. 1-9  The cell surface receptor specific delivery of siRNAs. After binding of aptamer to the target 
receptor, the receptor-ligand complex is internalized by endocytosis. Following translocation into 
the cytosol, DICER processes the RNA component and releases functional siRNA molecules 
that assemble into the RISC and mediate gene silencing. 
As discussed above, RNA aptamers are ideal drug delivery vehicles but they are 
particularly well suited for the delivery of siRNAs because the aptamer-siRNA can be 
synthesized as a single RNA transcript, which is convenient to handle and process and 
amenable for large-scale production. Furthermore, RNA generally is less immunogenic, 
so repeated administration of aptamer siRNA targeting complexes is well tolerated – in  
the abovementioned study by McNamarra et al., tumor growth in a prostate carcinoma 
mouse model was reduced after repeated intratumoral injection of aptamer siRNA 
chimeras [102]. Two other groups have also demonstrated aptamer-mediated siRNA 
delivery with non-covalent aptamer siRNA conjugates. Chu et al. created targeting 
complexes using streptavidin as a bridging carrier protein [109]. After biotinylated 
siRNAs and biotinylated aptamers were loaded onto streptavidin, cell surface receptor-
specific uptake and siRNA-mediated gene silencing effects were demonstrated. In a 
unique variation, Guo et al. exploited the affinity of interlocking right- and left-hand 
loops of packaging RNA (pRNA) [110]. A CD-4 specific aptamer was incorporated into 
one monomer and siRNAs targeting survivin into the other before the monomers were 
assembled via loop-loop interactions. Cell surface receptor specific siRNA delivery was 
demonstrated [111]. 
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1.13    Prostate specific membrane antigen (PSMA) 
In 1987, Horoszewicz et al. described a monoclonal antibody (7E11-C5) created by the 
immunization of mice with partially purified membrane preparations of the lymph node 
prostatic adenocarcioma cell line (LNCaP) taken from a human prostate carcinoma 
[112]. After further analysis, the antigen recognized by this antibody was shown to be 
the prostate specific membrane antigen (PSMA). PSMA is the prostate marker that is 
highly expressed in normal prostate as well as in prostate cancer cells. Its expression 
is increased in prostate cancer and is found primarily in the prostate. PSMA is 
considered to be a type II membrane protein with folate hydrolase activity produced by 
the prostatic epithelium and may therefore be involved in the neuroendocrine regulation 
of prostate growth and and differentiation. This antigen is with a 54% homology related 
to the transferrin receptor. However, in normal prostate, PSM', an alternatively spliced 
form of PSMA, is localized in the cytoplasm. Furthermore PSMA expression is closely 
associated with androgen-independent prostate cancer (PCa) and the expression level 
is elevated both in primary and metastatic tumor specimens [113]. The expression 
levels of PSMA in extraprostatic tissues are at least two orders of magnitude reduced 
compared to those observed in the prostate [114].  
PSMA is well suited as target for therapeutics because it is constitutively internalized 
from the surface of LNCaP cells when a ligand is specifically binding to its extracellular 
portion and its highly restricted expression in advanced carcinomas and metastatic 
prostate cancer. 
1.14    Human epidermal growth factor receptor 3: ERbB3/HER 3 
Members of the human epidermal growth factor receptor (EGFR) family are typical 
receptor tyrosine kinases, initially discovered in the early 1980s when the avian 
erythroblastosis tumor virus was found to encode an aberrant form of the human 
EGFR (also known as Erb1/HER1). Within the EGFR family, there are four ErbB 
genes, encoding proteins with a common structure comprising two cysteine-rich 
stretches in their extracellular region, and a kinase domain adjacent to the C-
terminus with tyrosine autophosphorylation sites [115]. ErbB genes are expressed in 
mesodermal and ectodermal tissues with few exceptions. The first signal-generating 
protein and proto-oncogene to be identified was EGFR/HER2, which is active in 
several forms of cancer [116]. ErbB3/HER3 is overexpressed together with HER2 in 
20-30% of invasive breast cancers.  
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In contrast to HER2, the kinase-deficient HER3 self-associates readily at low 
nanomolar concentrations and in the absence of its ligands (various isoforms of 
heregulin (Hrg)) [117]. Hrg disrupts HER3 oligomerization and leads to the formation of 
signaling-competent heterodimers, preferentially with HER2. Elevated levels of HER3 
contribute to increased drug resistance observed in HER2-overexpressing cells.  
Chen et al. used the oligomeric state of the extracellular domains of HER3 (HER3ECD, 
monomeric molecular mass 82 kDa) for the selection of RNA aptamers using the 
SELEX methodology described above [117]. One of the selected aptamers, A30, binds 
with high affinity to a limited number of binding sites in the oligomeric state of 
HER3ECD. Hrg does not compete with A30 for binding sites, indeed the disruption of 
HER3 oligomers by Hrg results in an approximately 10-fold increase in total binding 
sites, but the newly created binding sites are of lower affinity. High-affinity binding of 
A30 inhibits Hrg-dependent tyrosine phosphorylation of HER2 and the Hrg-induced 
growth response of MCF7 cells. As an example of an aptamer against a large 
macromolecular protein complex, A30 could facilitate the analysis of receptor 
interactions, and could be a lead compound for the development of inhibitors against 
overexpressed receptor tyrosine kinases in carcinomas or as a specific binding moiety 
for targeted immunotherapy. 
1.15    Aim of the thesis 
In this study, novel approaches for targeted therapy should be developed to improve 
the efficacy of applied drugs on their specific target cells and to prevent side-effects like 
incompatibility, potential resistance and unwanted interactions on healthy cells. 
Outgoing from today’s point of view drugs still negatively influence the patient’s 
immunesystem caused by unwanted influence of non-targeted drugs on healthy tissue. 
Due to these side-effects an improved development for targeted therapeutics which 
specifically bind to only diseased cells, e.g. immunotoxins is mandatory. For the 
evaluation of novel targeted therapeutics we had to consider many aspects.  
A major challange of drugs to be tolerated by the patient are non-human components. 
Many targeted therapeutics are based murine antibodies, ligands or Fab’s as binding 
moiety and a plant or bacterial toxin as toxic moiety. These components are recognized 
by the patient’s immunesysteme and identified as foreign particles. This defense 
negatively influences the efficacy of the drug and the patient’s health. We wanted to 
develop two different therapeutics which selectively target and kill diseased cells but 
which also are well tolerated by the patient’s immune system.  
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For one approach we decided to develop oligonucleotide-based therapeutics. In 1990 
aptamers were presented as attractive counterpart to usually used antibodies. Their 
unique binding properties, which are vailable for biochemical modifications, make 
aptamers perfectly suitable for different areas of biotechnology. Moreover, the approval 
of an aptamer for vascular endothelial growth factor by the US Food and Drug 
Administration highlights the potential of aptamers for therapeutic applications [118, 
119]. Additionally aptamers fold in a specific three-dimensional structure which 
prevents them to be recognized as viral RNA. The discovery of RNA interference 
(RNAi) by Fire and Mellow has been the major recent breakthrough in molecular and 
cell biology. RNAi machineries exert biological functions in gene regulation and 
genome defense as well as chromatin architecture and dynamics. This potential of 
RNAi to silence any gene of interest in a highly specific and efficient manner could be 
used as toxic component in an oligonucleotid-based drug. Silencing a protein which is 
crucial for the survival of a diseased cell leads the cell in apoptosis. As presented by 
McNamarra et al. we used this approach to fuse an aptamer to a siRNA to 1. target and 
2. subsequently eliminate the diseased cell via RNAinterfernce [99]. Together with Dr. 
Ulrich Wüllner the idea of developing aptamer siRNA transcripts was elaborated. 
Improving guidelines for the rational design of aptamer-siRNA transcripts, based on 
recent progress in understanding the mechanisms underlying RNAi, as well as the 
folding of both components are expected to improve their pharmacokinetic and 
pharmacodynamic properties for in vitro applications. Finally, successful therapeutic 
application of RNAi will depend on the development of improved siRNA delivery 
strategies that combine high specificity and efficiency with a low immunostimulatory 
and tumorigenic potential. In our approach we used two different aptamers targeting 
once the PSMA expressed on Prostate cancer cells and twice the HER 3 expressed on 
Breast Cancer cells. As toxic component we identified four different key proteins 
essential for the cell survival which we silenced via RNAinterference to induce cell 
death. 
For the other approach we selected a protein-based drug approach consisting of a 
binding and toxic moiety of human origine.  
In 1999 A. Kimchi et al. presented a kinase which had positive influence on the 
regulation of apoptosis. This kinase was later identified as death associated protein 
kinase (DAPK). In 1999 T. Kawai et al. presented this kinase family to have tumor-
suppresor activities operating at two different check points in the course of tumour 
development [75]: 1. in the early oncogene-activated apoptotic checkpoint mediated by 
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p19ARF-p53 pathway and 2. during the late stage of metatasizing cells. Screening 
showed that this kinase family is not expressed due to promotor hypermethylation in a 
variety of primary tumors including head and neck tumors, non-small cell lung cancers, 
B cell lymphomas and myeloma [120]. Based on these informations Fraunhofer IME 
(Aachen, Germany) submitted a patent application (Immunokinases, 
WO002005068616, Barth S., Tur M.K., Stöcker M., Fischer R.) which claims the fusion 
of this kinase domain to the single-chain Ki-4 to treat CD30+ Hodgkin Lymphoma cells 
to actively restore the lacking kinase domain to induce apoptosis. The claims are based 
on a truncated form lacking the regulatory CaM-domain and the death-domain [75]. 
Such a construct should result in a constitutively active domain which was reported to 
be more effective than the full-length kinase. 
Based on these ideas we screened Hodgkin Lymphoma cells towards their DAPK2 
expression to identify potential CD30+ target cells. As binding moiety we first used Ki-4 
as decribed in the patent application. However to develop a drug with a full completely 
human backbone Ki-4 was exchanged by the human ligand CD30L [121]. Monoclonal 
antibodies, single-chains or Fab-fragments specifically bind to target cells but if they 
are of murine origine they might induce immune reponses.  
In this study two completely different appoaches for cancer therapy should be 
developed as presented: 
1. Induction of apoptosis after active restoration of a tumor suppressor gene 
 
In this scheme the active restoration of a lacking tumor suppressor gene is presented. Via the binding 
moiety the protein construct can specifically bind to the target antigen. Inducing receptor-interfering 
endocytosis the construct is translocated via endosmal trafficking in to the cytoplasm of the cell. After 
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release of the construct the constitutively active kinase domain is able to phosphorylate its specific 
products to restore the apoptisis inducing signal kaskade. If the apoptosis pathway is induced the cell 
undergoes the cell death. 
2. Induction of apoptosis after specific silencing of main regulatory protein 
and oncogenes 
    
In this scheme the same trafficking process from a targted drug is presented. Here we use RNA-
based drugs with a binding and a toxic moiety. The difference is that we do not restore a lacking 
protein but we silence expressed proteins. These proteins protect the cell from the induction of 
apoptosis. Using siRNA we can silence these proteins and leas the cell in apoptosis. 
In this PhD thesis the basis for siRNA based drugs should be established. New siRNA 
targets should be identified and analyzed towards their degradation activities and their 
potential cytotoxicity. All aptamer-siRNA transcripts should be designed and 
synthesized in a reproducible way, purified and analyzed towards their binding and 
degradation specificity. Cytotoxic analysis were not requested but additionally 
performed in this thesis. For the protein-based immunokinases the idea described in 
the patent application was followed. The immunokinase Ki4-DAPK2 was cloned, 
expressed, purified and characterized towards their binding and cytotoxic activities 
(data not shown). As this fusion protein was less effective four completely new 
constructs were designed, expressed, purified and analyzed in parallel. As DAPK2’-
CD30L was identified to be the most effective fusion protein further analysis concerning 
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functionality, affinity and stability was performed. Additionally in vivo experiments were 
performed to investigate the therapeutic potential of this fusion protein. 
Immunokinases Immuno-RNA transcripts
Protein analysis of different 
target cells
MSP analysis of target cells
Design of immunokinases
- cloning
Production and purification
Characterization
-Western Blot analysis
-ELISA
-Mass spectometry
Kinase activity assay
Binding analysis
Internalization assays
Cell viability assays
Apoptosis assays
Serum stability assay
in vivo experiments
-Xenograph in SCID mice
-Immunohistochemistry
Selection of siRNA sequences
siRNA evaluation
-qPCR
-protein knock down experiments
-cytotoxicity
Design of Immuno-RNA transcripts
-Assembly PCR
A30 xPSM-A3-10
Production and folding analysis
Evaluation of all transcripts
Binding analysis
Internalization assays
Cell viability assays
Apoptosis assays
qPCR
protein knock down experiments
Interferon response
Affinity measurements
 
Fig. 1-10  Flow chart of PhD thesis. (blue: main ideas, green: Screenings and pre-experiments on target 
cells essential for the development of both drugs, beige: Design of all constructs, orange: 
production and purification, yellow: characterization of all drugs, pink: in vivo experiments. 
Definitions: MSP = Methylation-Specific PCR, qPCR = quantitative PCR, A30 = the aptamer 
A30 targeting HER3, xPSM-A3-10 = the aptamer xPSM-A3-10 targeting PSMA) 
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2 Materials and Methods 
2.1   Materials 
2.1.1 Chemicals 
Unless otherwise stated, consumables and chemicals were purchased from Acros Organics 
(Bruessel), Becton Dickinson Bioscience (Franklin Lakes, USA), Bio chrom (Berlin), BioRad 
(München), Biozym (Oldendorf), Clontech (Heidelberg), Corning Inc. (Schiphol-Rijk, 
Nederland), Cytogen (Obermörlen), Dharmacon (Lafayette, USA), Eppendorf (Hamburg), 
ICN (Eschwege), Greiner (Solingen), Hampton Research (Aliso Viejo), Hewlett-Packard 
(München), Invitrogen (Eggenstein), Kodak (Stuttgart), KMF Laborchemie (St. Augustin), 
Millipore (Eschborn), MWG-Biotech (Ebersberg), New England Biolabs (NEB; Schwalbach), 
Nunc (Wiesbaden), Novagen (Madison, USA), Pall Filtron (Northborough, USA), Perkin-
Elmer (Applied Biosystems, Foster City, USA), Pierce (Rockford), Promega (Mannheim), 
Qiagen (Hilden), Roche Molecular Biochemicals (Mannheim), Roth (Karlsruhe), Sarstedt 
(Nümbrecht), Schott-Glaswerke GmbH (Neufahrn/San Diego), Serva (Heidelberg), Sigma 
(Deisenhofen), Starlab (Ahrensburg), Whatman (Maidstone, England) or VWR (Darmstadt). 
2.1.2 Media stock solutions and buffers  
Standard buffer and media stock solutions were prepared according to established 
procedures using de-ionized water. Solutions were sterilized by autoclaving (25 min, 121°C, 
2 bar). Heat-sensitive components, such as antibiotics, were prepared as stock solutions, 
filter-sterilized (0.2 µm) and added to the medium/buffer after cooling below 50°C. 
All buffers and solutions intended for RNA work were prepared in water treated with 1.5 mL/L 
diethylpyrocarbonate (DEPC) stirred vigorously overnight and autoclaved.  
2.1.3 Standard buffer and media compositions 
The following standard buffers and media were used: 
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Table  2-1 Standard media and buffer compositions 
No. Buffer Composition Concentration 
1 10x PBS (pH 7.4) NaCl  
KCl  
Na2HPO4 x 12H2O  
KH2PO4  
1.37 
27  
81 
15 
 M 
 mM 
 mM       
 mM 
2 1x PBST 
 
1x PBS (pH 7.4) 
Tween 20  
 
0.05 
 
% (w/v) 
3 50x TAE 
Electrophoresis 
Buffer (pH 7.5) 
Tris-base  
Glacial acetic acid  
EDTA  
2      
5.7 
50  
M 
% (v/v) 
mM 
4 5x OrangeG 
Loading Buffer 
OrangeG  
Glycerol  
 
0,01 
30    
in1xTAE 
% (w/v) 
% (v/v) 
 
5 5x SDS PAGE 
running buffer  
 
Tris-HCl (pH 8.3)  
Glycine  
SDS  
125  
960 
0.5 
mM 
mM 
% (w/v) 
6 Coomassie 
Staining Solution 
Coomassie bb. G-250  
Methanol   
Glacial acetic acid  
0.25 
50    
9      
%(w/v) 
% (v/v) 
% (v/v) 
7 Coomassie 
Destaining 
Solution 
Methanol  
Glacial acetic acid  
10    
10 
% (v/v) 
% (v/v) 
8 5x Reducing 
Protein Loading 
Buffer 
Tris-HCl (pH 6.8)  
Glycerol  
SDS  
Bromphenolblue  
ß-Mercaptoethanol  
62.5 
30  
4    
0.05  
10  
mM 
% (v/v) 
% (w/v) 
% (w/v)  
% (v/v) 
9 5x Non-Reducing 
Protein Loading 
Buffer 
Tris-HCl (pH 6.8)  
Glycerol  
SDS  
Bromphenolblue  
62.5 
30 
4    
0.05  
mM 
% (v/v) 
% (w/v)  
% (w/v) 
10 10x TBE 
electrophoresis 
running buffer 
Tris-HCl 
H3BO3 
EDTA (0,5 M) 
0,685  
0,9      
0,02  
M 
M 
M 
11 2x denaturing 
RNA loading 
buffer 
Formamide 
EDTA 
SDS 
Bromophenol Blue. 
95     
18     
0.025 
0,01 
% (v/v) 
mM 
% (w/v) 
% (w/v) 
12 8% denaturing 
Urea PAGE gel 
(30 mL) 
Acrylamide/Bisacrylamide(30/1) 
Urea 
TEMED 
APS, (20%, w/v) 
H2O 
x 
7 
30 
200 
 
mL (8%) 
M 
µL 
µL  
add 30mL 
13 native PAGE gel Acrylamide/Bisacrylamide(30/1) 
Tris-HCl (pH: 8,8) 
TEMED 
APS (20%, w/v) 
x  
375 
0,1    
0,1 
mL 
mM 
% (w/v) 
% (v/v)  
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14 SDS PAGE gel  
(Separating gel) 
 
Acrylamide/Bisacrylamide (30/1) 
Tris-HCl (pH: 8,8) 
SDS (10 %, w/v) 
TEMED 
APS (20%, w/v) 
x  
375 
0,1    
0,1 
0,1 
mL 
mM 
% (w/v) 
% (v/v)  
% (v/v) 
15 SDS PAGE gel 
(stacking gel) 
Acrylamid/Bisacrylamide (30/1) 
Tris-HCl (pH : 6,8) 
SDS  
TEMED 
APS 
5 
150 
0,1  
0,1 
0,1  
% (w/v) 
mM 
% (m/v) 
% (v/v) 
% (v/v) 
16 LB (pH: 7) NaCl 
Peptone 
Yeast extract 
1 
1 
0,5 
% (w/v) 
% (w/v) 
% (w/v) 
 
2.1.4 Buffers for RNA work 
Table  2-2 Buffers 
No. Buffer Composition Concentration 
1 RNA PAGE elution 
buffer NaOAc pH: 5,4 0,3 M 
2 2x RNA denaturing 
PAGE loading buffer 
Formamide 
EDTA 
SDS 
95 
18 
0,025 
% (v/v) 
% (w/v) 
% (w/v) 
3 1x siRNA 
deprotection buffer 
pH: 3,8 with TEMED 
NaOAc 
TEMED 
100 
x 
mM 
µL 
4 5 x siRNA 
resuspension buffer 
pH: 7,4 – 7,6 (with 
KOH) 
HEPES 
KCl, 
MgCl2 
30 
1 
1 
mM 
mM 
mM 
5 1 x RNA binding 
buffer, pH: 7,4 
HEPES 
MgCl2 
CaCl2 
20 
1 
1 
mM 
mM 
mM 
6 1x RNA 
internalization buffer 
pH: 7,4 
HEPES 
MgCl2 
CaCl2 
Glucose 
20 
1 
1 
16 
mM 
mM 
mM 
mM 
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2.1.5 Buffers for protein work 
Table  2-3 Buffers 
No. Buffer Composition Concentration 
1 Talon buffer NaH2PO4, pH 8.0 
NaCl 
200 
1.2 
mM 
mM 
2 
4x Incubation buffer 
NaH2PO4, pH 8.0 
NaCl  
Imidazole 
200 
1.2 
40 
mM 
mM 
mM 
3 
Elutionbuffer 
NaH2PO4, pH 8.0 
NaCl  
Imidazole 
50 
300 
250 
mM 
mM 
mM 
4 
Kinase buffer 
Tris-HCl pH 7.5 
MgCl2 
BSA 
MLC 
ATP 
40 
20 
0,1 
5 
2,5 
mM 
mM 
% (w/v) 
µM 
µM 
5 
Kinase control buffer 
for PKA 
Tris-HCl pH 7.5 
MgCl2 
BSA 
Kemptide 
ATP 
40 
20 
0,1 
5 
1 
mM 
mM 
% (w/v) 
µM 
µM 
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2.1.6 Antibodies 
The following antibodies were used: 
Table  2-4 Antibodies used 
Antibody (Supplier) Target Characteristic 
mouse-anti-penta-his 
[α-penta His Ab] 
(Qiagen) 
C-terminal his-tag monoclonal 
goat-anti-mouse 
[GαMHRPO (α-IgG Fc)] 
(Sigma) 
Fc of mouse IgG 
polyclonal,  conjugated to 
horseradish peroxidase 
(HRPO) 
goat-anti-rabbit 
(Dianova) 
Fc of rabbit IgG 
polyclonal, conjugated to 
alkaline phosphatase 
goat-anti-rabbit 
 (Dianova) 
Fc of rabbit IgG 
polyclonal, conjugated to 
horseradish peroxidase 
(HRPO) 
rabbit-anti-eEF2 (Cell 
Signaling Technologies) 
eucaryotic elongation 
factor 2 (eEF2) 
polyclonal 
mouse-anti-PSMA-3C6 
(Northwest Biotherapeutics)  
prostate specific 
membrane antigen 
(PSMA) 
monoclonal 
mouse-Tag100 (Qiagen) 
MAPK1 
(human/mouse) 
monoclonal 
mouse-anti-DAPK2 
(BIOZOL) 
DAPK2 (human) monoclonal 
mouse-anti-CD30 
(Dianova) 
CD30 (human) monoclonal 
mouse-anti-Beta-Tubulin 
(abcam) 
Beta-tubulin (human) monoclonal 
mouse-anti-Beta-Actin 
(abcam) 
Beta-actin (human) monoclonal 
mouse-anti-ErbB3 (abcam) Her 3 (human) monoclonal 
Mouse-anti-his-Alexa 488 
(Qiagen) 
C-terminal his-tag monoclonal 
goat-anti-mouse-HRPO 
(Sigma-Aldrich) 
Fc of mouse IgG 
monoclonal, conjugated to  
HRPO 
goat-anti-mouse-FITC 
(Qiagen) 
Fc of mouse IgG 
monoclonal, conjugated to 
FITC 
 
2.1.7 Reaction kits and enzymes 
Unless otherwise stated, enzymes were purchased from NEB, Roche Molecular 
Biochemicals, MWG-Biotech, Invitrogen, Biozym or Promega. The following kits were used 
according to the manufacturers’ recommendations.  
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Table  2-5 Standard reagents and kits used 
Purpose Reagent / Kit Company 
DNA plasmid isolation 
(mini scale) 
QIAprep spin miniprep kit Qiagen 
DNA extraction form 
Agarose gels 
QIAquick gelextraction kit 
QiaExII agarose gel extraction kit 
Qiagen 
PCR product purification QIAquick „PCR-purification“ Kit Qiagen 
Ligation of restricted 
DNA ends 
Quick ligation kit NEB 
Total RNA isolation NucleoSpin® RNA II Macherey-Nagel 
PCR I PhusionTM High-Fidelity DNA 
Polymerase 
NEB 
PCR II Bioline Taq-DNA Polymerase Bioline 
PCR product cloning TOPO TA cloning kit with pCR 
2.1 TOPO Vector 
Invitrogen 
RNA transcription Durascribe T7 transcription kit Biozym 
RNA transcription T7 RNA polymerase Stratagene 
Transfection I Nucleofection Kit V Amaxa 
Tranfection II Rotifect Roth 
siRNA Transfection  RNAifect, Hiperfect Qiagen 
DICER cleavage In vitro Turbo DICER assay kit Peqlab 
qPCR Lightcycler Faststart DNA master 
SYBR Green I 
Roche 
RNA stabilization RNAlater Roche 
Chemoluminescence 
Detection Kit 
ECL chemiluminescence detection 
kit  
Pierce 
Interferon β detection Human IFN Beta ELISA kit PBL Interferon 
Source, USA 
Cell viability  Cell proliferation kit (XTT)  Promega 
Apoptosis assay I Annexin V/PI assay BD Biosciences 
Apoptosis assay II Apo-ONE caspase-3/7 assay  Promega 
 
2.1.8 Bacterial strains and vector systems 
Table  2-6 shows the bacterial strains that were used for the production and cloning of  
plasmid DNAs. 
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Table  2-6 Bacterial strains used 
Bacterial strain Genotype 
XL1-blue RecA1 endA1 gyrA96 thi-1 hsdR17supE44 relA1 lac 
(Stratagene, La Jolla, USA) 
DH5 α F- φ80lacZ∆M15 ∆(lacZYA-argF)U169 recA1 endA1 
hsdR17(rk-, mk+) phoA supE44thi-1 gyrA96 relA1 tonA 
(confers resistance to phage T1) 
 
2.1.9 Equipment and applications  
Table  2-7 Equipment used 
Application Equipment 
Centrifuges MicrofugeR, Avanti J-30I Centrifuge, Alegra 6KR Centrifuge 
(Beckman, Fullerton, USA) 
Biofuge Pico (Heraeus Instruments, Hannau, Germany) 
Picofuge (Stratagene, Heidelberg, Germany) 
Rotilabo Centrigue with Butterfly-Rotor (Roth, Karlsruhe, 
Germany) 
Rotors F241.5, 16.250, JA-30.50, GH 3.8 (Beckman, Fullerton, USA) 
#3324 (Heraeus Instruments, Hannau, Germany) 
Nucleofektor Amaxa, Köln, Germany 
Confocal microscope Leica DM RE + TCS SP confocal Laser Microscope (Leica, 
Wetzlar, Germany) 
Fluorescence 
microscope 
DM R Fluorescence microscope (Leica, Wetzlar, Germany) 
Gelelectrophoresis Mini Protean III gel chamber (BioRad), XCell II Blot 
Module (Invitrogen), Protein Gel-Apparatus and 
supplies Mini PROTEAN II™, Gel Air Dryer (BioRad) 
DNA sequencing ABI Prism 3700 Capillary-Sequencer (Perkin-Elmer) 
Incubators Innova™ 4340 incubator shaker (NewBrunswick 
Scientific), Thermomixer compact (Eppendorf) 
Vortex Vortex-Genie 2 (Scientific Industries Inc., Bohemia, USA) 
PCR-Cylers Primus 96 Plus (MWG-Biotech), Programmable Thermal 
Controller PTC-200™ (MJ Research Inc., Watertown, 
USA) 
Real time PCR Roche Lightcycler 1.0 system; Roche 
Incubators Innova™ 4340 incubator shaker (NewBrunswick 
Scientific), Incubator (Heraeus Instruments), 
Thermomixer compact (Eppendorf) 
Laminar flow Hera Safe HS12 (Kendro). 
Photometer Biophotometer (Eppendorf) 
ELISA plate reader Elisareader ELx808 (Bio-TEK) 
Transiluminator Molecular Imager Gel Doc XR System; Biorad 
Software AIDA image analyzer 
Electroblotting 
equipment 
Mini Trans-Blot Cell (Biorad) 
Flow cytometry FACS Excalibur, Becton Dickenson 
Pipetting Pipetman P (Gilson) Multichannel Pipettes (Eppendorf) 
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2.2    Methods 
2.2.1   Cell culture  
2.2.1.1 For Immuno-RNA-transcripts 
The human prostate carcinoma cell lines LNCaP (ATCC CRL-1740) and PC-3 (ACC 465) 
and the human mammary adenocarcinoma cell lines MCF-7 (ACC 115) and MDA-231 (HTB 
26) were cultured in GIBCO™ RPMI 1640 medium (Invitrogen, Karlsruhe, Germany) 
supplemented with 10% (v/v) heat-inactivated GIBCO™ fetal bovine serum (FBS, Invitrogen) 
and 50 µg/ml penicillin and streptomycin.   
2.2.1.2 For Immunokinases 
Human CD30+ Hodgkin lymphoma-derived cell lines L540 (DSMZ no.: ACC 72), L1236 (ACC 
530) and L428 (ACC 197), human CD30- Hodgkin lymphoma-derived cell line HD-MY-Z 
(ACC 346), histiocytic lymphoma-derived cell line U937 (ACC 5), human breast 
adenocarcinoma cell line MCF-7 (ACC 115), human prostate carcinoma cell line PC-3 
(ACC 465) and the eukaryotic expression host cell line 293T (ACC 305) were purchased 
from the DSMZ and cultured in GIBCO™ RPMI 1640 medium (Invitrogen) supplemented with 
10% (v/v) heat-inactivated GIBCO™ FBS (Invitrogen) and 50 µg/mL penicillin and 
streptomycin. For the selection of transfected cells, Zeocin (Invitrogen) was added to a final 
concentration of 100 µg/ml.  
All cells were maintained in vitro at 37°C in a humidified 5% CO2 atmosphere.  
2.2.2 Electrophoresis protocols 
2.2.2.1 Agarose gel electrophoresis 
DNA fragments (2.2.4.3) for were electrophoretically separated on 1.5-2.5% (w/v) agarose 
gels containing 0.1 µg/mL ethidium bromide prepared in TAE buffer (Table  2-1) at 100 V 
with a run time of 20-60 min. The 2log DNA ladder (NEB) was used as the molecular weight 
standard. DNA was visualized on a transilluminator (Geldoc XR; Biorad). The same method 
was used for analytical and preparative gels, with subsequent extraction and purification 
using the Qiagen gel extraction kit for DNA preparation (Table  2-5). 
2.2.2.2 Analytical SDS PAGE  
Discontinuous SDS PAGE was performed for the separation of proteins, using 8-15% (w/v) 
SDS gels. Proteins were visualized by staining with 0.25 % (w/v) Coomassie brilliant blue 
G250 (Table  2-1). Gels were run under non-reducing conditions in order to maintain native 
disulfide bonds.  
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2.2.2.3 Urea PAGE 
RNA fragments were separated by urea PAGE. The RNA sample was mixed with an equal 
volume of denaturing RNA loading buffer (Table  2-2) and heated to 95°C for 3 min. Then hot 
RNA solution was immediately loaded onto the gel and separated at 250 V (for preparative 
gels) or 160 V (for analytical gels) for between 30 min and 1.5 h. The RNA ribomax ladder 
(Ambion) was used as the molecular weight standard. For preparative gels, the RNA was 
visualized by UV shadowing. For analytical gels the gel was stained in 0.1 µg/mL ethidium 
bromide staining solution for 5 min. RNA bands were then visualized on an UV-
transilluminator.  
2.2.2.4 Analytical native PAGE  
The siRNAs were separated on a 15% (w/v) gel in TAE buffer. Samples were loaded in 1x 
non-denaturing orange G DNA loading dye (Table  2-1). RNAs were visualized after ethidium 
bromide staining on an UV-transilluminator.  
2.2.3 Methods for the evaluation of siRNA-mediated gene silencing 
2.2.3.1 siRNA transfection 
All transfections were performed using Hiperfect and RNAifect (Qiagen) following the 
manufacturer’s recommendations. Briefly, Hiperfect (1.5 µl) was mixed with 50 µl RPMI 
medium containing the appropriate concentration of siRNA (Table  2-2) and incubated for 10 
min at room temperature. The mixture was added dropwise into 96-well plates, and 1-3 x 104 
cells/well were seeded on top of the siRNA drop (final volume 100 µl) followed by further 
incubation for 12, 24 or 48 h. The cells were then harvested for gene and protein silencing 
analysis, or assays for cell viability.  
2.2.3.2 Analysis of transfection efficiencies by fluorescence microscopy and flow 
cytometry 
Transfection efficiencies were determined by fluorescent microscopy and flow cytometry 
(2.2.5.3). Transfection was performed as described in (2.2.3.1) using 200 nM of FITC-labeled 
control siRNA (Table  7-3). After 24 h, the medium was exchanged and cells were washed 
twice with ice-cold 1x PBS to remove free siRNA. The cells were then resuspended in 1x 
PBS and analyzed by flow cytometry or by adding 50µl of cell suspension on a glass slide to 
visualize the cells under an UV- microscopy. Transfection efficiencies were calculated by 
determining the ratio of stained to unstained cells.  
2.2.3.3 Total RNA preparation 
Total cellular RNA was isolated from as few as 1x 104 cells (2.2.1) using the Macherey Nagel 
NucleoSpin® RNA II kit according to the manufacturer’s recommendations. The final elution 
step was performed with 30 µL of water in order to achieve high RNA concentrations. 
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2.2.3.4 First strand cDNA synthesis  
First strand cDNA synthesis was carried out on 10 µL total cellular RNA (2.2.3.3) using 
random hexamer primers and Superscript III RNA polymerase (Invitrogen) following the 
manufacturer’s recommendations. 
2.2.3.5 siRNA deprotection and annealing 
siRNAs purchased from Dharmacon were deprotected by resuspending the appropriate 
amount of siRNA in RNA deprotection buffer (Table  2-2) and incubating at 60°C for 30 min. 
The deprotection buffer was then evaporated (freeze drying or speed vac) and the siRNAs 
resuspended in PBS. For annealing, equal amounts of the siRNA sense and antisense 
strand were mixed and heated to 70°C for 5 min and then incubated at 37°C for 60 min.  
2.2.3.6 Quantitative real time RT-PCR analysis (qPCR) 
Gene silencing was assessed by quantitative RT-PCR (qRT-PCR), using a Lightcycler 
Faststart DNA Master SYBR Green I (Roche) and a Roche Lightcycler 1.0 system. The 
reaction volume was 20 µl. Primers for human GAPDH and EEF2 (Table  7-1). Briefly, cells 
were transfected with 200 nM of non-silencing siRNA or varying amounts of siRNA (10–300 
nM for siEEF2 sequences 1 and 2) using Hyperfect (Qiagen) following the manufacturer’s 
recommendations. LNCaP cells (1-3 x 104) were seeded over the siRNA drop in 96-well 
plates and incubated overnight at 37°C. For aptamer-siRNA analysis, cells were seeded in 
96-well plates and incubated overnight at 37°C. Varying amounts of aptamer-siRNA 
transcripts (10-1000 nM) were added onto the cells for further incubation. Cells were lysed 
after 24 h. Total RNA was extracted using the NucleoSpin® RNA II kit (Machery Nagel) and 
treated with DNase I (Machery Nagel). RNA was eluted with 30 µl of RNase-free water. 
Equal amounts of RNA were used for cDNA synthesis with random hexamer primers and 
Superscript III RNA polymerase (Invitrogen) following the manufacturer’s recommendations. 
Appropriate amounts of cDNA (2 µl) were used for qRT-PCR. The relative amount of target 
gene mRNA was normalized to GAPDH mRNA by the delta delta Ct method. Amplification 
specificity was verified by melt curve analysis.  
2.2.3.7 Western blot analysis for protein silencing 
All transfections were performed using Hiperfect (Qiagen) following the manufacturer’s 
recommendations. Briefly, 2 x 105 cells/well (2.2.1) were seeded in 12-well plates and grown 
overnight. The siRNAs targeting EEF2 and MAPK1, or a non-silencing control siRNA 
(Qiagen) were transfected into the cells using 100 nM Hyperfect (Qiagen). For protein knock-
down analysis, cells were harvested after 12, 24 and 48 h. Cells were washed twice with 1x 
PBS and lysed using Nonidet P-40 (GE Healthcare) following the manufacturer’s 
recommendations. Soluble protein (30 µg) was separated on a 12 % (w/v) SDS 
polyacrylamide gel (2.2.2.2) electrotransferred to a nitrocellulose membrane and analyzed by 
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Immunoblotting. EEF2 expression was monitored using a polyclonal rabbit antibody specific 
for eEF2 (Cell Signaling technologies) and MAKP1 was detected with the monoclonal mouse 
antibody Tag 100 (Qiagen) both used according to manufacturer’s recommendations.  
2.2.3.8 Cell viability assay 
Cell viability was assayed using the Cell Proliferation Kit (XTT) (Promega, Mannheim, 
Germany). Briefly, cells were transfected with different concentrations of siRNAs (Table  7-3) 
or seeded in 96-well plates (Greiner) at a density of 1-3 x 104 cells (2.2.1) per well in 50 µl 
RPMI 1640 medium. The cells were allowed to attach overnight at 37°C for subsequent 
aptamer-siRNA incubation. After 48 h, 20 µl of XTT-Phenancin reaction solution was added 
(sodium 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzenesulfonic 
acid hydrate and N-methyl dibenzopyrazine methylsulfate). After 1-6 h incubation, the optical 
density at 405 nm was measured using an ELISA plate reader (0). 
2.2.4 Methods for the preparation of RNA aptamers  
2.2.4.1 RNA secondary structure prediction  
RNA secondary structure was predicted using the MFOLD algorithm 
(http://bioweb.pasteur.fr/seqanal/interfaces/mfold-simple.html) on aptamer xPSM-A10-3, and 
aptamer-siRNAs xPSM-A3-siEEF2, xPSM-A3-siGFP, A30, A30-siEEF2, A30-siGFP, A30-
siGRK2-1, A30-siGRK2-2, A30-siPLK1-1, A30-siPLK1-2 and A30-siSKIP5. The most stable 
structures with the lowest free energies for each construct were compared. 
2.2.4.2 Assembly polymerase chain reaction 
DNA templates of the monovalent aptamer siRNAs were generated by assembly PCR using 
four overlapping primers. In the first step, a small amount of full length DNA was produced. In 
the second amplification using flanking primers, full length DNA containing the T7 promoter 
for subsequent transcription was amplified (Fig. 2-1). The reaction components (50 µL total) 
are listed in Table 1.8 and the protocol is outlined in Table 1.9. 
 
Fig. 2-1 The assembly PCR reaction 
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Table  2-8 Components and concentrations of an assembly PCR reaction 
Component Final concentration 
10x PCR buffer 1x 
dNTP 0.2 µM of each four dNTPs 
each of four assembly 
primers 
0,3 µM 
Taq DNA polymerase 0.0125 U/µL 
 
Table  2-9 PCR protocol for an assembly PCR 
 
 
 
 
For the second PCR, 1 µL of the assembly PCR reaction mixture was used as the template 
and the reactions was set up as described in section 2.2.4.3. 
2.2.4.3 Polymerase chain reaction 
DNA templates (2.2.4.2) for the in vitro transcription of monovalent aptamer siRNA 
constructs were generated using a standard PCR with a 100-µL reaction volume comprising 
the components listed in Table 1.10 and the protocol outlined in Table 1.11. The optimal 
primer annealing temperature was determined experimentally (by temperature gradient PCR) 
as the highest annealing temperature at which the PCR still worked with adequate 
amplification rates.  
Table  2-10 Polymerase chain reaction composition 
Component Final concentration 
Template DNA 1 ng 
10x PCR buffer 1x 
dNTP 0.2 µM of each four dNTPs 
5’ forward primer 1 pmol/µL 
3 backward primer 1 pmol/µL 
Taq DNA polymerase 0.025 U/µL 
Table  2-11 PCR amplification protocol 
 temperature [°C] time [min] step  
1. 95 3 initial denaturation  
2. 95 1 denaturation 
3. Tanneal 1 primer annealing 
4. 72 1 elongation 
 
     25 cycles 
5. 72 5 final elongation  
 
2.2.4.4 DNA sequence analysis 
DNA sequencing was carried out using the Sanger dideoxy method with fluorescent 
dideoxynucleotides on an “ABI Prism 3700” capillary sequencer (Applied Biosystems) and 
 temperature [°C] time [min] step  
1. 95 3 initial denaturation  
2. 95 1 denaturation 
3. 54 1 primer annealing 
4. 72 1 elongation 
 
     10 cycles 
5. 72 5 final elongation  
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BigDye™ cycle sequencing terminator chemistry. The extension products were detected by 
exciting the unique dyes attached to each dideoxynucleotide with a laser, followed by a 
measurement of fluorescence emission using a CCD camera. The sequence was determined 
by running the fluorescence data through an Applied Biosystems Sequencing Analysis 
Program, and DNA-Star software (Lasergene, Konstanz, Germany). 
2.2.4.5 Phenol chloroform extraction  
Phenol chloroform extraction carried out to remove protein impurities from nucleic acid 
preparations. An equal volume of phenol was added to the nucleic acid solution and the 
mixture was vortexed for 10 s. After centrifugation (1 min, 13,000 x g) the upper phase was 
transferred to a fresh tube and two volumes of chloroform were added. The mixture was 
vortexed for 10 s and centrifuged as above, and the upper phase was transferred to a fresh 
tube. The nucleic acid was then recovered by ethanol precipitation (2.2.4.6). 
2.2.4.6 Ethanol precipitation 
Ethanol precipitation was used to increase the concentration of DNA fragments recovered 
from PCRs (2.2.4.3) and of RNA recovered from in vitro transcription (2.2.4.7) or labeling 
reactions (2.2.4.9). Precipitation was carried out by adding 0.1 volumes of 3M sodium 
acetate (pH 5.4) to the nucleic acid solution and 2.5 volumes of pure ethanol. After vortexing 
briefly, the mixture was incubated at -80°C for 15 min and then centrifuged at 6°C, 13,000 x g 
for 15 min. The pellet was washed with 150 µL 70% (v/v) ethanol and centrifuged as above 
for 5 min. After the pellet was dried at room temperature for 5 min to avoid overdrying, it was 
resuspended in water. 
2.2.4.7 in vitro transcription 
The aptamer (xPSM-A10-3) and the monovalent aptamer-siRNA transcripts (xPSM-A10-
siEEF2 and xPSM-A10-siGFP) were synthesized by in vitro transcription from a double-
stranded DNA template bearing a T7 promoter (2.2.4.3). Transcription was carried out in a 
20-µl reaction volume using the DuraScribe T7 Transcription Kit (Epicentre, Madison, WI) 
contaning 2 µg of DNA template, 5 mM ATP and GTP, 5 mM 2’F-dCTP and dUTP, and 2 µl 
of DuraScribe T7 Enzyme Mix. Reactions were carried out overnight at 37°C and the 
products were treated with DNaseI for 15 min at 37°C. The RNA products were purified by 
denaturing (7 M urea) gel electrophoresis on an 8% (w/v) polyacrylamide gel (2.2.2.3). RNA 
bands were excised and RNA was eluted in 0.3 M sodium acetate for 1 h at 60°C and 
recovered by ethanol precipitation (2.2.4.6). 
2.2.4.8 Measurement of DNA and RNA concentrations 
Nucleic acid concentrations were determined by UV spectrophotometry using 1:100 dilutions 
prepared in water. The OD260 was measured and the concentration was calculated according 
the following formula: 
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µg/ml of nucleic acid  = OD260  x  conversion factor  x dilution factor   
conversion factor:  for dsDNA: 50 µg/mL 
for ssRNA: 40 µg/mL 
2.2.4.9 Fluorescence labeling of RNA  
Fluorescent labeling was carried out in a 50 µL reaction volume comprising ~1.5 nmol of  
RNA transcript, 10 mM EDTA, 1 M urea, 100 mM Tris-HCl (pH 7.4), 0.5 mg/ml 5’-
iodoacetamidofluoresceine and 10% (v/v) dimethylformamide (DMF). The reaction was 
incubated at 4°C in the dark overnight. Labeled transcripts were purified by ethanol 
precipitation, washed several times with 70% (v/v) ethanol and then resuspended in DEPC-
treated water. 
2.2.5 Aptamer-siRNA transcript evaluation 
2.2.5.1 Flow cytometric binding analysis 
PSMA and HER3 expression, as well as aptamer binding to PSMA/HER3 positive and 
PSMA/HER3 negative cell lines, was determined by flow cytometry. The anti-PSMA specific 
antibody 3C6 (Northwest Biotherapeutics) and the anti-HER3 specific antibody (abcam) were 
used at a dilution of 1:500 in 1x PBS. A FITC-labeled GAM secondary antibody was used at 
a dilution of 1:500. Prior to analysis, cells were scraped and washed with 1x PBS, then 2x 
105 cells (2.2.1) were incubated with primary antibody in 500 µL 1x PBS on ice for 30 min. 
Cells were washed and incubated with the secondary antibody on ice for 30 min in the dark. 
Finally, the cells were washed twice with 1x PBS, and resuspended in 500 µl 1x PBS. 
Binding analysis of FITC-labeled aptamers was carried out accordingly at aptamer 
concentrations of 200 nM. Incubation with the secondary antibody was omitted. Finally, 
stained cells were detected in the FL-1 direction by flow cytometry. 
In order to determine the viability of a cell population, cells were stained with propidium 
iodide (PI). Therefore prior to flow cytometric analysis, propidium iodide was added to the cell 
suspension at a concentration of 5 µg/mL for 10 s. Dead cells were detected and shifted in 
the FL-3 direction.  
2.2.5.2 Cell-surface affinity measurement of aptamer-siRNA transcripts  
LNCaP cells (2.2.1) were analyzed by flow cytometry to determine the relative binding 
affinities of the aptamers xPSM-A3-siEEF2, xPSM-B1-siEEF2 and xPSM-B2-siEEF2 
(2.2.4.9) (bivalent constructs were provided by Dr. Ulrich Wüllner). The aptamer-siRNAs 
were heated to 80°C for 3 min and then incubated at 37°C for 10 min in 1x HEPES binding 
buffer (20 mM HEPES, 150 mM NaCl,1 mM MgCl2, 1 mM CaCl2, pH 7.4) (Table  2-2). The 
cells were scraped into microfuge tubes and washed with 1.8 ml 1x HEPES binding buffer, 
then 2–5 x 105 cells were incubated for 1 h at 4°C with the FITC-labeled aptamer-siRNAs at 
concentrations ranging from 0.02 to 2 µM. Cells were washed twice with 1.8 ml 1x HEPES 
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binding buffer and analyzed by flow cytometry. Negative control cell lines were treated as 
described above using aptamer concentrations of 400 nM. Data analysis was performed with 
CellQuest Software (BecktonDickenson). Data represent the average ± SEM of four 
independent experiments. Each curve was normalized to the maximum Mean Fluorescent 
Intensity (MFI) obtained.  
2.2.5.3 Internalization assay 
LNCaP cells (2 x 105) (2.2.1) were washed with 500 µl 1 x HEPES internalization buffer 
(Table  2-2) and incubated with 400 nM FITC-labeled aptamer-siRNA in 1 x HEPES binding 
buffer supplemented with 16 mM glucose. The “no internalization” controls for each transcript 
were kept on ice. All other samples were incubated in the dark at 37°C for 30 or 60 min. At 
the end of the incubation, cells were cooled on ice for 5 min. In order to degrade cell surface 
PSMA and to remove aptamer-siRNA transcripts bound to PSMA, 0.5 mg/ml proteinase K 
was added to the cells in 1 x HEPES binding buffer. For the “100% internalization” value of 
each transcript, the proteinase K treatment was omitted so that the maximum amount of 
internalized transcripts reflected the amount of bound fluorescence. After 15 min, cells were 
collected, washed twice, resuspended in 400 µl HEPES binding buffer and analyzed by flow 
cytometry (2.2.5.1). For each transcript, data were normalized to the untreated samples 
(100% internalization) and the ones kept at 4°C (no internalization).  
MCF-7 cells (2 x 105) (2.2.1) were washed with 500 µl 1 x HEPES internalization buffer 
(Table  2-2) and incubated with 400 nM FITC-labeled aptamer-siRNA in 1 x HEPES binding 
buffer supplemented with 16 mM glucose. The “no internalization” controls for each transcript 
were kept on ice. All other samples were incubated in the dark at 37°C for 30 min, 60 min, 90 
min, 120 min, 12 h and 24 h. All samples were initially analyzed by confocal microscopy 
without proteinase K treatment. To stain the nucleus, cells were incubated with DRAQ5TM. 
Cells were then washed to remove unbound FITC-labeled RNA transcripts and afterwards 
resuspended in 100 µl PBS before incubating for 2 min at 37°C in 10 µM DRAQ5TM. Finally, 
10µl stained cell suspension was transferred to a cover slide for confocal microscopy (0).  
For flow cytometric analysis (2.2.5.1), cells were prepared as described above for xPSM-A10 
transcripts. Cells were incubated with RNA transcripts for 30, 60, 90 or 120 min at 37°C. At 
the end of the incubation, cells were cooled on ice for 5 min. In order to degrade cell surface 
Her3 and to remove aptamer-siRNA transcripts bound to Her3, 0.5 mg/mL proteinase K was 
added to the cells in 1 x HEPES binding buffer.  
2.2.5.4 Interferon β assay 
Interferon β secreted into the medium of treated and untreated LNCaP/MCF-7 and PC-
3/MDA-231 cells was detected using a human interferon β ELISA kit following the 
manufacturer’s recommendations (PBL, Biomedical Laboratories). Briefly, cells were seeded 
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at 1-3 x 104 cells/well (2.2.1) in 96-well plates and incubated overnight at 37°C. The following 
day, 1 µM aptamer-siRNA transcript was added to the cells and incubated for a further 48 h 
(final volume 150 µl). Then 100 µl of the supernatant was transferred to a pre-coated ELISA 
plate and incubated for 24 h at room temperature. Interferon β was detected using a specific 
antibody following the manufacturer’s recommendations. 
2.2.5.5 DICER cleavage assay 
Each aptamer-siRNA (25 pmol) was incubated with recombinant human TURBO DICER for 
2h at 37°C or human DICER kit for 3h at 37°C according to the manufacturer’s 
recommendations (recombinant human TURBO DICER and human DICER kit, Peqlab). 
Samples were then separated by electrophoresis on a 12 % (w/v) nondenaturing PAGE gel 
(2.2.2.4). After ethidium bromide staining (2.2.2.1), bands were visualized using a 
GELDOCXR image analyzer (BioRad) (0). 
2.2.5.6 Apoptosis assay 
LNCaP and MCF-7 cells were analyzed using the Apo-ONE caspase-3/7 assay (Promega). 
Briefly, cells were seeded in 96-well plates (Greiner) at a density of 1 x 104 cells per well in 
100 µl RPMI 1640 medium, and were allowed to attach overnight at 37°C. Transcripts or 
siRNAs were added at 1 µM in triplicates (100 µl final volume per well). After 48 h, 100 µl of 
Apo-ONE reagent was added and incubated overnight before the optical density was 
measured at 485-535 nm using an ELISA plate reader (0). Data represent the average of 
triplicates ± SEM. 
2.3 Methods for immunokinases 
2.3.1 Construction of Immunokinases 
2.3.1.1 Bacterial strains and oligonucleotides 
Escherichia coli strain XL1-blue (Stratagene Europe, Amsterdam, Netherlands) was used for 
the cloning, maintenance and propagation of plasmids according to the manufacturer’s 
instructions. The template plasmid pCMV6-XL4 (Origene Technologies, Rockville, Maryland, 
United States) contained the human DAPK2 cDNA (accession no. NM_014326.3). Synthetic 
oligonucleotides were synthesized by MWG Biotech (Ebersberg, Germany) (Table  7-2).  
2.3.1.2 Polymerase chain reaction 
The pCMV6-XL4 vector was used for the amplification of DAPK2∆73 (Table  7-5). PCR was 
carried out using the Phusion High Fidelity DNA polymerase (NEB) in a 50-µl reaction 
volume. 
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Table  2-12 Polymerase chain reaction composition 
Component Final concentration 
Template DNA 1 ng 
5x Phusion HF buffer 10µl 
10mM dNTP 1µl 
5’ forward primer 0,5µM 
3’ backward primer 0,5µM 
Taq DNA polymerase 0,5µl 
The following PCR protocol was applied for the amplification reaction:  
Table  2-13 PCR amplification protocol 
 temperature [°C] time [sec] step  
1. 95 30 initial denaturation  
2. 95 10 denaturation 
3. Tanneal 30 primer annealing 
4. 72 30 elongation 
 
     25 cycles 
5. 72 10min final elongation  
2.3.1.3 Cloning 
Plasmids (2.3.1.1) were prepared by alkaline lysis and purified using kits from Qiagen 
(Hilden, Germany). Plasmids and PCR products (2.3.1.2) were separated by horizontal 
agarose gel electrophoresis (2.2.2.1) and isolated with the QIAquick Gel Extraction Kit 
(Qiagen, Hilden, Germany). Cloning was carried out according to standard methods, using 
eukaryotic expression vector pMS, which is derived from pSec-Tag2 (Invitrogen). The sense 
and antisense primers (Table  7-2) were used to amplify several DAPK2∆73 (DAPK2∆CaM) 
PCR products from the template plasmid pCMV6-XL4 and introduced appropriate restriction 
sites. The PCR fragment was digested with XbaI and BlpI (Cel II for Roche) or XbaI and NotI, 
then gel-purified and inserted into the corresponding restriction sites of pMS-L-EGb-CD30L-
IV, which carried the CD30L sequence. The resulting plasmids were named pMS-DAPK2′-
CD30L (accession no. EU447259). Control constructs named pMS-DAPK2′, lacking the 
CD30 binding domain and pMS-SNAP-CD30L (cloned by Florian Kampmeier), lacking the 
DAPK2’ domain, were generated using the XbaI and NotI or XbaI and BlpI restriction sites, 
respectively. The plasmid constructs were verified by DNA sequencing. 
2.3.1.4 Eukaryotic cell transfection and recombinant protein production 
The transient transfection of 293T cells (2.2.1) was carried out in standard 12-well cell-
culture plates using 10 µl Rotifect (Carl-Roth, Karlsruhe, Germany) and 2 µg plasmid DNA 
(2.3.1.3) according to the manufacturer’s instructions. The transfection efficiency (60-85%) 
was determined by counting green fluorescent cells. Three days after transfection, cell 
culture supernatants were analyzed for secreted functional recombinant fusion protein. The 
transfected cells were then transferred into 85-cm2 cell culture flasks (Nunc, Wiesbaden, 
Germany) and grown in RPMI complex medium supplemented with 100 mg/mL Zeocin. After 
1-2 weeks, transfected clones were detected by fluorescence microscopy and sub-cultivated 
to establish transfected cell populations. 
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2.3.1.5 Nucleofection of eukaryotic cells 
To analyze the effects of DAPK2 expression in DAPK2-deficient cells (2.3.1.4), L540 and 
U937 cells were transfected with the plasmid pMS-DAPK2∆73 using the Nucleofection 
technique. The pMS-Egb-CD30L vector was used as a positive control. The pmaxGFP vector 
(Amaxa) was used to examine the transfection rate and as a negative control. Transfection 
was carried out according to the manufacturer’s recommendations. 
2.3.1.6 Protein purification 
Purification of His-tagged proteins was accomplished by the nickel-nitrilotriacetic acid (Ni–
NTA) metal-affinity chromatography method (Qiagen). Protein purification was carried out 
essentially according to the manufacturer’s instructions. For protein mini-scale preparation, 
900 µl 293T cell culture supernatant (2.3.1.4) cleared by centrifugation was supplemented 
with 300 µl 4x incubation buffer (200 mM NaH2PO4, pH 8.0; 1.2 M NaCl, 40 mM imidazole) 
and 30 µl 50% (v/v) Talon metal affinity resin (BD Biosciences, Heidelberg, Germany) (Table  
2-3). After 1-h incubation, the Talon resin was pelleted by centrifugation (700 x g, 5 min) and 
the sediment was washed twice in 175 µl 1x incubation buffer. Bound protein was eluted with 
300 µl of elution buffer (50 mM NaH2PO4, pH 8.0; 300 mM NaCl, 250 mM imidazole) for 20 
min at room temperature. Large-scale protein purification from up to 500 ml 293T cell culture 
supernatant was performed on a BioLogic workstation (Bio-Rad, Munich, Germany) (0). Cell 
culture supernatants were loaded onto an equilibrated Ni–NTA column, and bound His-
tagged recombinant proteins were eluted under the conditions described above. Re-buffering 
of the recombinant protein in PBS was carried out using a Slide-A-Lyzer dialyze cassette 
(Pierce, Rockford, Illinois, United States). Total protein concentration was determined using 
the Bio-Rad DC protein assay kit.  
2.3.1.7 SDS-PAGE and Western Blot analysis (2.2.2.2, 2.2.3.7) 
The amount of expressed protein (2.3.1.6) in each sample was determined by densitometry 
from SDS-polyacrylamide gels (2.2.2.2) stained with Coomassie Brilliant Blue G250 (Table  
2-1). In addition, the gel-separated protein extract was immunoblotted and detected using a 
horseradish peroxidase-conjugated monoclonal anti-Penta-His antibody (Qiagen) followed by 
visualization using Sigma Fast chemiluminescence (Sigma-Aldrich).  
2.3.1.8 Mass spectrometry 
For mass spectrometry, the protein gel band (2.2.2.2) was excised, washed in water, 
reduced with DTT, alkylated with iodoacetamide and digested with trypsin (5). Peptide 
analysis was carried out using a nanoHPLC (Dionex, Germering, Germany)/ESI-Q-TOF-2 
mass spectrometer (Waters Micromass, Eschborn, Germany). The sequences of individual 
peptides were identified using the Mascot algorithm (Matrix Science, London, United 
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Kingdom) to search and correlate the MS/MS spectra with amino acid sequences in the 
protein database.    
2.3.2 Methods for screening different cell lines for DAPK2 expression 
2.3.2.1 Western blot analysis of cell lysates 
Hodgkin lymphoma cells (1-2 x 106; DAC-treated or untreated) (2.3.2.4, 2.2.1) were washed 
and pelleted by centrifugation, and then incubated in 100 µl RIPA lysis buffer (150 mM NaCl, 
1.0% (v/v) NP-40, 0.5% sodium deoxycholate (v/v), 0.1% SDS, 50 mM Tris, pH 8.0) 
containing protease inhibitors (CompleteTM, Roche, Mannheim, Germany) for 30 min at 4°C 
with constant agitation. The cell extracts were centrifuged for 20 min at 12,000 x g, 4°C. The 
supernatant protein concentration was determined by the Bradford assay and 20 µg of boiled 
protein extract was separated by 12% (v/v) SDS-PAGE, transferred onto nitrocellulose 
membranes, blocked with 4% (w/v) milk powder in PBS containing 0.05% Tween-20 (PBST) 
for 1 h at room temperature and incubated overnight with the primary mouse anti-human 
DAPK2 antibody (BIOZOL, Eching, Germany) according to the manufacturer’s instructions. 
Anti-human β-tubulin antibody (Abcam, Cambridge, United Kingdom) was used as the 
loading control. After several washing steps, the membrane was incubated with a secondary 
goat anti-mouse HRPO antibody (Sigma-Aldrich) for 1 h at room temperature followed by 
visualization using the ECL chemiluminescence Detection Kit (Pierce). 
2.3.2.2 DNA isolation, bisulfite treatment and methylation-specific PCR 
The methylation status of the DAPK2 promoter region was analyzed using methylation-
specific PCR (MSP). Approximately 1 µg of genomic DNA was treated with sodium bisulfite 
as previously described and subjected to MSP using primers specifically recognizing the 
unmethylated DAPK2 sequence and the methylated sequence (Table  7-1). PCR-reactions 
were hot-started at 95°C for 5 min and held at 80°C before adding 0.625 U Taq DNA 
polymerase (Sigma-Aldrich) and carrying out 35 cycles at 95°C for 30 s, 58°C for 30 s and 
72°C for 30 s, followed by a final extension step at 72°C for 5 min. Normal DNA from 
peripheral blood was treated in vitro with SssI methyltransferase (New England Biolabs, 
Frankfurt, Germany) in order to generate a positive control for methylated DAPK2 alleles 
[122]. PCR products were separated on 2.5% (w/v) agarose gels and visualized by ethidium 
bromide staining (2.2.2.1). 
2.3.2.3 RNA isolation and reverse transcription polymerase chain reaction (RT-PCR) 
Total RNA was isolated using a Qiagen kit (2.2.3.3) and 1 µg of total RNA was reverse 
transcribed using SuperScript II reverse transcriptase (Invitrogen) according to the 
manufacturer’s instructions in a 20 µl final volume. For PCR, cDNA was amplified using 
DAPK2 sense and antisense primers (Table  7-1) in a 25 µl final volume with a primer 
concentration of 0.8 µM and 1.25 U of TaqGold (PE Applied Biosystems, Weiterstadt, 
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Germany). RNA from the housekeeping gene GAPDH was amplified using primers provided 
in a commercially available kit (Applied Biosystems) and commercially available human RNA 
(Applied Biosystems) served as control for the reverse transcription reaction and PCR. 
Cycling conditions for DAPK2 comprised an initial activation step at 95°C for 10 min followed 
by 36 cycles of 95°C for 15 s, 60°C for 30 s and 72°C for 30 s, and then a final extension 
step at 72°C for 5 min. For GAPDH, the cycling conditions comprised an initial activation step 
at 95°C for 10 min followed by 30 cycles of 95°C for 15 s, 60°C for 30 s and 72°C for 30 s, 
then a final extension step at 72°C for 5 min. 
2.3.2.4 Drug treatment 
L540 cells (2.2.1) were treated with the demethylating drug DAC (Sigma-Aldrich, Steinheim, 
Germany) at final concentrations of 1.0, 2.0 and 4.0 µM for 96 h, and then harvested for RNA 
and DNA isolation. 
2.3.3 Methods for Immunokinase evaluation  
2.3.3.1 in vitro kinase assay 
Purified DAPK2′-CD30L fusion protein was analyzed with an in vitro kinase assay, based on 
phosporylation of the myosin light chain (MLC), using the PKLight® assay kit according to the 
manufacturer’s instructions (Lonza, Rockland, United States). Purified DAPK2′-CD30L, and 
its recombinant derivatives DAPK2′ and CD30L′ as controls, were incubated in kinase 
reaction buffer (40 mM Tris-HCl pH7.5, 20 mM MgCl2, 0.1% (w/v) BSA, 5 µM MLC and 2.5 
µM ATP) while the kit’s internal positive control kinase, cyclic AMP-dependent protein kinase 
(PKA) was incubated in kinase reaction buffer as above, but including 5 µM kemptide and 1 
µM ATP. After 20-min incubation, the bioluminescent signal (which is inversely proportional 
to kinase activity) was measured in the Modulus Microplate Luminometer (Turner 
Biosystems).  
2.3.3.2 Flow cytometric binding assay 
Specific binding of the expressed DAPK2′-CD30L fusion protein (2.3.1.6) to CD30+ cell lines 
was determined by flow cytometry. Briefly, 5 x 105 CD30+ L540, L1236 and L428 cells and 
CD30- U937, HD-MY-Z, MCF-7, LNCaP and 293T control cells (2.2.1) were washed twice in 
ice-cold PBS and resuspended in 500 µl PBS. After adding 50 µl of the protein sample (0.12 
µg/µl), cells were incubated for 30 min on ice followed by two additional washing steps. 
Bound protein was then labeled with the monoclonal anti-His5 Alexa Fluor 488 secondary 
antibody (Qiagen) which recognizes the histidine tag of the recombinant fusion protein. Flow 
cytometric profiles were acquired based on the analysis of at least 10,000 events in a 
FACSCalibur (Becton Dickinson, Heidelberg, Germany).  
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2.3.3.3 Cell-surface affinity measurements 
The functional affinity to cellular CD30 was determined using a flow cytometry-based 
saturation binding method. The DAPK2′-CD30L fusion protein (2.3.1.6) was FITC-labeled at 
a 1:50 ratio (protein/FITC) and incubated in PBS at 4°C overnight according to the 
manufactorers’ recommandations. Labeled protein was separated from unbound FITC using 
Nanosep ME ultrafiltration columns (Pall, New York, United States). L540 and L1236 cells 
(2.2.1) were stained with different dilutions of FITC-labeled DAPK2′-CD30L fusion protein in 
PBS for 45 min at 4°C. Cells were washed and protein binding was analyzed in a 
FACSCalibur (2.3.3.2). Background fluorescence was subtracted prior to data collection. To 
determine the dissociation constant (KD), the mean fluorescence intensity (MFI) was plotted 
versus immunokinase concentration and analyzed using the Marquardt-Levenberg algorithm 
for non linear regression with Prism software (GraphPad software, San Diego, California, 
United States).   
2.3.3.4 Proliferation assay (2.2.3.8) 
The cytotoxic effect of the DAPK2′-CD30L immunokinase (2.3.1.6) on L540, L1236 and L428 
target cells, and HD-MY-Z, U937, MCF-7, LNCaP and 293T control cells (2.2.1) was 
determined by measuring the conversion of XTT into a water-soluble orange formazan dye 
using a commercially available proliferation kit (XTT Proliferation Kit II, Roche, Mannheim, 
Germany). Briefly, various dilutions of the recombinant immunokinase fusion protein were 
distributed in 100 µl aliquots in 96-well plates. A total of 1 x 104 target cells (2.2.1) were added 
in 100 µl aliquots of culture medium, and the plates were incubated for 48 h at 37°C. The 
cells were then pulsed with 50 µl fresh XTT/phenazine methosulfate for 6 h according to the 
manufacturer’s instructions. The spectrophotometric absorbance of the samples was 
measured at 450 and 650 nm (reference wavelength) with an ELISA reader (Molecular 
Devices, Ismaning, Germany). The concentration required to achieve a 50% reduction in 
protein synthesis (IC50)
 relative to untreated control cells was calculated using GraphPad 
Prism software (GraphPad). All measurements were performed in triplicate.  
2.3.3.5 Apoptosis assay 
Approximately 5 x 105 L540 or U937 control cells (2.2.1) per well were seeded in flat-
bottomed 12-well plates in RPMI 1640 supplemented with 10% (v/v) FCS in triplicate. A total 
of 360 ng/ml (~5.1 nM) immunokinase fusion protein (2.3.1.6) was added to each well, and 
the cells were cultured for 24 h at 37°C in a 5% CO2 air atmosphere. Apoptotic cells were 
detected using the Annexin V-FITC apoptosis detection kit I (BD PharMingen, San Diego, 
California, United States) according to the manufacturer’s protocol. Briefly, 1 x 105 target 
cells were incubated simultaneously with FITC-conjugated Annexin V (AnnV) and propidium 
iodide (PI) in 1x binding buffer, and were analyzed by flow cytometry. The AnnV-/PI- (R1), 
AnnV+/PI- (R2), AnnV+/PI+ (R3) and AnnV-/PI+ (R4) subpopulations were counted.  
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2.3.3.6 in vitro mouse serum stability 
To determine the serum stability of DAPK2′-CD30L (2.3.1.6), 100 µg/ml of the purified 
immunokinase fusion protein was incubated with 50% (v/v) normal mouse serum at 37°C in 
PBS for different time periods (0, 4, 8, 12, 24 and 48 h). To measure the amount of functional 
protein remaining after incubation in mouse serum, samples were separated by 12% (w/v) 
SDS-PAGE (2.2.2.2) and analyzed by western blot (2.3.1.7) and flow cytometry (2.3.3.2) as 
described.  
2.3.4 Animal experiments 
2.3.4.1 in vivo SCID mouse studies 
Female C.B.-17 NOD/SCID mice were purchased from Jackson Laboratories (Bar Harbor, 
Maine, United States) and were used at an age of to 6-8 weeks. For DAPK2′-CD30L therapy 
studies, 30 SCID mice were injected intravenously through the tail vein with 1 x 107 L540 
cells (2.2.1) on day 0. The mice were then randomly distributed into groups of 10 and 
received treatment with a PBS control, an irrelevant immunokinase DAPK2′-H22(scFv) 
(2.3.1.6) or with the MTD of DAPK2′-CD30L (2.3.1.6), starting 24 h after injection of L540 
cells. Animals were killed at the onset of hind leg paralysis and/or 20% weight loss. Complete 
antitumor responses were defined as animals that survived for greater than 120 d with no 
symptoms.     
2.3.4.2 Histological procedures 
Tissues from DAPK2′-CD30L-treated (2.3.4.1) and PBS-treated SCID mice (2.3.4.1) were 
fixed with 4% (v/v) formaldehyde for 1 d and washed with PBS. The tissues were dehydrated 
overnight, embedded in paraffin and serial sections 3 µm in thickness were cut. After heat-
pretreatment with EDTA buffer (pH 8) tissue slides were washed with PBS. To avoid 
nonspecific binding, the slides were incubated with avidin and biotin (Avidin/Biotin Blocking 
Kit, Vector) according to the manufacturer’s instructions, and then in rabbit serum diluted 
1:10 in PBS containing 1% milk powder. The slides were incubated with the primary mouse 
anti-human CD30 antibody (Dianova, Hamburg, Germany) diluted 1:70 in PBS containing 1% 
(w/v) milk powder for 1 h at 37°C. After several PBS washes, slides were incubated with the 
secondary biotin-labeled rabbit anti-mouse antibody (DAKO, Hamburg, Germany) diluted 
1:300 in PBS containing 1% (w/v) milk powder for 30 min at room temperature. Sections 
were washed several times in PBS and then treated with 100 µl ABC-Complex solution 
(Vectastain ABC Kit, Vectorlabs, United Kingdom) for 30 min at room temperature. To 
visualize bound antibody complexes, tissue sections were incubated with activated DAB-
solution (Sigma-Aldrich) for 5 min, washed again with water and finally treated with 
‘Hämalaun’ solution for 18 s to visualize cell nuclei by fluorescent microscopy (2.2.3.2). 
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2.3.4.3 Data analysis 
Statistical analyses and curve fitting were performed with GraphPad Prism software 
(GraphPad software). Data are presented as mean ± standard deviation (SD). The Student’s 
t-test and one-way ANOVA were used to assess the significance of independent 
experiments. Overall survival was calculated using the method of Kaplan-Meier, and a 
comparison between groups was carried out with the log-rank test using the SPSS statistical 
software (14.0) program (SPSS GmbH, Munich, Germany). The criterion p < 0.05 was used 
to determine statistical significance.  
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3 Results 
3.1 Characterization of siRNA targeting different genes 
For all experiments analyzing the activity of siRNAs targeting EEF2 in LNCaP and PC-3 cells 
Dr. Ulrich Wüllner (SCRIPPS, San Diego, USA) and I worked closely together so that it was 
not possible to split up all data. There are some pictures that will be found in both theses 
because they were generated together or are content of our common publication [99]. 
3.1.1 Transfection efficiency 
The evaluation of new siRNA sequences requires efficient and reliable transfection protocols 
to achieve the strongest gene silencing effects. Many protocols and reagents have been 
developed for the transfection of siRNAs into eukaryotic cell lines. Transfection efficiencies 
were determined by flow cytometry and fluorescence microscopy using FITC-labeled siRNAs 
transfected at a concentration of 200 nM with different transfection protocols. After a 12-h 
incubation, cells were washed twice and the relative amount of shifted cells in channel FL-1 
in G1 was monitored via flow cytometry.  
 
Fig.  3-1   Flow cytometric analysis of cells transfected with FITC-labeled siRNA. Cells were transfected with 200 
nM siRNA (2.2.3.1). After 12 h, cells were washed twice with 1x PBS and the fluorescence in FL-1 
(FITC) was analyzed. (A) MCF-7 cells showed > 95% transfection efficiency in FL-1. (B) MDA-MB-231 
cells showed > 90% transfection efficiency in FL-1. 
Fig. 3-1 shows the transfection efficiency when 200 nM FITC-labeled siRNA was introduced 
into MCF-7 and MDA-MB-231 cells using the lipofection solution Hiperfect (Qiagen). After a 
12-h incubation, more than 90% of both cell lines were stained.  
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Fig.  3-2   Analysis of transfection efficiencies by fluorescence microscopy (2.2.3.2). LNCaP cells were transfected 
with FITC-labeled siRNA at a concentration of 200 nM using Hiperfect (2.2.3.1). 12 h after transfection, 
the cells were washed and analyzed visually. (A) LNCaP cells under wight light. (B) LNCaP cells under 
green fluorescent light. (C) overlay of A and B. Specific intracellular FITC staining was detected. 
Pictures were generated together with Dr. Ulrich Wüllner who already presented these pictures in his 
PhD thesis. 
Fig.  3-2  provides an example of the transfection of 200 nM FITC-labeled siRNA into LNCaP 
cells. After 12 h, more than 90% of LNCaP cells were stained by the labeled siRNA indicating 
a high transfection efficiency. Most of the cell lines could be transfected efficiently with 
RNAifect. Table  3-1 summarizes the transfection efficiencies obtained.  
Table  3-1 Transfection efficiencies obtained for various cell lines 
Cell line  Transfection reagent Protocol Transfection efficiency 
LNCaP RNAifect standard > 90 % 
PC-3 RNAifect standard > 90 % 
MCF-7 RNAifect standard > 95 % 
MDA-MB-231 RNAifect standard > 90 % 
3.1.2 Establishment of a q-PCR protocol for mRNA expression 
To determine the efficacy of siRNAs against their target genes, the degradation of target 
mRNA after the application of siRNA needs to be tested. The mRNA expression levels were 
evaluated by quantitative real time RT-PCR (qPCR).  
In cooperation with the Max-Planck-Institute in Berlin, five highly potent siRNA sequences 
were identified: siPLK1-1, siPLK1-2, siGRK4-1, siGRK4-2 and siSKIP5. All siRNAs 
specifically induced apoptosis following degradation of their target mRNAs. The sixth and 
seventh siRNA sequences target eukaryotic elongation factor 2, an essential house-keeping 
gene for protein biosynthesis. 
A qPCR protocol has been established for the analysis of EEF2 mRNA expression in cancer-
derived cell lines together with Dr. Ulrich Wüllner. Gene-specific primers flanking the 
predicted siRNA cleavage site were synthesized according to common primer design 
standards for qPCR applications. The length of the expected PCR product was 221 bp. In 
order to ensure highly specific amplification, both primer sequences were analyzed for 
matches to unrelated genes using the basic local alignment search tool (BLAST; 
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http://www.ncbi.nlm.nih.gov/BLAST ). No significant homology to any sequence in the human 
genome was found.  
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Fig.  3-3   RT-PCR of siRNA transfected cells. (A) Ethidium bromide stained 2% (w/v) agarose gel (2.2.2.1) after 
RT-PCR using EEF2-specific primers. Total RNA was isolated from 2x 10
5
 LNCaP cells and cDNA 
synthesis was carried out with random hexamer primers (2.2.3.4). From this reaction, 1 µL was used as 
template DNA for the subsequent PCR amplification (2.2.4.3). Lanes 1-3: Cells were transfected with 
150 nM siEEF2-2. Lanes 4-6: Cells under normal growing conditions. A stronger 220-bp PCR product 
was observed than in lanes 1-3. Lane 7: negative control, with 1 µL of isolated RNA as the template 
(confirming the absence of contaminating DNA). (B) Inhibition of mRNA expression. Compared to cells 
under normal growing conditions cells transfected with 150 nM siRNA against eEF2 expressed less of 
the target mRNA. Experiment was performed together with Dr. Ulrich Wüllner. Data already presented 
in his PhD thesis 
The predicted cleavage site of siEEF2 and thus the RT-PCR primer binding sites were 
located close to the 5’ end of the EEF2 mRNA (which is ~12 kb in length). The cDNA 
synthesis reaction was therefore carried out using random hexamers as reverse transcription 
primers because the length limit for oligo dT primers was in the range of 12-13 kb.  
Optimal PCR reaction conditions were determined by systematically varying the following 
parameters starting from a standard PCR protocol (2.2.4.3).  
To transfer these conditions to the LightCycler ® 2.0 Real-Time PCR System we initiated the 
experiments using SYBR Green. The experiments were performed in close collaboration to 
the Department of Virology at the University Hospital Aachen under the supervision of Dr. 
Michael Kleines.  
Because specific amplification of EEF2 mRNA by RT-PCR was demonstrated previously, the 
nonselective staining of unrelated amplification products was not an issue. SYBR-Green 
fluorescence was used for all subsequent experiments involving mRNA analysis.  
3.1.3 Gene silencing efficiency of siEEF2 sequences 1 and 2 
After establishing the protocol for EEF2 mRNA quantitation, it was applied to test the gene 
silencing activity of two siRNA sequences targeting the EEF2 gene (siEEF2-1 and siEEF2-2). 
Both sequences were designed by Qiagen according the “HP OnGuard siRNA Design” 
algorithm(http://www1.qiagen.com/Products/GeneSilencing/HPOnGuardsiRNA Design.aspx). 
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In order to compare the potency of these siRNAs, their gene silencing activity was assayed 
in a dose-dependent manner. Prior to transfection, the synthetic siRNAs were resuspended 
and annealed according to the manufacturer’s recommendations. Transfections were carried 
out according to (2.2.3.1) in 96-well plates. Both sequences were transfected into 2x 104 
LNCaP cells at concentrations ranging from 300 to 10 nM. After a 12-h incubation at 37°C, 
cells were harvested and EEF2 mRNA levels were assayed (2.2.3.6).  
 
Fig.  3-4 The silencing activity of siEEF2 was monitored by quantitative RT-PCR (2.2.3.6). mRNA levels were 
normalized to GAPDH mRNA expression. (A) siRNAs were transfected into LNCaP cells at various 
concentrations (10–300 nM). EEF2 mRNA expression was quantified 12 h after transfection. Both 
sequences induced a dose dependent decrease in EEF2 mRNA levels. Sequence 2 (∀): IC50: 23.0 ± 
1.9 nM; Sequence 1(8): IC50: 76.0 ± 3.7 nM. (B) Transfection of an unrelated siRNA (light grey bar) at 
200 nM into LNCaP cells did not alter EEF2 mRNA expression. Transfection of siEEF2 seq 2 (grey) 
and siEEF2 seq1 (black) led to potent EEF2 mRNA degradation. Error bars represent SEM. n: 2. This 
picture is content of a joint publication [99]. The data was elaborated together with Dr. Ulrich Wüllner. 
As shown in Fig.  3-4A, both siRNAs induced dose dependent EEF2 mRNA degradation. 
siEEF2-2 proved to be approximately 3-fold more potent, with an IC50 value of 23.0 ± 1.9 nM 
compared to sequence 1 with an IC50 of 76.0 ± 3.7 nM. Both siRNAs showed a similar 
efficacy, reaching a maximum knockdown of EEF2 mRNA of approximately 80%. GAPDH 
was used as the non-silencing control for data normalization.  
To confirm these results, MCF-7 and MDA-MB-231 cells were transfected with 150 and 15 
nM siEEF2-1 and -2. To determine the efficacy of the other five siRNA sequences against 
PLK1, GRK4 and SKIP5, these were also transfected into MCF-7 and MDA-MB-231 cells.  
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Fig.  3-5   Relative mRNA expression of MCF-7 and MDA-MB-231 cells 12 h after the addition of siRNA (2.2.3.1) 
monitored via qPCR (2.2.3.6). mRNA levels were normalized to GAPDH mRNA expression. siRNAs 
were transfected into MCF-7 and MDA-MB-231 cells at two concentrations (15–150 nM). mRNA 
expression was quantified 12 h after transfection (2.2.3.3, 2.2.3.4). All sequences induced a dose-
dependent reduction in target mRNA levels. MCF-7 (grey) and MDA-MB-231 (black) cells showed 
specific sensitivity to all siRNA targets. Error bars represent SEM n: 3. 
As shown in Fig.  3-5, siEEF2-2 was also more effective than siEEF2-1 in MCF-7 and MDA-
MB-231 cells, and on this basis sequence 2 was selected for all subsequent experiments. 
The five additional siRNA sequences also achieved the highly potent degradation of their 
target mRNAs in both cell lines. An unrelated control (non-silencing) siRNA called siNON had 
no effect on any of the target mRNAs (Fig. 3-6 shows EEF2 expression as an example) 
confirming the sequence specificity of the active siRNAs.  
3.1.4 The impact of EEF2 knockdown at the protein level 
The specific knockdown of EEF2 mRNA should have a corresponding effect on the protein. 
For the siRNAs against PLK1, GRK4 and SKIP5, protein knockdown effects had already 
been demonstrated by Nikolaus Machuy from the Max Planck Institute in Berlin (internal data 
of the MPI, Berlin). To show the corresponding data for siEEF2-2, LNCaP and MCF-7 target 
cell lines were transfected with the siRNA at a concentration of 100 nM. After 12 and 24 h, 
the cells were lyzed and EEF2 protein levels were assayed by western blot using an EEF2-
specific polyclonal antibody (Cell Signalling Technologies) (2.2.3.7). As a negative control, 
100 nM of the non-silencing siRNA was transfected in parallel. As a positive control, a siRNA 
targeting mitogen activated protein kinase 1 (MAPK1) was transfected in parallel and MAPK1 
levels assayed by western blot with the MAPK1-specific Tag 100 antibody (Qiagen). The 
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housekeeping protein β-tubulin was used to normalize the data and was detected with an 
anti-human β-tubulin antibody (abcam). 
 
Fig.  3-6  Western blot analysis of EEF2 protein expression (2.2.3.7). siRNA was transfected into LNCaP and 
MCF-7 cells at a concentration of 100 nM (2.2.3.1). After 12 and 24 h, cells were lysed using NP-40 
and protein expression was analyzed by western blot. MAPK1, β-tubulin and EEF2 were detected with 
specific antibodies. Band intensities were quantified using AIDA Image analyzer software. Target 
protein expression was normalized to cells treated with the transfection agent alone. MAPK1 (grey 
bars), β-tubulin (black bars) and EEF2 expression (white bars) are shown. Error bars represent SEM. 
n: 3.  
A and B: Protein analysis 12 h after transfection showed a significant knockdown of EEF2 protein in siEEF2-
transfected LNCaP (A) and MCF-7 (B) cells. Control siRNA against MAPK1 reduced MAPK1 protein 
levels by up to 20%. Non-silencing siRNA (siNON) had no effect.  
C and D: Protein analysis 24 h after transfection showed a strong reduction of EEF2 levels in siEEF2-transfected 
LNCaP (C) and MCF-7 (D) cells. Since knockdown of EEF2 inhibits protein biosynthesis as a whole, 
MAPK1 and β-tubulin levels were also reduced. Control siRNA against MAPK1 reduced MAPK1 levels 
by up to 80%. Non-silencing siRNA (siNON) had no effect.  
E: Western blot analysis of MAPK1, EEF2 and β-tubulin, showing how the relative protein levels were calculated. 
E represents the western blots for the calculation of diagram C. 
The bar diagrams in Fig.  3-6 show the relative levels of EEF2, MAPK1 and β-tubulin as 
determined by western blot analysis after the transfection of 100 nM of siEEF2, siMAPK1 or 
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siNON into LNCaP and MCF-7 cells after 12 and 24 h. The band intensities were quantified 
by the AIDA image analyzer software and were normalized to the band intensities observed 
for samples treated with transfection agent alone (Fig.  3-6 A-D). White bars represent EEF2, 
grey bars MAPK1 and black bars β-tubulin.  
Twelve hours after transfection with siRNAs targeting MAPK1, the levels of MAPK1 protein 
were reduced by about 20% whereas EEF2 levels were not affected (Fig.  3-6 A and B). 
Transfection with siEEF2-2 reduced EEF2 levels by 20-30%, whereas MAPK1 and β-tubulin 
were not affected, confirming the specificity of the siRNA. After 24 h, siMAPK1 had reduced 
MAPK1 levels by up to 85%. Transfection with siEEF2 caused a significant reduction in 
EEF2 levels, but MAPK1 and β-tubulin levels were also reduced (Fig.  3-6 C and D). This 
was expected because the efficient knockdown of EEF2 should inhibit general protein 
biosynthesis, which in turn should affect the levels of untargeted proteins. 
3.1.5 Evaluation of the cytotoxic siRNAs 
In addition to the siRNA against EEF2, siRNAs against the mitotic regulator PLK1, the GPCR 
regulator GRK4 and the SKIP5 protein are also expected to induce apoptosis due to the 
essential nature of the target proteins in signaling, the cell cycle and protein turnover (1.11). 
To examine whether the siRNA-mediated depletion of these proteins did induce apoptosis, a 
colorimetric cell viability assay based on the activity of mitochondrial enzymes present in 
viable cells was carried out 48 h after transfection. The siRNAs were transfected into LNCaP, 
MCF-7 and MDA-MB-231 cell lines at concentrations ranging from 0.002–2 µM.  
Results                                                                                                                                                 65 
 
Fig.  3-7 XTT-viability assay on MCF-7 (A) and MDA-231 (B) cells (2.2.3.8) transfected with different 
concentrations of siRNA using RNAifect (Qiagen) (2.2.3.1). Cell viability was assayed 48 h after 
transfection. Data acquisition was performed after 6 h substrate incubation. Dose-dependent 
cytotoxicity was induced by siRNAs in both cell lines. Data represent the average of triplicate samples 
± SEM.  
Apoptosis was induced efficiently after siRNA transfection in all cell lines, although 
differences in cytotoxic effects were observed depending on the construct used. MCF-7 cells 
were highly sensitive towards siPLK1-1, siEEF2-2 and siSKIP5 treatment, whereas MDA-
MB-231 cells were most potently affected by siGRK4-1 and siEEF2-2. The control constructs 
siTOX (positive) and siNON (negative) had the anticipated effects. The siEEF2 construct 
showed the most potent effects in LNCap cells, but dose-dependent siEEF2 cytotoxicity was 
observed in LNCaP, PC-3 and MCF-7 cells (Fig.  3-8).  
Results                                                                                                                                                 66 
 
Fig.  3-8  Cell viability assay of transfected cells. (A) XTT Viability Assay of transfected LNCaP(●) and MCF-7 (▼) 
cells (2.2.3.8). Cells were transfected with different concentrations of siEEF2 and siNON using 
RNAifect (Qiagen) (2.2.3.1). Dose-dependent cytotoxicity was induced by siEEF2 in both cell lines. The 
average half maximum inhibitory concentration (IC50) value was 80 nM in LNCaP cells and 150 nM in 
MCF-7 cells. siNON showed no cytotoxic activity in any concentration in both cell lines. Data represent 
the average of triplicate samples ± SEM. (B) represents an overview about the cytotoxic effects of 
siEEF2 in MCF-7 (black bars), in PC-3 (gry bars) and in LNCaP (white bars) cells in four different 
concentrations compared to a non-silencing siRNA applied in the same concentrations. Data represent 
the average of triplicate samples ± SEM. 
In contrast to the other targets, the knockdown of EEF2 appeared to work well regardless of 
the type of cancer, since both mammary carcinoma cell lines (MCF-7 and MDA-231) and 
prostate cancer cell lines (LNCaP and PC-3) were sensitive to the treatment. 
3.1.6 Summary 
Eukaryotic elongation factor 2, Polo-like kinase 1, G-protein coupled receptor kinase 4 and 
SKIP 1 interacting partner 5 are central components of every cell. The results presented here 
clearly demonstrate that siRNA sequences targeting these proteins efficiently induce the 
specific knockdown of mRNA and protein levels. All the siRNAs induced apoptosis in every 
cell line used, but the cells differed in their sensitivity towards each siRNA. Because siEEF2-
2 had the most potent effect on LNCaP cells, it was used for all subsequent experiments in 
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which aptamer siRNA transcripts were used to targeting cells displaying PSMA. In contrast to 
monovalent aptamer siRNA transcripts targeting HER3 positive MCF-7 cells where applied 
siRNA sequences were used. 
3.2 Evaluation of aptamer siRNA transcripts   
The design, synthesis and all experimental work involving the bivalent aptamer siRNA 
transcript xPSM-A3-siEEF2 were carried out by Dr. Ulrich Wüllner (SCRIPPS, San Diego, 
USA). A detailed description of the results of his experiments can be found in his PhD thesis. 
Data concerning xPSM-B1 and xPSM-B2 are presented here are for comparative analysis 
only and also do not form part of the practical work described in this thesis.    
3.2.1 Binding analysis of two specific RNA aptamers 
As stated above PSMA is a well-characterized tumor marker that is strongly expressed on 
the surface of LNCaP prostate carcinoma cells. It is constitutively internalized from the cell 
surface after ligand binding. In 2002, Lupold et al. presented a novel RNA ligand (aptamer), 
xPSM-A10-3, which was selected on the soluble extracellular domain of PSMA and was also 
proven to bind specifically to the natural antigen expressed on LNCaP cells.  
HER3 is a member of the EGFR family and is overexpressed together with HER2 in 20-30% 
of invasive breast cancers. In contrast to HER2, a well-characterized drug target for breast 
cancer cells, the kinase-deficient HER3 self-associates readily at low nanomolar 
concentrations and in the absence of its ligands, also associates with various isoforms of 
heregulin (Hrg) [123]. Hrg binding disrupts HER3 oligomerization and leads to the formation 
of signaling-competent heterodimers, preferentially with HER2. Chen et al. used the 
oligomeric state of the extracellular, soluble domain of HER3 for the selection of a 
nonmodified RNA aptamer, called A30, using the SELEX methodology. Binding of A30 and 
its natural ligand Hrg are not competitive. The specific binding of A30 to HER3 has yet to be 
demonstrated, and no internalizing activities have been observed. 
To check the specific binding of each aptamer, cells were first analyzed towards their antigen 
expression. As positive control cells were incubated with the anti-ErbB3 antibody (abcam) to 
determine the amount of HER3 on the cell surface (Fig.  3-9 C and D). 
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Fig.  3-9 Flow cytometry of both target cell lines for detection of surface antigen expression (2.2.5.1). Cells (2.2.1) 
were incubated with PSMA- and HER3-specific antibodies detected with the secondary antibodies 
either GAM-FITC (FITC/FL-1) or GAM-PE (Red/FL-2). (A) LNCaP cells were incubated with PSMA-
specific antibody for 30min on ice, washed and afterwards incubated with the secondary antibody for 
30min on ice in the dark (green line). As control LNCaP cells under normal growing conditions (red) 
and cells incubated with only secondary antibody (black line) were used. (B) shows the same 
experiment as in A but using PSMA-negative PC3 cells. (C) MCF-7 cells were incubated with HER3-
specific antibody  for 30min on ice, washed and afterwards incubated with the secondary antibody for 
30min on ice in the dark (black line). As control MCF-7 cells under normal growing conditions (red) and 
cells incubated with only secondary antibody (green line) were used. (D) shows the same experiment 
as in C but using HER3-negative L540 cells. 
The same experiment was performed with PSMA-positive LNCaP cells. LNCaP and PC-3 
cells were incubated with the PSMA-specific antibody 3C6 (Nothwest Biotherapeutics) as a 
positive control, to detect the amount of PSMA expression on the cell surface (Fig.  3-9 A 
and B). Both target antigens could be detected on the corresponding cell lines. 
3.2.2 Design and synthesis of novel aptamer siRNA transcripts 
Because the binding specificity of aptamers depends on their three-dimensional structure, it 
is important that aptamer siRNA transcripts retain the active conformation of the aptamer 
moiety. RNA secondary structure analysis was carried out using the Mfold server 
(http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/rna-form1.cgi), which predicts the 
secondary structure of single stranded RNA molecules by minimal free energy calculations.  
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Fig.  3-10 RNA secondary structure prediction for both monvalent aptamers x-PSM-A10-3 (A) and A30 (C) and 
two aptamer siRNA transcripts xPSM-A10-siEEF2 (B) and A30-siEEF2 (D) (2.2.4.1) using the Mfold 
server. The aptamers fold into a stable stem loop structure. The potential binding and siRNA domain 
are outlined. (E) The general design of a monovalent aptamer siRNA transcript (sen = sense, as = anti-
sense). 
The predicted secondary structure of the truncated anti-PSMA aptamer xPSM-A10-3 is 
shown in Fig.  3-10 A. The aptamer folds into a stable stem loop structure including three 
bulges of one, three and two nucleotides, respectively. It has previously been shown that the 
target-binding moiety is located in the boxed region. Therefore this characteristic folding motif 
must be retained after fusion to the siRNA. Fig.  3-10C shows the predicted secondary 
structure of the anti-HER3 aptamer A30. Three characteristic stem loops for the target-
binding moiety are visible and one smaller loop is present, which is necessary to stabilize the 
whole RNA structure. 
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Extensive folding analysis revealed the sequences that showed the greatest stability in terms 
of the secondary structure. After many sequences had been screened, those most suitable 
for combining different aptamers and siRNAs were identified (Fig.  3-11). 
 
Fig.  3-11 The modular system for aptamer siRNA construction. Primers 1-4 can be used for assembly PCR to 
generate the essential part of the transcript. The specific 5’ primer contains a T7 promoter region for 
subsequent in vitro transcription using T7 RNA polymerase. The 3’ primer contains the final siRNA 
sequence to complete the transcript. 
As all the transcripts were synthesized using one strand of DNA as the template for in vitro 
transcription the aptamer siRNA transcripts do not contain typical siRNAs, but rather shRNAs 
(small hairpin RNA). As shown in Fig.  3-10 B and D, the siRNA sense and antisense strands 
are linked by a short hairpin sequence. 
3.2.3 in vitro transcription of aptamer siRNA transcripts 
To synthesize the DNA templates for all aptamer siRNA transcripts, two PCRs were 
necessary. Starting with the assembly PCR, which fused four individual primers (Table 7-1) 
as shown in Fig.  3-11, the assembled DNA was completed using the 5’ primer containing the 
T7 RNA promoter and the specific 3’ primer containing the antisense siRNA sequence. 
Following amplification, all DNA templates were checked in a 2.5% (w/v) agarose gel stained 
with ethidium bromide . 
M         1             2           1             2             n    M 
PLK1                  GRK4          SKIP5     A30       GFP     EEF2
200bp
100bp
 
Fig.  3-12 Agarose gel electrophorese of DNA templates for all A30 aptamer siRNA transcripts (2.2.2.1, 2.2.4.2, 
2.2.4.3). All templates (PLK1 1-2, GRK4 1-2, SKIP5, GFP and EEF2) have a size of 160 bp expect the 
single aptamer, A30, i(101 bp). As marker NEB 2log ladder was used. Negative control (n): all 
components of the PCR Mastermix (2.2.4.3) except DNA template. 
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RNA transcripts were produced by in vitro transcription using purified DNA as the template 
(Fig.  3-12). As the aptamer xPSM-A10-3 was 2’F-modified, all aptamer siRNA transcripts 
were synthesized using the standard 20 µL DURASCRIBE transcription reaction, and the 
yield was 0.4–1 nmol. Aptamer A30 was unmodified. All transcripts containing this aptamer 
sequence were synthesized using the T7 RNA polymerase mix from Stratagene, and were 
visualized by UV shadowing on urea polyacrylamide gels (Fig.  3-13).  
GFP      EEF2    GRK4    GRK4     PLK1     PLK1    SKIP5
1            2            1            2
RNA
 
Fig.  3-13 8% (w/v) urea polyacrylamide gel of A30 siRNA transcripts visualized by UV shadowing (2.2.2.3, 
2.2.4.7).Using a certain amount of DNA templates (2.2.4.3) in vitro transcription was performed over 
night at 37°C. Then RNA samples were digested with 1µl DNAse for 30min. To load the samples on 
the gel, 0,5V 2x RNA denaturating loading buffer (Table 2-2).and heated for 1min at 94°C. RNA was 
visualized on a silica-gel plate by UV shadowing.  
All aptamer siRNA transcripts based on A30 and PSMA (data not shown) were transcribed 
successfully in vitro and high yields were achieved. The size and integrity of each transcript 
was confirmed by analytical denaturing PAGE.   
3.2.4 Analysis of aptamer siRNA binding specificity  
The next step was to investigate the binding characteristics of the monovalent aptamer 
siRNA transcripts by flow cytometry, with initial experiments designed to determine whether 
the binding specificity of the aptamers was retained in the aptamer siRNA transcripts. 
Therefore, the binding affinity of the xPSM-A10 and A30 transcripts was determined using 
PSMA positive LNCaP and PSMA negative PC-3 cells, and HER3 positive MCF-7 and HER3 
negative MDA-MB-231 cells.   
Binding analysis with the fluorescent aptamer siRNA transcripts was carried out as described 
in (2.2.5.2). The final concentration of FITC-labeled aptamer siRNA transcripts in these 
assays was 10 or 100 nM. The data for MCF-7 (A), LNCaP (B), MDA-MB-231 (C) and PC-3 
(D) cells are shown in Fig.  3-14. 
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Fig.  3-14 Flow cytometric analysis of FITC-labeled xPSM-A10 siRNA transcripts (2.2.4.9) binding to PSMA 
positive and negative cell lines (2.2.1) (2.2.5.1) and of FITC-labeled A30 siRNA transcripts binding to 
HER3 positive and negative cell lines. (A) HER3 positive MCF-7 cells were incubated 100nM (green 
line) and 10nM (blue line) monovalent A30 siRNA transcripts and showed a specific, dose-dependent 
shift in FL-1. (B) PSMA positive LNCaP cells were incubated with 100nM monovalent (black line) and 
two bivalent (green and blue line) xPSM-A10 siRNA transcripts showed a specific shift in FL-1. (C) 
HER3 negative MDA-MB-231 cells: no binding of A30 siRNA was observed. (D) PSMA negative PC-3 
cells: no shift was detectable for any aptamer construct.  
The HER3- and PSMA- specific aptamer siRNA transcripts showed binding activity to the 
corresponding antigen-positive cell lines MCF-7 and LNCaP (Fig.  3-14 A and B) whereas no 
binding activity was detected on the antigen-negative cell lines MDA-MB-231 and PC3 (Fig.  
3-14 C and D). These results clearly demonstrate that the aptamer siRNA transcripts that 
recognize PSMA and HER3 bind specifically to their targets. 
To further ensure the binding specificity of A30 and xPSM-A10 containing aptamer-siRNA 
transcripts we used the xPSM-A10-siEEF2 transcripts as nonbinding RNA control for MCF-7 
cells and A30-siEEF2 as nonbinding RNA control for LNCaP cells. Both RNAs were FITC 
labeled, purified and afterwards incubated with HER3-positive/PSMA-negative MCF-7 and 
HER3-negative/PSMA-positive LNCaP cells.  
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Fig.  3-15 Fow cytometric analysis of LNCaP and MCF-7 cells (2.2.5.1). (A) To exclude any unspecificity LNCaP 
cells were incubated with 100nM aptamer-siRNA transcript A30-siEEF2 (green line) or xPSM-A10-
siEEF2 (blue line). On LNCaP cells only the PSMA-specific transcript xPSM-A10-siEEF2 showed a 
binding signal. A30-siEEF2 did not bind to LNCaP cells. (B) The same experiment was performed with 
MCF-7 cells. On this cell line only A30-siEEF2 (blue line) bound to the cells. xPSM-A10-siEEF2 (green 
line) was used as negative control. 
As shown in Fig.  3-15 A xPSM-A10-siEEF2 specifically bound to PSMA expressing LNCaP 
cells. No binding of A30-siEEF2 could be detected on LNCaP cells. In contrast to Fig.  3-15 B 
where a specific binding of A30-siEEF2 to HER3 expressing MCF-7 cells could be observed. 
xPSM-A10-siEEF2 showed no binding to MCF-7 cells.  
3.2.5 Internalization assays 
Since ligands that bind PSMA on LNCaP cells are efficiently internalized, it was useful to 
establish whether the aptamer-siRNA transcripts behaved in the same manner. The 
internalization of xPSM-A10 was therefore monitored by flow cytometry with monovalent and 
bivalent transcripts provided from Dr. Ulrich Wüllner monitored in parallel. Cells were 
incubated with FITC-labeled aptamer siRNA transcripts as described in (2.2.5.3).  
The exclusion of fluorescence resulting from aptamers bound to the cell surface was very 
important, so a non-specific serine protease (proteinase K) was used to degrade cell surface 
proteins and remove surface ligands, as previously demonstrated [124, 125].  
LNCaP cells were incubated on ice (no internalization) with 400 nM FITC labeled aptamer 
siRNA transcripts for 1 h. After proteinase K treatment (0.5 mg/mL for 15 min on ice) cells 
were washed twice, resuspended in 1x binding buffer and analyzed by flow cytometry. The 
quantities of aptamer-siRNA internalized at 37°C were calculated from the percentage of 
cells shifted in the FL-1 (FITC) direction. Each sample was normalized to the no-
internalization control, which was kept at 0°C and served as the reference (0% value). The 
binding control sample, which was not treated with proteinase K, was set as the 100% 
internalization value. The results of these experiments are shown in Fig.  3-16. 
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Fig.  3-16 Flow cytometric internalization assay (2.2.5.3). FITC-labeled aptamer siRNA transcripts were incubated 
with LNCaP cells (2.2.1) at 37°C for 30 and 60 min. After removal of cell surface transcripts by 
proteinase K treatment, the relative amount of internalized aptamer siRNA transcripts was determined. 
After 30 and 60 min, 17% and 32% of the initially bound bivalent transcript, respectively, was 
internalized (white bars) whereas only 5% (30 min) and 8% (60 min) of monovalent xPSM-siEEF2 was 
internalized. Average values from three independent experiments are shown. Error bars represent 
SEM n = 3. This data is part of the common publication with Dr. Ulrich Wüllner [99]. 
A time-dependent increase in internalization was detected for both aptamer siRNA 
transcripts. Significantly more of the bivalent xPSM-B2-siEEF2 transcript was taken up at 
both time points. After 30 and 60 min, respectively, 17.4 ± 0.3% and 32.1 ± 3.7% of the 
initially bound xPSM-B2-siEEF2 was internalized. Only 5.5 ± 2.6% (30 min) and 8.46 ± 5.6%  
(60 min) of the monovalent xPSM-A3-siEEF2 was taken up by PSMA positive LNCaP cells.  
An unpaired students t-test indicated that p<0.05 at both time points, i.e. the differences were 
statistically significant.  
These results show that bivalent aptamer siRNA transcripts are taken up much more 
efficiently than a corresponding monovalent construct, apparently due to avidity effects 
(presented in the PhD theses of Dr. Ulrich Wüllner). Bivalency could therefore improve the 
performance of novel monvalent aptamer siRNA transcripts. 
As the internalization of aptamer A30 has yet to be studied, initial experiments were 
documented by confocal microscopy. HER3 positive MCF-7 and HER3 negative MDA-MB-
231 cells were incubated with 400 nM FITC-labeled RNA (2.2.4.9). The experiment was 
performed as described above but with different time points (30 min, 60 min, 90 min, 120 
min, 12 h and 24 h). After proteinase K treatment, cells were incubated with DRAQ5TM to co-
stain the nucleus (2.2.5.3). Then the cells were analyzed via confocal microscopy. 
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Fig.  3-17 Confocal microscopy of MCF-7 (A) and MDA-MB-231 (B) cells incubated with 400 nM FITC-labeled 
A30-siEEF2 (2.2.5.3) after 90 min. A. MCF-7 cells clearly showed the accumulation of FITC signals in 
the cytoplasm. B. In contrast, no strong signals could be detected in MDA-MB-231 cells. The slight 
background fluorescence represents free unbound FITC in the RNA sample. 
Fig.  3-17 shows the internalized aptamer siRNA transcripts after 90 min incubation at 37°C. 
After 30 and 60 min incubation, there was no increase in cytoplasmic FITC signals. Without 
proteinase K treatment, there was strong membrane staining in MCF-7 cells but not MDA-
MB-231 cells. After 120 min incubation, internalization was still detectable. After 12 and 24 h, 
there was high background fluorescence in the culture medium. After proteinase K treatment, 
no cytoplasmic FITC could be detected. 
Because no internalization was observed at any time point in HER3 negative MDA-MB-231 
cells, which were incubated in the same way as HER3 positive MCF-7 cells, this constitutes 
the first data showing HER-specific internalization after aptamer binding.  
To confirm these results, the same assay was carried out followed by flow cytometric 
analysis as described above for aptamer siRNA transcript xPSM-A10-siEEF2 on LNCaP 
cells. 
Results                                                                                                                                                 76 
 
Fig.  3-18 Flow cytometric internalization assay (2.2.5.3). FITC-labeled aptamer siRNA transcripts were incubated 
with MCF-7 and MDA-MB-231 cells (2.2.1) at 37°C for 30, 60, 90 and 120 min. After removal of cell 
surface transcripts by proteinase K treatment, the relative quantity of  internalized aptamer siRNA 
transcripts was determined. The greatest uptake was observed after 90 and 120 min incubation of 
HER3 positive MCF-7 cells. No significant signals were detected in the negative control line MDA-MB-
231. Average values are shown from three independent experiments. Error bars represent SEM. 
3.2.6 in vitro DICER assays 
Functional aptamer siRNAs must be recognized by the enzyme DICER following 
internalization. Recent publication showed that aptamer siRNA chimeras could only enter the 
RNAi pathway after processing by endogenous DICER. Therefore, it was important to 
determine whether all our transcripts were similarly processed to generate active siRNAs. An 
in vitro DICER cleavage assay was carried out using recombinant human DICER and 
TURBO DICER enzyme (Fig.  3-19 and Fig.  3-20). Equimolar amounts of aptamer siRNA 
transcripts were subjected to in vitro DICER processing (2.2.5.5).  
 
Fig.  3-19 in vitro DICER cleavage assay (2.2.5.5). Equimolar amounts of RNA (2.2.4.7) were incubated with 
recombinant human DICER for 3h at 37°C. Cleavage products were resolved on a nondenaturing 12% 
(w/v) polyacrylamide gel (2.2.2.4), and revealed by ethidium bromide staining (2.2.2.1). All aptamer 
siRNA transcripts were processed by DICER.   
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As shown in Fig. 3-19 xPSM-A3-siEEF2 was cleaved by DICER and resulted in cleavage 
products of ~25 and 21nt. Beside the aptamer siRNA transcript also the aptamer alone was 
processed by DICER. This result was conflictive to that presented by McNamarra et al. [102] 
where no cleavage of the aptamer without siRNA sequence was presented.  
Using the same assay for the unmodifed A30 siRNA transcripts no processed bands could 
be detected. By analyzing the processed aptamer siRNA transcripts, RNA could be detected 
but was completely digested (data not shown). Next step was to try the more potent and 
sensitive human TURBO DICER enzyme. 
 
Fig.  3-20 in vitro TURBO DICER cleavage assay (2.2.5.5). Equimolar amounts of RNA (2.2.4.7) were incubated 
with recombinant human TURBO DICER for 0, 1 and 2h at 37°C. Cleavage products were resolved on 
a nondenaturing 12% (w/v) polyacrylamide gel (2.2.2.4), and revealed by ethidium bromide staining. All 
aptamer siRNA transcripts were processed by DICER.  
In Fig. 3-20 is presented that the separation of cleaved products by nondenaturating 12% 
(w/v) gel electrophoresis clearly confirmed the processing of all aptamer siRNA transcripts by 
TURBO DICER. At 0h RNA showed nearly no cleavage. After 1h TURBO DICER started to 
digest RNA which resulted in bands of different lengths. Finally after 2h incubation transcripts 
were processed into fragments of approximately the size of an active siRNA (21–27 bp). 
When transcripts were incubated with TURBO DICER for longer than 2h at 37°C, RNA was 
again completely digested. The same experiment as presented in Fig. 3-20 but performed at 
room temperature resulted in completely undigested RNA even after 8h incubation (data not 
shown). 
3.2.7 Cytotoxic potential of the monovalent xPSM-A10 and A30 siRNA transcripts 
In section 3.1.5 it was shown that the cytotoxic siRNAs used induced specific mRNA 
degradation in transfected cells, ultimately inducing apoptosis. To establish whether the 
monovalent aptamer siRNA transcripts were able to produce functional siRNAs capable of 
inducing apoptosis through the same mechanism, MCF-7 cells were incubated with 15 and 
150 nM aptamer siRNA transcripts for 12 and 24h. Total RNA was isolated, cDNA synthesis 
was performed and qPCR was carried out to quantify EEF2 mRNA (2.2.3.6). After 12 h there 
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was little response in either LNCaP or MCF-7 cells (data not shown). After 24 h there was a 
significant knockdown effect on specific mRNA. GAPDH mRNA was used to normalize the 
results.  
 
Fig.  3-21 qPCR analysis of MCF-7 and LNCaP cells incubated with different aptamer-siRNA transcripts (2.2.3.6) 
(A) qPCR analysis of MCF-7 cells incubated with 150nM and 15nM aptamer-siRNA transcripts for 24h. 
As shown in the diagram all transcripts containing a siRNA targeting a specific mRNA selectively 
degradate specific mRNA levels. The controls A30 alone and A30 fused to a nonsilencing siRNA (A30-
siGFP) showed no effects. (B) qPCR analysis of LNCaP cells incubated with 200nM mono- and 
bivalent aptamer siRNA transcripts. Cells incubated with RNA containing siEEF2 showed specific 
reduction in corresponding mRNA expression levels after 24h. Cells incubated with nonsilencing 
controls remained uneffected. Data represent the average of triplicate samples ± SEM. 
These results confirm that the siRNA portion of the aptamer fusion retains its function and 
can induce RNAi specifically targeting mRNA (Fig.  3-21 A). The same experiment was 
performed on LNCaP cells (Fig.  3-21). Cells were incubated with 200nM mono- and bivalent 
aptamer siRNA transcripts. As already discussed in the PhD thesis of Dr. Ulrich Wüllner 
xPSM-A10-siEEF2 specifically reduced EEF2 mRNA expression level after 24h. As above, 
the next step was to determine whether silencing reduced the amount of available EEF2 
protein. Thus, LNCaP and MCF-7 cells were incubated with 100 nM aptamer siRNA 
transcripts for 12 and 24 h. Cells were lysed and assayed for EEF2 protein levels by western 
blot using the specific polyclonal anti-EEF2 antibody described above (2.2.3.7). The protein 
knock down for the other gene targets used could not be performed as the specific 
antibodies for protein detection were not available. A non-silencing aptamer-siGFP transcript 
(100 nM) was used as the negative control, and β-tubulin was used as a non-silencing 
control and was detected using an anti-human β-tubulin antibody (abcam). 
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Fig.  3-22 Western Blot analysis of LNCaP and MCF-7 cells incubated  siEEF2 containing aptamer-siRNA 
transcripts (2.2.3.7). After incubation with aptamer-siRNA transcripts cells were lyzed and analyzed 
towards the protein expression of EEF2 (white bars), MAPK1 (grey bars) and Beta-Tubulin as 
housekeeping gene (black bars). Band intensities were quantified using AIDA Image analyzer software. 
Target protein expression was normalized to cells treated with the transfection agent alone. (A) LNCaP 
cells were incubated with 100nM mono- and bivalent RNA targeting EEF2 mRNA. As controls mono- 
and bivalent RNA containing nonsilencing siRNA was used. (B) Same experiment was performed on 
MCF-7 cells incubated with 100nM aptamer-siRNA transcripts. As controls an aptamer-siRNA 
transcript containing a non-silencing siRNA and the aptamer alone were used. Data represent the 
average of triplicate samples ± SEM 
As shown Fig.  3-22 the aptamer siEEF2 transcripts specifically inhibited the expression of 
EEF2 protein.  
In the next experiment, the antigen specificity of xPSM-A10-siEEF2 was investigated by 
incubating 2 µM of the transcript with PSMA positive LNCaP and PSMA negative PC-3 cells 
in the absence of transfection agent at 37°C for 48 h. In parallel, cells were incubated with 
the bivalent transcripts from Dr. Ulrich Wüllner to compare their efficacy. Cell viability was 
then determined as described in (2.2.3.8). 
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Fig.  3-23 XTT viability assay (2.2.3.8) after aptamer siRNA application. (A) XTT viability assay after 48 h 
incubation of 2 µM bivalent aptamer siRNA transcripts on PSMA negative MCF-7 (grey bars) and PC-3 
cells (white bars) and on PSMA positive LNCaP cells (black bars) (2.2.1). Cytotoxic effects caused by 
xPSM-B1-siEEF2 and xPSM-B2-siEFE2 were restricted to the PSMA positive cell line. At a transcript 
concentration of 2 µM viability was reduced up to 95%. Mean values of triplicate experiments are 
shown (n:4, ± SEM). (B) Dose-dependent decrease of viability was achieved after 48h aptamer siRNA 
application. Mean values of triplicate experiments are shown (n:3, ± SEM). This picture contains data 
from the common publication with Dr. Ulrich Wüllner (99).   
These results clearly demonstrated that all aptamer siRNA transcripts (xPSM-A10-siEEF2, 
xPSM-B1-siEEF2 and xPSM-B2-siEEF2) efficiently induced apoptosis in PSMA-expressing 
LNCaP cells and that these effects were cell type selective since PSMA-negative cell lines 
were not affected (Fig.  3-23). Both bivalent transcripts showed higher cytotoxicity than the 
monovalent transcript, as anticipated because of their more efficient internalization. Non-
silencing monovalent and bivalent transcripts were used as controls. 
HER3 positive MCF-7 and HER3 negative MDA-MB-231cells were incubated with the A30 
aptamer siRNA transcripts up to a concentration of 1 µM at 37°C for 48 h. As shown in Fig.  
3-24 all transcripts demonstrated antigen-specific, cytotoxic effects on MCF-7 cells, but not 
on HER3 negative MDA-MB-231 cells. 
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Fig.  3-24 XTT-viability assay of (A) HER3-positive MCF-7 and (B) HER3-negative MDA-MB-231 cells (2.2.3.8). 
Cells were incubated with different concentrations of aptamer-siRNA transcripts (2.2.4.7). After 24h 
decreased viability could be detected in the samples treated with transcripts containing cytotoxic 
siRNAs but not in the samples containing aptamer fused to nonsilencing siRNA or containing the 
aptamer alone. Mean values of triplicate experiments are shown (n:3, ± SEM).   
As shown in Fig.  3-24 the different siRNA sequences showed different levels of toxicity (IC50 
values are presented in Table  3-2). Control transcripts had no cytotoxic effect, showing that 
the target-specific activity of the siRNAs was responsible for the observed effects, rather than 
the non-specific effects of RNA uptake. 
Table  3-2 Transfection efficiencies obtained for various cell lines 
siRNA  IC50 
siSKIP5 89nM 
siPLK1-1 125nM 
siGRK4-1 501nM 
siPLK1-2 316nM 
siGRK4-2 -- 
siEEF2-2 199nM 
 
3.2.8 Monovalent aptamer siRNA transcripts specifically induce apoptosis 
The inhibition of EEF2 by bacterial and plant toxins selectively induces apoptosis via the 
intrinsic pathway, which is accompanied by the upregulation of various apoptosis-related 
caspases. In order to show that the cytotoxicity observed in previous experiments reflected 
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the induction of apoptosis, a colorimetric caspase 3/7 apoptosis assay (Promega) was 
carried out (2.2.5.6). LNCaP and MCF-7 cells were incubated with 1-2 µM aptamer siRNA 
transcripts for 48 h and the level of activated caspase 3 and 7 was determined. Increased 
levels of these prominent caspases confirm that the apoptotic pathway has been triggered. 
The results were normalized to untreated cells (representing 0% apoptosis). 
 
Fig.  3-25 Caspase 3/7 apoptosis assay (2.2.5.6) on (A) MCF-7 and (B) LNCaP cells (2.2.1) incubated with 1 µM 
of aptamer siRNA transcripts (2.2.4.7) for 48 h. Caspase 3/7 levels were normalized to untreated cells 
(0% apoptosis). The known apoptosis inducer Zeocin was used as a positive control.  
Fig.  3-25 A shows the proportion of MCF-7 cells induced to enter apoptosis following 
incubation with 1 µM of the various A30 siRNA transcripts, confirming that all transcripts 
except the non-silencing control specifically induced apoptosis in antigen-positive cells. Fig.  
3-25 B shows analogous results for xPSM-A10-siEEF2, which induced apoptosis in PSMA-
expressing LNCaP cells, whereas no caspase activity was observed when cells were treated 
with the nonsilencing control xPSM-A10-siGFP. In both cases, the aptamer alone showed no 
effects on either target cell line. 
3.2.9 Interferon β detection assay 
Although the aptamer siRNA transcripts appear to induce apoptosis specifically in target cells 
via the RNAi pathway, it is possible that siRNA-based drugs might also induce non-specific 
inflammatory responses resulting in general cellular cytotoxicity. Long double stranded RNAs 
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(> 30 bp) are especially prone to elicit strong interferon-β responses, which constitute a 
general defense mechanism against viruses.  
To confirm the absence of an interferon β response, LNCaP and MCF-7 cells were incubated 
with aptamer siRNA transcripts (1 µM) for 48 h before an interferon β assay was carried out 
on the cell culture supernatant. Interferon β was detected using a commercially available 
sandwich interferon β ELISA kit (PBL) comprising two interferon β specific monoclonal 
antibodies. The results were compared to serial dilutions of an interferon β positive control 
provided with the kit. The results are shown in (Fig.  3-26). 
 
Fig.  3-26 Interferon β detection assay (2.2.5.4). (A) Different concentrations of poly(I:C) RNA were transfected 
into LNCaP and MCF-7 cells as a positive control (2.2.1). (B) LNCaP and (C) MCF-7 cells (2.2.1) were 
incubated for 48 h with 1 µM aptamer siRNA transcripts before interferon β detection using a 
commercially available sandwich interferon β ELISA kit (PBL). 
None of the aptamer siRNA transcripts induced interferon β above the background levels 
found in untreated cells. This indicated that the aptamer siRNA transcripts did not trigger a 
type I interferon β response under our experimental conditions. 
3.2.10 Summary 
These results confirm that aptamer siRNA transcripts are attractive suitable alternative to 
current immunotoxins for the specific targeting of cancer cells, and that aptamer A30 binds to 
the full-length antigen HER3 expressed on MCF-7 cells. All RNA transcripts with aptamers 
recognizing PSMA and HER3 were antigen specific and able to induce apoptosis strongly 
and specifically in their target cell lines when a cytotoxic siRNA was fused to the 3’ end of the 
Results                                                                                                                                                 84 
aptamer. It was shown that these transcripts were substrates for recombinant DICER and 
that their effects reflected activation of the RNAi pathway (specific mRNA degradation 
resulting in protein knockdown) and not a more general type I interferon β response.   
3.3 Evaluation of novel immunokinases 
Many oncogenes and tumor suppressor genes encode protein kinases [73], including the 
death-associated protein kinases (DAPKs), whose activity promotes apoptosis. DAPK mRNA 
is present at high levels in many normal cells [73, 76], but is scarce or absent in leukemic 
myeloid cell lines [77]. In 1999, Kawai et al. identified a novel calcium/calmodulin 
(Ca2+/CaM)-dependent protein kinase that they termed death-associated protein kinase 2 
(DAPK2), comprising an N-terminal protein kinase domain followed by a conserved CaM-
binding domain homologous to those of DAP kinase, a protein kinase involved in apoptosis 
[75]. DAPK2 binds directly to CaM and is activated in a Ca2+/CaM-dependent manner. 
Kawai constructed a constitutively active DAPK2 mutant by removing the CaM-binding 
domain (∆CaM). Treatment with agonists that elevate intracellular Ca2+ levels led to the 
activation of DAPK2. Transfection studies showed that DAPK2 is localized in the cytoplasm 
and could, when activated, induce the morphological changes associated with apoptosis.  
By combining this active mutant with a ligand that is internalized after binding to its cell 
surface-specific antigen, we demonstrate that it is possible to use this kinase domain as the 
toxic component of novel immunokinases that work by restoring DAPK2 kinase activity in 
tumor cells lacking it. 
3.3.1 Expression of DAPK2 
Huang et al. analyzed the regulation of DAPK expression in gastrointestinal cancer cell lines 
by examining the methylation status of a 5' CpG island upstream of the DAPK gene [164]. 
Methylation of the 5' CpG island was detected in 3 of 9 colorectal and 3 of 17 gastric cancer 
cell lines, and among 4 of 28 (14%) colorectal and 4 of 27 (15%) gastric primary tumors. 
Treatment with 5-aza-2'-deoxycytidine (DAC), a methyltransferase inhibitor, restored gene 
expression.Thus, aberrant DNA methylation of the 5' CpG island appears to play a key role in 
silencing DAPK expression in gastrointestinal malignancies.  
Many human primary tumor cells and cell lines lack DAPK1 activity [76]. The reactivation of 
silent tumor suppressor genes is one mechanism for the induction of terminal differentiation 
in cancer cells, leading to senescence and apoptosis. DAPK2 is known to be downregulated 
in cervical cancer, and in lung and leukemic myeloid cancer cells [77]. The first experiments 
therefore involved screening different cell lines to determine how DAPK2 expression was 
regulated.  
In order to investigate the potential role of DNA methylation in DAPK2 regulation, we 
analyzed the genomic sequence using NCBI's Entrez Gene database 
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(http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene) and located clusters of CpG 
dinucleotides fulfilling the criteria for a CpG island. To detect hypermethylation of the DAPK2 
promoter region, we carried out a methylation-specific polymerase chain reaction (MSP) 
using primer pairs specific for either methylated and non-methylated template DNA. Different 
cell lines were treated with 1-4 µM DAC to determine whether demethylation of the promoter 
could restore DAPK2 activity (2.3.2.2, 2.3.2.3, 2.3.2.4). This revealed DAPK2 CpG island 
methylation in the human L540 cell line (Fig.  3-27). 
 
Fig.  3-27 Methylation-specific PCR of DAC-treated L540 cells (2.3.2.2, 2.3.2.4). L540 cells were treated with 1-4 
µM DAC to restore DAPK2 expression. Different primer pairs were used to detect methylated (M) and 
unmethylated (U) DNA. This data was achieved in cooperation with Egar Jost and Oliver Galm from the 
University Hospital in Aachen.  
Next, DAPK2 expression levels were analyzed using a semi-quantitative reverse 
transcription polymerase chain reaction (RT-PCR), which showed that DAPK2 mRNA was 
normally absent from Hodgkin lymphoma-derived L540 cells, but present in cells treated with 
DAC at various concentrations for 96 h. This showed that the epigenetic silencing of DAPK2 
could be reversed in a dose-dependent manner, consistent with partial demethylation of the 
promoter region (Fig.  3-28).  
 
Fig.  3-28 RT-PCR of DAC treated (+) and untreated (-) L540 cells (2.3.2.3, 2.3.2.4). L540 cells were treated with 
1-4 µM DAC to restore DAPK2 expression, and mRNA levels were normalized to those of the 
housekeeping gene GAPDH. DAPK2 mRNA was absent from untreated cells (DAC 0) whereas DAPK2 
expression was restored in those treated with 1 µM DAC. This data was achieved in cooperation with 
Egar Jost and Oliver Galm from the University Hospital in Aachen. 
These data confirm that DAPK2 expression in the L540 cell line is epigenetically silenced by 
promoter methylation.  
Further analysis was carried out on additional Hodgkin lymphoma-derived cell lines L1236 
and L428. Whereas L540 lacked DAPK2 mRNA, but treatment with 1 µM DAC for 96 h was 
sufficient to restore DAPK2 expression, DAPK2 mRNA was present in the other cell lines 
both before and after treatment. 
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Fig.  3-29  RT-PCR of DAC treated (+) and untreated (-) L540, L1236 and L428 cells (2.3.2.3, 2.3.2.4). Cells were 
treated with 1 µM DAC for 96 h to restore DAPK2 expression, and mRNA levels were normalized to 
those of the housekeeping gene GAPDH. In contrast to L540 cells, DAPK2 mRNA was present in 
L1236 and L428 cells before and after treatment. This data was achieved in cooperation with Egar Jost 
and Oliver Galm from the University Hospital in Aachen. 
This result indicated that the DAPK2 promoter region is not hypermethylated in L1236 and 
L428 cells.  
To determine DAPK2 protein levels in the three HL target cell lines, the above experiments 
were repeated but the cells were analyzed by ECL western blotting with the commercially 
available monoclonal antibody specific for human DAPK2 (abcam) (Fig.  3-30).  
 
Fig.  3-30 ECL Western blot of untreated and DAC-treated L540, L1236 and L428 cells (2.3.2.1, 2.3.2.4). Cells 
were icubated with 1 µM DAC for 96 h to restore DAPK2 expression, with β-tubulin used as a loading 
control. DAPK2 was detected in L540 cells after treatment, in L428 cells before and after treatment and 
in L1236 neither before nor after treatment. 
L540 cells showed no detectable DAPK2 before treatment, but incubation with the 
demethylating agent DAC restored DAPK2 expression resulting in the synthesis of DAPK2 
protein. These protein data mirror the mRNA data, confirming that DAPK2 expression in the 
L540 cell line is epigenetically silenced by promoter methylation.    
In contrast to the results presented in Fig.  3-29 no DAPK2 protein was present in L1236 
cells either before or after treatment, suggesting methylation-independent regulation of 
DAPK2. As expected, DAPK2 protein could be detected in treated and untreated L428 cells 
in agreement with the mRNA data presented in Fig.  3-29. Further analysis was carried out 
on U937, MCF-7 and PC-3 cells (data not shown), all three of which expressed DAPK2 and 
were considered suitable as negative controls.  
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3.3.2 Nucleofection studies in cell lines containing and lacking DAPK2  
To determine whether the restoration of a constitutively active kinase can induce apoptosis in 
cells lacking DAPK2, the DAPK2∆CaM cassette (Fig.  3-31) was transferred into the 
eukaryotic expression vector pMS-L-EGb-CD30L-IV for transfection into DAPK2-negative 
L540 cells, with DAPK2-positive U937 cells used as controls (2.3.1.3). 
Kinase domain CaM
DAPK2
wild type
DAPK2∆73
Deletion mutant
360 aa
287 aa
 
Fig.  3-31 Structure of the human DAPK2 protein, comparing the wild type and mutant versions. The wild type 
protein contains an N-terminal protein kinase domain followed by a CaM-regulatory domain (above) 
while the mutant has a loss-of-function mutation in this domain (∆73/∆CaM, below). 
Because L540 cells are difficult to transfect with standard methods, nucleofection (Amaxa) 
was chosen as an alternative approach (2.3.1.5). After several optimization steps, the 
highest transfection efficiency using the commercially available plasmid pmaxGFP (Amaxa) 
was 33.9% for L540 cells and 77% for U937 cells (data not shown). After the best 
transfection protocol (2.3.1.5) was determined, the vector pMS-DAPK2’ was transfected into 
both cell lines. After 24 h, the cells were analyzed by PI staining using flow cytometry 
(2.3.3.2) to measure the increase in the proportion of dead cells (Fig.  3-32). 
 
Fig.  3-32 Flow cytometric analysis of nucleofected L540 and U937 cells (2.3.1.5). Cells were transfected with 2 
µg purified DNA (2.3.1.3) (red: normal cells; black: cells treated with transfection reagent only; green: 
negative control pmaxGFP; blue: positive control pMS-Egb-CD30L; turquoise: pMS-DAPK2’). After 24 
h, cells were stained with propidium iodide to identify dead cells (2.3.3.2). (A) L540 cells transfected 
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with the positive control and pMS-DAPK2’ show a shift in FL-3 which indicates an increase in the 
proportion of dead cells. (B) The proportion of dead cells did not increase in the U937 sample 
transfected with pMS-DAPK2’. 
A small increase in the proportion of dead L540 was observed even though the transfection 
rate was low, whereas no such increase was observed in U937 cells. To exclude the 
possibility that cell death was caused by the toxicity of transfection, a non-toxic negative 
control plasmid (pmaxGFP) was used at the same concentration, and no increase in cell 
death was observed. These results could be interpreted to mean that the restoration of a 
missing kinase activity can induce apoptosis.  
3.3.3 Construction and cloning of immunokinase fusion proteins 
The overexpression of DAPK2, but not of its catalytically inactive mutants (K42A and K52A), 
induces apoptosis in several transfected malignant cell lines via a range of apoptotic and/or 
autophagic signals. In order to determine whether DAPK2 could also induce apoptosis when 
expressed as a fusion protein, we constructed the expression vector pMS-DAPK2′-CD30L 
encoding the catalytic domain of human DAPK2 (DAPK2′) joined by a linker to the 
extracellular domain of human CD30L (2.3.1.3). This ligand targets HL cells such as L540, 
L1236 and L428 expressing the CD30 tumor-associated cell surface [72]. As shown in Fig.  
3-33, the fusion gene was expressed using the strong human cytomegalovirus (CMV) 
promoter and the immunoglobulin kappa leader sequence for secretion into the culture 
medium. The downstream expression cassette encoded a His6 tag for purification and 
detection of the recombinant fusion protein, and the enhanced green fluorescent protein 
(EGFP) as a quantitative reporter for gene expression. Control vectors were constructed 
lacking the CD30 ligand component (pMS-DAPK2′) or the DAPK2’ kinase component (pMS-
CD30L, provided by Florian Kampmeier).   
 
Fig.  3-33 Bicistronic eukaryotic expression vector used for the transient transfection of 293T cells (2.3.1.4). The 
vector encodes a constitutively active mutant of DAPK2 joined in-frame to the CD30 ligand (above) 
whereas the control vectors lack the CD30 or DAPK2 moieties (below). The recombinant gene is linked 
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to a gene for enhanced green fluorescent protein (EGFP) via a synthetic intron and internal ribosome 
entry site (IVS/IRES) all under the control of the human cytomegalovirus (CMV) promoter. The cassette 
ends with a TGA stop codon situated immediately downstream of the C-terminal His-tag (H). The open 
reading frame commences with Ig-k-L, the immunoglobulin kappa leader sequence. L represents an 
11-aa linker whose DNA sequence contains the BlpI/SfiI restriction sites. 
3.3.4 Expression and purification of immmunokinase fusion proteins 
For the expression of DAPK2’ fusion proteins, eukaryotic HEK 293T expression cells were 
transfected with 1.5 µg of purified plasmid (2.3.1.4). Protein expression was evaluated by 
SDS-PAGE and immunoblot analysis of supernatants from transfected 293T cells using a 
monoclonal antibody specific for the His6 tag (Qiagen). The calculated size of the fusion 
protein DAPK2’-CD30L was 58kDa, but the detected protein was 70 kDa, probably reflecting 
the occupation of one or more of the five glycosylation sites on CD30L. The antibody 
detected the 70-kDa fusion protein, the 33-kDa DAPK2’ control protein and the 64-kDa 
CD30L’ control as expected (Fig.  3-34). The results were confirmed by mass spectroscopy 
as described in 2.3.1.8.  
 
Fig.  3-34 Immunoblot analysis of the purified DAPK2′-CD30L and control constructs DAPK2′ and CD30L’ from 
transfected 293T cells (2.3.1.6, 2.3.1.7) using an antibody recognizing the C-terminal His-tag. 
Molecular weight markers (M) are shown on the left. (A) SDS-PAGE (2.3.1.7) of purified fragments of 
the DAPK2’-CD30L fusion protein, confirming the expected size of 70kDa. (B) SDS-PAGE of purified 
DAPK2’ control protein (expected size 33k Da). (C) SDS-PAGE of purified CD30L’ control protein 
(expected size 64 kDa). 
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3.3.5 Binding analysis of immunokinase fusion proteins 
To test the binding specificity of the purified fusion proteins on target cells, we used several 
CD30-positive (L540, L1236 and L428) and negative (HD-MY-Z, U937, MCF-7, LNCaP, PC-
3 and 293T) cell lines. Binding was assessed by flow cytometry, using a monoclonal antibody 
against the histidine tag conjugated to Alexa Fluor 488 (Qiagen). We observed robust 
binding of DAPK2′-CD30L and CD30L’ to the CD30+ target cells, whereas the control 
constructs showed no binding activity. Furthermore, neither DAPK2′-CD30L nor the control 
constructs bound to the CD30- control cell lines (Fig.  3-35). The DAPK2’ control protein did 
not bind to any of the tested cell lines. 
 
Fig.  3-35 Flow cytometric analysis of DAPK2′-CD30L binding to human CD30
+
 L540 and CD30
-
 control 
cells (2.3.3.2). Target cells were incubated with DAPK′2-CD30L (blue line), positive control 
CD30L’ (green line) and negative control DAPK2’ (purple line) (2.3.3.2). Samples lacking the 
immunokinase were used as a control to exclude nonspecific staining by the anti-His5 Alexa 
Fluor 488 detection antibody (black line). (A) DAPK2’-CD30L and CD30L’ bound strongly to the L540 
cells. (B) DAPK2′-CD30L and CD30L’ did not bind to the CD30- U937 cells. 
The affinity of DAPK2′-CD30L was determined by a flow cytometry-based procedure using 
CD30+ L540 and L1236 cells, revealing a functional KD of 9.1 ± 2.1 nM and 15.8 ± 1.5 nM, 
respectively (Fig.  3-36).  
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Fig.  3-36 Flow cytometric binding saturation curves were produced with CD30
+
 L540 and L1236 cells incubated 
with different concentrations of FITC-labeled DAPK2′-CD30L (2.3.3.3). (A) The KD for L540 cells was 
9.1 ± 2.1 nM. (B) The KD for L1236 cells was lower, at 15.8 ± 1.5 nM due to weaker antigen expression 
on the cell surface (performed with Gernot Jäger). 
3.3.6 Internalization studies 
DAPK2’-CD30L must be internalized after binding to CD30 on the surface of target cells to 
promote apoptosis. This was confirmed by direct labeling of the immunokinase with FITC (to 
eliminate any cross-linking with a secondary antibody) and incubating it with CD30+ L540 and 
CD30- U937 cells for 1, 2, 6, 12 and 24 h at 37°C. Samples were then washed with PBS and 
analyzed by confocal microscopy and flow cytometry to determine whether the labeled 
protein had been taken into the cytoplasm. The results after 2 h are shown in Fig.  3-37, with 
DRAQ5TM used to counterstain the nucleus (2.2.5.3). 
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Fig.  3-37 Confocal microscopy of L540 cells after a 2-h incubation with 0.5 µg FITC-labeled DAPK2’-CD30L at 
37°C (2.3.3.3, 2.2.5.3). (A) L540 cells show strong membrane staining but some internal dots indicating 
that some of the protein has already been internalized. (B) L540 cells incubated with DAPK2’. (C) L540 
cells under normal growing conditions.  
After a 2-h incubation at 37°C there was some evidence of initial internalization of the fusion 
protein by L540 cells (Fig. 3-37 A). Small endosomal, fluorescent dots could be detected 
(Fig. 3-37 A FITC). As non-binding control the protein DAPK2’ was used in the same 
concentration (Fig. 3-37 B). No internalization activities could be determined. To exclude any 
autofluorescence of the cells themselves L540 cells under normal growing conditions were 
also analyzed (Fig. 3-37 C). No signal could be detected. 
As negative controls the same experiment was performed on CD30- U937 where wether 
membrane staining nor internalization was observed (Fig.  3-38). 
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Fig.  3-38 Confocal microscopy of U937 cells incubated with 0.5µg FITC-labeled fusion protein after 2h incubation 
at 37°C (2.3.3.3, 2.2.5.3). (A) U937 cells incubated with DAPK2’-CD30L (2.3.1.6). No internalization of 
the protein could be determined. (B) U937 cells incubated with DAPK2’. This protein without any 
binding domain showed no binding and no internalization activities. (C) U937 cells under normal 
growing conditions. 
To quantify these results, the experiment was repeated but measured by flow cytometry. 
Furthermore, the cells were treated with proteinase K (2.2.5.3) to remove residual membrane 
bound immunokinases so that only the internalized protein would be detected.  
 
Fig.  3-39 Flow cytometric internalization assay (2.2.5.3). FITC-labeled DAPK2’-CD30L fusion proteins were 
incubated with L540 and U937 cells (2.2.1) at 37°C for 1, 2, 6 and 12 h. After removal of cell surface 
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proteins with proteinase K, the relative amount of internalized immunokinase was determined. Average 
values from three independent experiments are shown. Error bars represent SEM. 
As shown in Fig.  3-39 internalization of the purified FITC-labeled DAPK2’-CD30L protein 
began after 2 h, and peaked at 12 h (76% relative internalization). L540 cells showed the 
highest uptake of protein after 6 and 12 h incubation, whereas the signal from U937 cells 
was barely above background, indicating negligible uptake. 
3.3.7 in vitro kinase activity 
Kawai et al. showed that DAPK2 is autophosphorylated and phosphorylates myosin light 
chain (MLC) as an exogenous substrate [75]. Because we used a constitutively active 
DAPK2 mutant generated by removing the CaM-binding domain, the next step was to 
characterize its kinase activity in an in vitro kinase assay using MLC (PKLight® Assay Kit, 
Lonza ) (2.3.3.1). Cyclic AMP dependent protein kinase (PKA) was used according to 
manufacturer’s recommendations as a positive control.  
 
Fig.  3-40 Bioluminescent PKLight Assay (2.3.3.1). The signal is inversely proportional to kinase activity. 
Cyclic AMP dependent protein kinase (PKA), positive control, was incubated in kinase 
reaction buffer containing 40 mM Tris-HCl pH7.5, 20 mM MgCl2, 0.1% (w/v) BSA, 5 µM 
Kemptide and 1 µM ATP. Purified proteins (DAPK2′-CD30L, DAPK2′ and CD30L ) were 
incubated in kinase reaction buffer containing 40 mM Tris-HCl pH7.5, 20 mM MgCl2, 0.1% 
(w/v) BSA, 5 µM MLC and 2.5 µM ATP. 
The results show that the kinase domain is catalytically active with and without fusion to 
CD30L (Fig.  3-40). The control protein CD30L had no kinase activity.     
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3.3.8 Evaluation of cytotoxic activities of immunokinase fusion proteins 
The above experiments have shown that both components of the immunokinase – the 
binding ligand and the catalytic domain, are functional. CD30L specifically binds to CD30+ 
cells and is internalized after binding to the antigen, and the kinase domain phosphorylates 
its substrate MLC in vitro. We used the constitutively active fusion protein DAPK2′-CD30L to 
determine whether receptor-specific replacement of DAPK2 catalytic activity could induce 
apoptosis in HL-cells that lacked endogenous DAPK2 activity. The concentration-dependent 
cytotoxic effect of DAPK2′-CD30L was evaluated using an XTT-based colorimetric cell 
proliferation assay, which was carried out on CD30+ L540, L1236, L428 and CD30- U937, 
MCF-7, PC-3 and 293T cells. The reintroduction of constitutively-active DAPK2 into L540 
and L1236 cells inhibited cell proliferation in a dose-dependent manner, with IC50 values of 
20 and 27 nM, respectively, lending support to the hypothesis that DAPK2 is a tumor 
suppressor protein (Fig.  3-41). This result correlates with the initial screens, where it was 
found that only L540 and L1236 lack DAPK2 protein. As expected, only CD30+/DAPK2+ 
L428 cells showed any signs of toxicity. The control proteins, lacking either the binding 
domain or the catalytic domain, appeared to be completely non-toxic. 
 
Fig.  3-41 Proliferation analysis of recombinant DAPK2′-CD30L immunokinase fusion protein (2.3.3.4) (A) XTT 
proliferation assay. CD30
+
 L540 and L1236 target cells were incubated with various concentrations of 
DAPK2′-CD30L and control protein DAPK2′ for 48 h. In both CD30
+
 cell lines DAPK2’-CD30L 
specifically induced cell death. (B) 200nM of DAPK2’-CD30L, DAPK2’ and CD30L’ were incubated on 
different CD30
+ and CD30- cell lines and analyzed after 48 h. DAPK2’-CD30L induced cell death only 
in those cell lines that were DAPK2
-
 and CD30
+
. There was no cytotoxic effect on cells that were 
CD30
+
 but DAPK2
+
 or those that were CD30
-
 and DAPK2
+
 . 
We next studied the ability of DAPK2′-CD30L to trigger apoptosis in HL target cells, using 
Annexin V and PI staining to distinguish different populations. L540, L1236 and L428 target 
and U937 control cells were incubated for 24 h with 360 ng/ml (~5,1nM) DAPK2′-CD30L. We 
found that 18% of CD30+ L540, and 10% of L1236 cells treated with DAPK2′-CD30L were 
early apoptotic (R2) and 60% and 45%, respectively, were late apoptotic or dead (R3). 
CD30+/DAPK2+ L428 and CD30- U937 control cells were unaffected by DAPK2′-CD30L (Fig.  
3-42). 
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Fig.  3-42 Annexin V-FITC/PI double-staining, followed by flow cytometry to test for apoptosis in CD30
+
 L540 and 
CD30
-
 U937 cells (2.3.3.5). (A) Cells were treated with 200 nM DAPK2′-CD30L and analyzed at 
different times. Data in the left upper (R4), right upper (R3) and right lower (R2) quadrants represent 
the proportion of apoptotic cells at different stages. (B) The percentage within the quadrants (R1-R4) is 
represented in the histogram. Data are representative of three independent experiments.  
In summary, the above data confirm that DAPK2’-CD30L is an active immunokinase that 
specifically targets CD30+ cells, is then translocated into the cytosol and induces apoptosis 
only in CD30+ and DAPK2- cells in vitro.  
3.3.9 Mouse serum stability 
To predict the efficacy of immunokinases in vivo it is necessary to determine their stability in 
mouse serum, particularly if immunokinases are likely to be administered intravenously. We 
therefore analyzed the stability of the DAPK2′-CD30L immunokinase (2.3.1.6) in 50% (v/v) 
normal mouse serum at 37°C for different durations, followed by SDS-PAGE and western 
blotting (2.3.1.7). The protein was detected using a monoclonal antibody specific for the His6 
tag (Qiagen). The in vitro serum stability assay showed no degradation of the fusion protein 
after a 12-h incubation and only a slight reduction after 24 h. In addition, flow cytometry 
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confirmed that the fusion protein retained full functionality after 12 h, and showed only a 
slight reduction in binding activity after 48 h (Fig.  3-43).  
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Fig.  3-43 in vitro serum stability assay (2.3.3.6). (A) Western blots (2.3.1.7) were performed to determine the 
stability of the recombinant DAPK2′-CD30L immunokinase fusion protein (2.3.1.6). 100 µg/ml 
recombinant protein was incubated in 50% (v/v) mouse serum (diluted in PBS) at different incubation 
times (M: Pre-stained marker, 1-6: 0, 4, 8, 12, 24 and 48 h) at 37°C. As a positive control, the same 
amount of protein was incubated for 0, 24 and 48 h in PBS (7-9). As a negative control, mouse serum 
was analyzed after 0, 24 and 48 h (10-12). After SDS-PAGE and immunoblotting, the filter was 
incubated with horseradish peroxidase-conjugated monoclonal anti-His5 antibody (Qiagen) followed by 
visualization in a Sigma Fast (Sigma) chemiluminescence reaction. (B) Flow cytometry was used to 
analyze the residual binding activity of all samples mentioned above. L540 cells were incubated with all 
different protein samples for 30 min on ice, washed with PBS and then incubated with anti-His5 Alexa 
Fluor 488 (Qiagen). 1: L540 cells + PBS + PBS, 2: L540 cells + 50% (v/v) serum + anti-Penta-His 
Alexa Fluor 488, 3 - 8: L540 cells + PBS + DAPK2’-CD30L incubated in 50% serum for 0, 4, 8, 12, 24 
and 48h + anti-Penta-His Alexa Fluor 488, 9: L540 cells + PBS + anti-Penta-His Alexa Fluor 488, 10 - 
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12: L540 cells + PBS + DAPK2’-CD30L incubated in PBS for 0, 24 and 48h + anti-Penta-His Alexa 
Fluor 488. (C) The histogram demonstrates the residual functional protein remaining after incubation in 
50% (v/v) mouse serum and 50% (v/v) PBS at different time points. The values result from the 
fluorescence intensity of each sample measured in B after subtraction of the fluorescent background. 
The sample containing cells in PBS, DAPK2′-CD30L in PBS and anti-Penta-His Alexa Fluor 488 were 
used as the 100% value (performed with Gernot Jäger). 
DAPK2’-CD30L was apparently very stable in mouse serum, with no loss of detectable 
protein after 12 h and only a slight reduction after 24 h. This data was essential to 
understand the results of the subsequent experiments in SCID mice.  
3.3.10 Toxicity of DAPK2’-CD30L in SCID mice  
The maximum tolerable dose (MTD) of DAPK2’-CD30L control protein was determined in a 
dose-escalation study in groups of five mice intravenously treated with 20, 40, 60, 70 and 
80 µg immunokinase. The MTD was 70 µg (1 nM) per animal (data not shown).  
3.3.11 Therapeutic effect of DAPK2′-CD30L in a disseminated HL model 
In SCID mice, intravenous injection of L540 cells reliably leads to the disseminated growth of 
tumor cells within 5-6 weeks and ultimately to tumor-associated death (153). To investigate 
the influence of DAPK2′-CD30L on overall survival, the immunokinase was administered 1 
day after tumor challenge. A nonspecific immunokinase, DAPK2′-H22(scFv), targeting the 
irrelevant antigen CD64, was used as negative control, as was control injection regime 
consisting of PBS. All proteins were purified and filter-sterilized to exclude any risk of 
bacterial contamination. Recombinant fusion proteins were administrated at the MTD of 70 
µg/mouse. The overall survival rate of the PBS control and nonspecific immunokinase-
treated groups was significantly lower than that of the DAPK2′-CD30L group (p = 0.028). The 
mean survival times for the PBS-treated and nonspecific immunokinase-treated control 
groups (n = 10) were 55 and 60 days, respectively. In the DAPK2′-CD30L treatment group, 8 
of 10 mice were long-term survivors (>175 days) and showed no signs of disease. Two 
animals died (days 60 and 100) without developing any macroscopic signs of disease, 
suggesting that the cause of death was unrelated to the tumor (Fig.  3-44).  
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Fig.  3-44 Effect of DAPK2′-CD30L treatment on disseminated L540 tumors in SCID mice (2.3.4.1). Mice were 
injected intravenously with L540 tumor cells and were left untreated (PBS control) (none, yellow line), 
nonspecifically treated (nonspecific, green line) or were treated with 70 µg DAPK2′-CD30L (specific, 
blue line) (MM). Survival was plotted using the Kaplan-Meier method. 
After confirming the specificity of DAPK2’-CD30L in vitro the in vivo experiments clearly show 
the potential of the applied fusion protein. To analyze the differences in tumor growth, 
several treated and untreated mice were scarified and immunohistochemical analysis carried 
out on various tissues. 
3.3.12 Growth of L540 cells in SCID mice  
Inoculation of 1 × 107 L540 cells through the tail vein induced tumor growth in 100% of 
untreated SCID mice [162]. Untreated animals developed signs of progressive disease 
approximately 5-6 weeks after tumor cell challenge. Histological examination revealed L540 
tumor dissemination of in various organs of the PBS-treated SCID mice, as previously 
reported. Tumors were stained with the mouse anti-human CD30 monoclonal antibody, as 
demonstrated by immunohistochemistry for the CD30 antigen. Immunohistochemical staining 
for tissue-infiltrating Hodgkin lymphoma cells is shown in Fig.  3-45. Liver, lung, spleen and 
brain tissue from non-treated (PBS-control) mice showed robust human CD30-staining, 
whereas no tumor cells were detectable in immunokinase-treated animals.  
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Fig.  3-45 Immunohistochemical analysis of organ sections after DAPK2′-CD30L injection from SCID mice with 
disseminated Hodgkin lymphoma, using a monoclonal anti-CD30 antibody (2.3.4.2). Right, organ 
sections from a SCID-mouse i.v. treated with 70 µg DAPK2’-CD30L immunokinase, showing normal 
organ tissue without infiltration of tumor cells. Left, organ sections from untreated (PBS) or 
nonspecifically treated SCID-mice, showing tumor cell infiltration confirmed by the immunological 
detection of CD30
+
 cells. 
In addition, we observed that the spleens of PBS-treated animals were enlarged by up to 
threefold in comparison to DAPK2’-CD30L-treated animals (data not shown).  
For further morphological analysis, tissue slides were visualized by Hematoxylin-Eosin 
staining. As shown in Fig.  3-46 tumor cells infiltrate healthy tissue in nearly all organs. 
Additionally brain, lymph nodes and kidney were analyzed and showed evidence of tumor 
infiltration (data not shown). 
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Fig.  3-46 Immunohistochemical analysis of organ sections after L540 injection into SCID mice with disseminated 
Hodgkin lymphoma using Hematoxylin-Eosin staining (2.3.4.2). Organ sections from SCID-mouse i.v. 
injected 1 x 10
7
 L540 cells. All tissues show tumor cell infiltration. 
These results confirm that DAPK2’-CD30L is effective in vitro and in vivo. Treatment with this 
immunokinase prevented the development of cancer and cancer-related death in all treated 
mice. Tissue slides from treated mice showed no evidence of tumor growth in any organ or 
tissue, even after a single application. There were no apparent side effects since none of the 
treated mice showed any changes in behavior, weight and viability. 
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4 Discussion 
4.1 Aptamer siRNA transcripts 
A prerequisite for successful RNAi-based cancer therapy is the identification of potent siRNA 
sequences that selectively silence genes crucial for tumor cell survival. Most studies reported 
to date have focused on cancer-associated genes such as the anti-apoptotic genes Bcl-2, 
Mdm2 and IAP [126], but the ultimate goal is the selective elimination of tumor cells directly. 
Most published studies have focused on the siRNA mediated knock-down of overexpressed 
oncogenes of the c-myc or ras/raf pathway [127, 128]. Although the inhibition of these 
oncogenes significantly slowed down tumor growth, it was not possible to eliminate cancer 
cells entirely. As protection from viral infection every cell contains the RNAi machinery which 
enables great potential for siRNA for the discovery of new cancer-associated target genes 
and for therapeutic applications [129-132]. Using high throughput screenings analyzing gene 
expression profiling in cancer cells, a wealth of information concerning new and promising 
target genes, oncogenes and tumor suppressor genes become more and more available 
[96]. But recent studies show that silencing of these genes only sensitized the cancer cells to 
chemotherapeutic agents rather than inducing apoptosis directly. 
Therefore we have addressed this challenge by silencing key components that are very 
sensitive to apoptosis after single administration [133, 134]. The EEF2-specific siRNA 
represents a new contribution to the repertoire of apoptosis-inducing siRNAs [99]. 
Additionally the screening of a siRNA library identified beside the common used traget of the 
Polo-like kinase 1 [102, 135] the potential target genes G protein-coupled receptor kinase 4 
(GRK4) and SKIP1 interacting partner 5 (SKIP5). One of the major challenges for the 
application of siRNA-based drugs is the development of effective strategies for cell type-
specific siRNA delivery. Therefore we searched for novel promising antigens and 
corresponding ligands. Until now there are some possibilities to fuse siRNAs to specific 
ligands: using polyethylenimine nanoparticles [105], immunoliposomes [165], Fab-siRNA 
complexes [166] and noncovalent attachment of siRNAs to antigen specific ligands [167]. We 
choose another promising stratagy by using nucleic acid aptamers as binding moiety. Most 
published studies dealing with aptamers-mediated drug delivery refer to the anti-PSMA 
aptamer xPSM-A10-3 [136-139]. This aptamer specifically binds to the very promising tumor 
marker PSMA, which is predominantly expressed on prostate cancer cells, and furthermore it 
contains pyrimidine nucleotides with 2’fluoro-ribose modifications that increase aptamer 
stability [140]. Beside the already known PSMA which is targeted by the specific aptamer 
xPSM-A10-3 we focussed on the epidermal growth factor receptor family member HER3 is 
overexpressed in diverse human cancers and has been associated with poor prognosis in 
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breast, lung and ovarian cancer [141]. Deregulated signaling through the HERs is involved in 
chemoresistance [142]. HER3 forms heterodimers with HER2 and has idependently been 
implicated as key coreceptor that dirve HER2-amplified breast cancer. Lee-Hoeflich et al. 
suggested HER3 to be a more important, clinical therapeutic target than HER2 [143]. 
Published data present HER3 to be an interesting target whose silencing blocks the signaling 
pathways of HER3/HER2 [143]. They tryed to block HER2/HER3 signaling by adding 
peruzumab, a HER2 antibody which inhibits HER3 signaling, to trastuzumab, monoclonal 
antibody used for the treatment of HER2 positive breast cancer, or by silencing HER3 
expression using RNAinterference [142]. All these therapeutic approaches to overcome the 
chemoresistance of cells expressing high levels of HER2 and HER3 are based on blocking 
the interactions between the receptors. Due to these reasons Chen at al. searched for an 
aptamer which was selected on the ECD of HER3 to further analyze the interactions between 
HERs [117].  
McNamarra et al. and Wüllner et al. proved that the fusion of an aptamer and siRNA resulted 
in highly efficient transcripts which specifically target their receptor and leads the cell into 
apoptosis [99, 102]. For our proof of principle we used the already established xPSM-A10-3 
for the evaluation of novel RNA-based cancer therapeutics.  
As we could establish specifically binding and cytotoxic RNAi-based therapeutics targeting 
PSMA expressing LNCaP cells we wanted to use this approach to specifically eliminate 
chemoresistant cells by only targeting HER3 expressing MCF-7 cells. Analyzing the results 
of the xPSM-A10 siRNA transcripts we identified EEF2 as a potential target for RNAi but the 
efficacy of the siRNA used needed to be improved. Therefore we screened for highly 
cytotoxic siRNAs and analyzed their efficacy by qPCR (Fig.  3-4, Fig.  3-5) and XTT-viability 
assay (Fig.  3-7, Fig.  3-8) in cooperation with the MPI in Berlin. All siRNA sequences 
specifically degradated their homologous mRNA sequences. Due to the downregulation of 
the different genes we could detect a high decrease of viability 24h after siRNA transfection. 
Both breast cancer cell lines used were sensitive in blocking theses specific target genes. In 
these first experiments SKIP5 could be identified as a novel interesting target for 
RNAinterference in cancer cells. To our knowledge this is the first study which presents 
SKIP5 and GRK4 as novel targets for therapeutic applications in cancer cells.  
4.1.1 Characterization of siRNAs targeting different genes 
The major aim of this study was to identify a target protein whose siRNA-induced knockdown 
would efficiently trigger the apoptotic pathway without further exogenous stimuli.  
One target protein used for this study was eukaryotic elongation factor 2 (EEF2), a central 
component of the translational machinery. Inhibition of EEF2 by bacterial or plant derived 
toxins leads to the arrest of protein biosynthesis and the subsequent, highly efficient 
induction of apoptosis. Therefore in cooperation with Dr. Ulrich Wüllner we estimated that the 
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siRNA-mediated depletion of EEF2 mRNA would slow down protein biosynthesis and finally 
induce cell death. These experiments provide the first data showing the effects of siRNA 
mediated gene silencing on proteins involved in or regulating protein biosynthesis. Three 
additional target proteins whose silencing leads directly to apoptosis were identified by the 
Max Plack Institute in Berlin: Polo-like Kinase 1, G-protein receptor Kinase 4 and SKIP 
interacting partner 5.  
In this study we could identify siRNA sequences that efficiently reduced targeted mRNA 
expression by up to 80% with an IC50 value in the range 15–150 nM (Fig.  3-4, Fig.  3-5). 
Currently the most potent siRNAs available display gene silencing potency in the sub- to low 
nanomolar range. From this point of view the siRNAs used has only modest gene silencing 
activity, but mRNA secondary structure analysis might generate information concerning the 
accessibility of the siRNA target sequences and could be used for siRNA sequence 
optimization [129, 144]. In comparison, the PLK 1 siRNA had an IC50 value in the 5-10 nM 
range in HeLa cells. The efficacy of each siRNA thus depended not only on the choice of 
target protein but also on the cell lines used. 
As shown in Fig.  3-6, cells transfected with siEEF2 were lyzed and analyzed at different time 
points to ascertain the effect on EEF2 protein levels, with a siRNA against MAPK1 used as a 
positive control and confirmation for correct experimental setup. Most comparable studies 
measure protein knockdown 72 h after transfection [102]. But in this case cells were 
analyzed after 12 and 24 h because cell death was expected at 72 h and the silencing of 
EEF2 affects general protein biosynthesis leading to the downregulation of all proteins. To 
show that the transfection of siEEF2 activates this mechanism, it was therefore necessary to 
take measurements at earlier time points. The results of EEF2 downregulation 12 h after 
transfection are shown In Fig.  3-6 A and B. The positive control functioned as expected, 
specifically silencing the target protein MAPK1. The same phenomenon was observed in 
samples transfected with siEEF2, i.e. EEF2 protein levels were reduced. In Fig.  3-6 C and D 
all three proteins EEF2, MAPK1 and Beta-tubulin in all cells transfected with siEEF2 after 
24h , reflecting the shutdown of protein synthesis and the onset of apoptosis. 
The most important question which had to be addressed regarding the characterization of 
siRNAs was whether the siRNA-mediated silencing of specific mRNA would induce cell 
death in cancer-derived cell lines [99, 102]. Studies already showed that the inhibition of 
overexpressed oncogenes, blocking cell division by interfering with cyclin E and related 
genes or promoting apoptosis by suppressing antiapoptotic genes are promising targets for 
RNAi. Cell viability assays showed that transfection of all siRNA duplexes specifically 
induced cell death in several cancer derived cell lines (Fig.  3-7, Fig.  3-8). In our approach 
we could identiy SKIP5 and EEF2 to be highly effective in cancer cells. 
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In conclusion, the siRNA-based targeting of the housekeeping gene EEF2, SKIP5 and GRK4 
is an attractive alternative to popular target genes such as PLK 1 or Bcl-2 for the siRNA-
mediated induction of apoptosis. The advantage of targeting such a ubiquitously expressed 
proteins is that in principle every neoplastic cell will be eliminated regardless of its genetic 
background or phenotype.  
4.1.2 Evaluation of aptamer siRNA transcripts 
One of the major challenges for the in vivo application of siRNA-based drugs is the 
development of effective strategies for cell type-specific siRNA delivery [145]. In this respect 
RNA aptamers are very well suited for the targeted delivery of therapeutically active 
molecules since they possess affinities and specificities similar to those of antibodies [146, 
147].  
The EEF2 siRNA was joined to the 3’ end of the anti-PSMA aptamer xPSM-A10-3 in the form 
of a shRNA. This aptamer siRNA transcript was specifically taken up by PSMA-expressing 
LNCaP cells and led to siRNA sequence-specific degradation of the target mRNA, which 
finally resulted in the induction of cell death. The observed toxicities were moderate: the 
overall efficacy was 45% cytotoxicity with an IC50 value of >0.8 µM. These results can 
probably be explained by the poor cellular uptake of the monovalent aptamer siRNA 
transcript (Fig.  3-16).  
We anticipated that the efficiency of internalization could be improved by increasing the 
valency of the anti-PSMA aptamer. This work was performed by Dr. Ulrich Wüllner, who 
synthesized bivalent aptamer-siRNA transcripts to improve the overall efficacy. As presented 
in this study, he achieved better internalization rates, higher affinities and higher cytotoxic 
effects on LNCaP cells. He showed that increasing the valency can improve the efficacy of 
aptamer siRNA transcripts. Another point which have to be discussed is the endosomal 
release of internalized aptamer siRNA transcripts. We don’t know yet which pathway is 
choosen by RNA transcripts and if increased valency has any effect on that. By confocal 
microscopy we could determine the release of the FITC-labeled transcripts but could not 
explain the mechanism.  
The novel aptamer presented here is the HER3 binding aptamer A30 [117]. This aptamer 
was shown to bind the extracellular domain of HER3 but was not shown to bind specifically 
to the natural HER3 molecule expressed on MCF-7 cells. Membrane expression of HER3 on 
MCF-7 cells is shown in Fig.  3-9. This experiment was performed several times because 
HER3 is expressed at low levels in cultured cells. When different culture and separation 
methods were used, the level of HER3 antigen could be increased.  
In contrast to the aptamer xPSM-A10-3, it was not known whether or not fusing a siRNA to 
aptamer A30 would result in a transcript that retained its selective binding activity. To fuse 
aptamer and siRNA moiety together we had to transform the siRNA sequences to short 
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hairpin RNAs (shRNA). An often discussed theme is that it is not possible to compare siRNA 
and shRNA efficacy even both RNAs are targeting the same mRNA sequence and are both 
entering the RNAi pathway [148]. Due to these reasons we fused all siRNA sequences to the 
aptamer moiety to identify the different cytotoxicities. To exclude any unspecificity we used 
the aptamer A30 alone and the aptamer fused to a nonsilencing siRNA as negative controls 
in each experiments. To use A30 alone as negative control was important as the effects of 
A30 binding to HER3 on MCF-7 cells were not yet documented. As A30 and the natural 
ligand heregulin are not binding competitive [117], A30 itself could had any effects on the 
viability of cells. As Chen et al. only documented the specific binding on the soluble ECD of 
HER3 we had to prove the specific binding of A30 to HER3 expressed on MCF-7 cells. 
Therefore RNA was FITC-labeled, incubated with HER3+ and HER3- cells and analyzed 
towards any binding activities. We could identify the binding of the aptamer alone to be 
specific but very weak (data not shown). The reason might be the low stability of the RNA. In 
contrast to the aptamer xPSM-A10-3 which is 2’ F-modified meaning protected against 
RNAses A30 was selected from a nonmodifed library. The specific folding is the only 
protection against the cleavage of proteases (Fig.  3-10). In Fig.  3-14 the binding of A30-
siRNA transcripts are presented. The binding signal detected was compared to the aptamer 
alone much higher. Reasons for this phenomenon might be the fusion of shRNA to the 3’ end 
of the aptamer. Compared to siRNAs shRNA are proved to be more stable [130]. After the 
fusion of the shRNA to the 3’ end the aptamer might be protected from one site which 
resulted in higher binding signaling.  
To analyze the internalization of A30-siRNA transcripts FITC-labeled RNA was incubated 
with antigen-positive and –negative cells and observed at different time-points. Until now 
there was no data available if an aptamer binding to a different epitope than its natural ligand 
heregulin [117] will be internalized after attaching to HER3. Jeschke et al. presented in 1995 
an immunotoxin consisting of the binding part hrg and the toxin part Pseudomonas Exotoxin 
A (ETA’) being effective against HER3 and HER4 expressing breast cancer cell lines [149]. 
In 1998 Landgraf et al. pubshlished an Immunotoxin containing hrg as binding domain and 
Diphteria toxin as toxic domain [150]. He compared the efficacy of his fusion protein on 
different breast cancer cell lines among MCF-7 and MDA-MB-231 cells. In his studies the 
fusion protein Hrg-DT killed MCF-7 cells but showed nearly no effects on MDA-MB-231 cells. 
Refering to the publications of Jeschke et al. for MDA-MB-231 cells and of Siegall et al. both 
cell lines were identified to be HER3+ but MDA-MB-231 cells only express a very low amount 
of this antigen compared to MCF-7 cells [151]. We analyzed HER3 expression on both cell 
lines using the commercially available antibody anti-human ErbB3 (abcam) (Fig.  3-9). Using 
Flow cytometry we could detect no antigen expression on MDA-MB-231 cells (data not 
shown). In contrast to MCF-7 cells MDA-MB-231 cells show a high expression of HER2 but 
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no expression of HER4. MCF-7 cells do not express or a very low amount of HER2 but they 
express a low amount of HER4. Landgraf et al. achieved an internalization rate of 40% in 
both cell lines after 4h incubation. Only in cell lines expressing high amounts of HER3 (BZ 
474, BT20 and MCF-7 breast cancer cells) he could observe high efficacy of the fusion 
protein [150]. Because no data on the uptake of A30 were available, we carried out similar 
experiments with this aptamer-siRNA transcript and assessed the efficiency of uptake by flow 
cytometry and confocal microscopy. In the initial experiments, the cells were not incubated 
with proteinase K to exclude any step that could limit the signal from the FITC-labeled 
aptamer-siRNA transcripts. As shown in Fig.  3-17, HER3+ MCF-7 and HER3- MDA-MB-231 
cells were incubated with FITC-labeled RNA to check for staining in the cytosol. In 
comparison to the negative control, FITC-labeled RNA accumulated to high levels in the 
cytosol of MCF-7 cells. In MDA-MB-231 cells, there was a small increase in the amount of 
detectable FITC. We analyzed the sample with FITC-labeled RNA on a small 7M Urea-SDS-
Gel and could detect remaining free FITC in the solution (data not shown). To completely 
exclude any unspecificity a similar experiment was performed in which cells were treated 
with proteinase K prior to analysis by Flow cytometry (Fig.  3-18). This removed RNA bound 
to the cell membrane and ensured that only internalized RNA was detected. The results 
confirmed that A30 not only bound specifically to its antigen but was also internalized into the 
cytosol. 
The translocation of xPSM-A10-3 into the cytosol after binding PSMA has already been 
demonstrated [102], and experiments were performed to confirm these findings (Fig.  3-16) 
[99].  
The RNA transcripts were then analyzed towards DICER processing, which is essential for 
siRNA activity. Chu et al. [109] have shown that DICER is an essential component of the 
siRNA machinery by comparing the silencing activity of different siRNAs in cells expressing 
and lacking DICER. This countered the common theory that DICER is responsible for 
processing long dsRNA molecules but does not play a role at the siRNA processing stage. In 
vitro DICER cleavage assays showed that all aptamer siRNA transcripts were efficiently 
processed into small RNA fragments 21–23 nt in length, the typical size for a siRNA. When 
xPSM-A10-3 was incubated with DICER, an additional RNA band was observed that was 
also present in reactions involving the other siRNAs, this data was also already presented 
and discussed in the thesis of Dr. Ulrich Wüllner. The same assay was performed with all 
transcripts containing the A30 aptamer, but these produced highly degraded RNA strands 
with no distinct band. This might reflect the unmodified nature of the RNA sequence, 
reducing the stability compared to the modified aptamer in the reaction sample. To reduce 
the reaction time, the TURBO DICER enzyme was used for 1 h at 37°C, and this generated 
discrete bands of the correct length (21-23 nt). 
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After demonstrating the functionality of the aptamer and siRNA components, both target cell 
lines (LNCaP and MCF-7) were incubated with different concentrations of the aptamer siRNA 
transcripts. The cells were analyzed to determine the level of mRNA degradation, protein 
knockdown and the cytotoxic efficacy of the siRNA. Controls were used to exclude unwanted 
off-target effects such as nonspecific binding, toxicity towards non-target (antigen-negative) 
cells and the nonspecific induction of apoptosis. 
The level of mRNA degradation was assessed by qPCR. Both target cell lines were 
incubated with different concentrations of aptamer siRNA transcripts and the level of mRNA 
was measured at several time points (Fig.  3-21). As discussed above, most protocols 
suggest measurement at 72 h [102]. But in this case measurements were taken earlier to 
ensure that specific effects were recorded, not the general effects caused by the loss of a 
certain gene ushering the cells into apoptosis. After several experimental runs, it was found 
that the latest assay point where specific effects could be demonstrated was 48 h after 
transfection; analysis after 72 h produced diagrams where no significant knockdown effect 
could be demonstrated because the housekeeping gene GAPDH was also affected. 
Comparing published studies mRNA silencing was rather low [152, 153]. There was 
documented mRNA silencing up to 90% after application of 0,5nM siRNA in HeLa cells but 
most of the targets used in those cases were not apoptosis-inducing targets. Another point to 
discuss is the different sensitivities of cells towards siRNA silencing. The siRNA sequence 
siPLK1-1 used in this study showed on HeLa cells a mRNA knock down up to 95% at a 
concentration of 5nM (data not shown). Compared to our results MCF-7 cells showed a 
mRNA silencing of 80% at a concentration of 150nM (tranfection rate >90%). 
For protein knock down the same conditions and time points were used. The results at 48 h 
confirmed those obtained at the mRNA level by qPCR. After 48 h it was clear that the 
aptamer siEEF2 transcripts specifically inhibited EEF2 mRNA and EEF2 protein expression, 
a feat not achieved by their non-silencing control counterparts (Fig.  3-22). 
The next step was to determine the cytotoxic efficacy of the siRNAs on the target cell lines 
LNCaP and MCF-7. The aptamer siRNA transcripts containing a toxic siRNA sequence 
induced cytotoxic effects in cell lines carrying the corresponding antigen, but not in those 
lacking the antigen. Aptamer siRNA transcripts containing non-silencing siRNAs had no 
effect on either antigen-positive or antigen-negative cell lines (Fig.  3-23, Fig.  3-24). The 
cytotoxic efficacy of xPSM-A10-siEEF2 was lower than that reported McNamarra et al. 
targeting PLK1 because no IC50 could be calculated [102]. As shown in Fig.  3-7 MCF-7 and 
MDA-MB-231 cells reacted differently towards different siRNA sequences, some of which 
were more potent than others. It is possible that EEF2 is not the most efficient target for the 
induction of apoptosis in LNCaP cells, and more suitable targets could be selected by 
screening. Nevertheless EEF2 was the only target whose silencing induced cell death in all 
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cancer cell lines used in this study, so it may be an omnipotent target for novel anti-cancer 
drugs. Aptamer transcripts containing siEEF2 were more effective in MCF-7 cells than in 
LNCaP cells (Fig.  3-23, Fig.  3-24). However, as shown in Fig.  3-18 A30 was taken up into 
MCF-7 cells three times more efficiently than xPSM-A10-3 was taken into LNCaP cells (Fig.  
3-16). Comparing all RNAi targets, SKIP5 was the most potent siRNA sequence with an IC50 
of ~89 nM, making SKIP5 a novel, attractive target for cancer therapy. 
As already stated, controls are required to ensure that the induction of apoptosis is only 
caused by specific mRNA degradation followed by specific protein knockdown and not be 
nonspecific effects. When cells recognize dsRNA (often an indicator of viral infections) they 
react by releasing interferon-β and initiating a strong inflammatory response, which needs to 
be avoided when using RNAi as a therapeutic strategy. Because the three-dimensional 
structure of the aptamer siRNA transcripts was unknown, it was unclear how the cell would 
react after the translocation of the RNA into the cytosol, and it was therefore necessary to 
carry out interferon-β assays. However, in agreement with Chu et al. and McNamara et al. no 
such response was detected [102, 109]. This experiment confirmed that the cytotoxic effects 
of the transcripts were caused by siRNA-mediated gene silencing. 
Cell-specific siRNA delivery is particularly important for apoptosis-inducing siRNAs because 
nonspecific uptake could also kill healthy cells. In this respect PSMA is a very promising 
target for cell specific drug delivery because it is predominantly expressed on prostate 
cancer cells and on the neovasculature of many other solid tumors [154]. Only a low level of 
PSMA has been detected in normal tissues (e.g. kidney, colon and duodenum) and this does 
not diminish the immunotherapeutic potential of PSMA [136, 155-157].  
This is the first report that shows HER3 to be a useful target in cancer therapy. It is 
predominantly expressed on breast ovarian and lung cancer cells. In combination with the 
highly specific HER3 aptamer, target specific siRNAs could be developed into a universal 
apoptosis-inducing agent for the selective elimination of HER3-expressing cells in malignant 
diseases.  
4.2 Immunokinases 
Chemotherapy and extended-field radiotherapy already improved the healing possibilities of 
patients diagnosed with Hodgkin’s disease. Large screening on primary cells isolated from 
the patient should give more detailed results for new approaches treatment HL cells.  
Another tumor-specific property that can be exploited therapeutically is the epigenetic 
modification that often accompanies the inactivation of tumor suppressor genes, as seen in 
apoptosis-associated pathways [23]. Therapeutic strategies using demethylating agents such 
as DAC and azacytidine can target the epigenome in order to reactivate these genes, and 
this has met with some success in the clinical treatment of myelodysplastic syndromes 
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(MDS) [79, 141]. However, the systemic administration of demethylating agents can have 
unpredictable effects due to the lack of specificity.  
By using a more targeted approach, it has previously been shown that tumor development 
can be suppressed by re-establishing the expression of individual tumor suppressors such as 
the retinoblastoma protein (Rb) and tumor protein 53 (p53) [5, 158]. In each case, however, 
the expression construct was delivered on a plasmid or viral vector, making the approach 
unsuitable for specific tumor targeting in vivo.  
Many new approaches like antibody-based drugs showed promising results in the first clinical 
trials. One approach is using monoclonal antibodies which target CD52 and CD20 on non-
Hodgkin Lymphoma (NHL)and chronic lymphocytic leukaemia (CLL) cells with a remission 
rate of 50% in clinical trials. Another approach is immunotoxins containing different binding 
and toxin moieties. There are immunotoxins binding to CD25, CD30, CD64 and more 
combined to different toxins like Ricin A, saporin, viral proteins like RIP and PAP, Diphteria 
toxin (DT) and Pseudomonas exotoxin A (ETA’). One FDA-approved agent is the 
immunotoxin Myelotarg™ (Gemtuzumab Ozogamicin) for the treatment of acute myeloid 
leukemia [159, 160]. Additionally there are bispecific constructs on the market which target 
CD2, CD3, TCR, CD16, CD28, CD32 or CD64 via bispecific monoclonal antibodies (Bi-
MAbs). Bi-MAbs are obtained to be chemically crosslinked of two MAbs or Fab’s with 
different specificities, to be linked via somatic fusion of two hybridoma cell lines or to be 
linked via recombinant technology. These bispecific constructs are able to activate natural 
killer cells, monocytes or T cells.  
These kinds of novel targeted drugs have great potential in specifically eliminating diseased 
cells but have two major problems: moderate tolerability including immunogenicity and the 
development of vascular leak syndrome (VLS). Therefore novel therapeutic approaches try 
to use humanized antibodies or recombinant constructs with human ligands and toxins.  
The pathophysiology of tumor development, such as the modulation of gene expression 
becomes now a key of interest. Many of the key players in apoptosis have been identified 
over the last few years, including membrane receptors, adaptor proteins, proteases and 
other positive and negative regulators. Until recently, only a few kinases were identified in the 
positive and negative regulation of cell death [30, 77]. In this research for novel regulating 
proteins the death-associated protein (DAP) kinase was discovered. The DAP kinase family 
comprises positive mediators of apoptosis and is involved in extrinsic and intrinsic death-
regulating signaling pathways [75].    
In parallel to the above mentioned antigen-targeting therapeutics the development of specific 
drugs against disease targets such as kinases aberrantly expressed specifically in malignant 
cells became more and more popular. This means in practice that all cells receive the drug 
but only the malignantly-transformed cells are affected. One prominent example is Gleevec™ 
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(Imatinib), which efficiently blocks an aberrantly expressed serine/threonine kinase activity in 
chronic myelogenous leukaemia cells [48].  
We have combined both strategies to deliver a tumor suppressor protein specifically to 
Hodgkin lymphoma cells carrying the tumor-associated CD30 receptor. This was achieved by 
genetically fusing a constitutively active version of DAPK2 to the CD30 ligand, thus 
decreasing the likelihood of systemic toxicity and providing proof-of-principle that compounds 
ineffective or unsuitable as systemic drugs can be developed as targeted therapeutic 
reagents.   
We could show that DAPK2 protein is downregulated in different CD30+ Hodgkin lymphoma-
derived tumor cells and that receptor-specific targeting of those cells with a constitutively-
active DAPK2 fused to the CD30 ligand can restore this kinase activity and induce cell death 
in vitro and in vivo. This is not only the first functional evidence that DAPK2 acts as a tumor 
suppressor in Hodgkin lymphoma, but also that the corresponding gene is downregulated by 
DNA promoter hypermethylation. In conclusion, our data support the therapeutic potential of 
restoring the catalytic activity of kinases such as DAPK2, if the kinase can be targeted 
specifically to tumor cells. 
4.2.1 Evaluation of immunokinases 
The work described in this thesis started with cell screening which was performed in 
cooperation with the group of Prof. Dr. Osieka from the University Hospital, Aachen, 
Germany to identify potent cancer cells that do not express DAPK2. This is a kinase closely 
related to DAPK1, both being members of the death associated protein kinase family. As 
DAPK1 is often silenced in cancer cells due to promoter hypermethylation, cells were 
screened to identify hypermethylated regions in the DAPK2 promoter [78]. As shown in Fig.  
3-27, the DAPK2 promoter was hypermethylated in L540 cells, which did not express the 
protein. The related cell lines L1236 and L428 were also analyzed but the DAPK2 promoter 
was not hypermethylated in these lines. Western blot analysis (Fig.  3-30) showed that both 
L540 and L1236 cells lacked the DAPK2 protein. For L540 and L428 cells the results of MCP 
(Fig.  3-27), RT-PCR (Fig.  3-28) and western blot experiments (Fig.  3-30) were in 
agreement, but this was not the case for L1236 cells, where the promoter methylation status 
was normal yet DAPK2 was still not expressed. This indicated that DAPK2 was subject to an 
alternative regulatory pathway in L1236 cells. 
These results suggested that L540 and L1236 cells might be sensitive towards the active 
restoration of DAPK2. Therefore, plasmid pMS-DAPK2∆73 was transfected into DAPK2- 
L540 and DAPK2+ U937 cells (2.3.1.5) and as shown in Fig.  3-32, L540 cells were more 
sensitive towards the restoration of DAPK2 activity than U937 cells, even though the latter 
achieved a much higher transfection efficiency via nucleofection (~70%) compared to L540 
cells (~31%). Only L540 cells showed evidence of increased apoptosis. To confirm that this 
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effect was specific, the cells were also transfected with a negative control (pmaxGFP) and a 
positive control (pMS-GB-CD30L). It is possible that the nucleofection technique could 
influence the results because this method also affected cell vitality (dummy transfections also 
killed ~30% of the cells). Although it would be ideal to identify higher efficiency transfection 
solutions that show lower toxicity, this experiment was nevertheless the first demonstration of 
the toxicity of restored DAPK2 activity in cancer cells. 
The DAPK2∆73 coding sequence joined to the human ligand CD30L in a pMS-vector 
(2.3.1.3) containing a leader sequence facilitating secretion of the recombinant protein into 
the cell culture supernatant and subsequent purification (Fig.  3-34). The negative control 
was a plasmid containing CD30L alone, fused to a small peptide (provided by Florian 
Kampmeier). This control was necessary because CD30L is known to affect certain CD30-
expressing cells; the control allowed us to confirm that any changes were due to the 
restoration of DAPK2 activity and not solely due to the binding of CD30L to CD30. 
DAPK2∆73 alone was also used as a control to ensure that both components of the 
immunokinase are required for cytotoxic activity. All recombinant proteins were expressed in 
293T cells (2.3.1.4) because it proved difficult to express functional proteins in E. coli as 
described Huhn et al. [121]. The five potential glycosylation sites in CD30L might be a reason 
for this phenomenon. Glycosylation can improve the stability of proteins. As in E. coli the 
protein is expressed in a aglycosylated form it might be not stable enough for purification. We 
also analyzed the expression in CHO cells but the proteins were expressed at a low level  
(0.2 mg/L) and were retained in the cytosol. In contrast, optimized expression in 293T cells 
resulted in a yield of 1.2mg/ml which was consistant with previously published data [168].  
The purified proteins were tested by flow cytometry for specific binding activity (Fig.  3-35), 
which showed that DAPK2∆73-CD30L and CD30L’ specifically bound to CD30+ L540, L1236 
and L428 cells whereas the control protein DAPK2∆73 did not. Several CD30- cell lines were 
used as negative controls to ensure binding specificity. Additional flow cytometric analysis 
was carried out to determine the affinity of DAPK2∆73-CD30L for its target cells, but to 
exclude any interference between CD30 and the fusion protein, the latter was directly labeled 
with FITC. As shown in Fig.  3-36, the affinity of DAPK2∆73-CD30L for CD30 expressed on 
L540 cells averaged 9.1 ± 2.1 nM which was in accordance with published data [169]. 
Because CD30 was expressed at a lower level on L1236 cells, the functional KD was 15.8 ± 
1.5 [121]. The FITC-labeled protein was next used for internalization assays based on 
confocal microscopy. CD30+ L540 cells (Fig.  3-37) and CD30- U937 cells (Fig.  3-38) were 
exposed to the same amount of immunokinase, and after 2 h there was clear membrane 
staining in L540 cells, as well as increasing fluorescence accumulating in the cytosol as 
discrete dots. In U937 cells neither membrane nor cytosolic FITC signals were observed. 
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The results were confirmed by flow cytometry (Fig.  3-39) and agree with the data presented 
by Lang et al. [161]. 
This thesis is the first publication in which an active kinase domain has been fused to a 
ligand, so it was not clear whether or not the kinase domain remained active. DAPK2 
naturally phosphorylates the myosin light chain (MLC) [73], so a PLK Light Chain Assay was 
performed which calculated the phosphorylation activity of DAPK2∆73-CD30L. DAPK2∆73 
was the positive control, to determine whether the fused ligand might inhibit the kinase 
activity (Fig.  3-40), CD30L’ was the negative control, and the assay itself was validated with 
PKA as supplied (2.3.3.1). A comparison with results published elsewhere was difficult 
because different substrates and buffer components were used. Nevertheless the results 
clearly showed that fusing the kinase domain to a ligand did not reduce the phosphorylation 
activity.  
Having established the activity of both components of the immunokinase, it was necessary to 
investigate whether the molecule could induce apoptosis in targeted cells through cell-type 
specific restoration of DAPK2. Therefore, CD30+/DAPK2- L540 and L1236 cells were 
incubated with increasing amounts of DAPK2∆73-CD30L, as well as DAPK2∆73 and CD30L’ 
controls in parallel experiments. CD30+/DAPK2+ L428 cells, and CD30-/DAPK2+ HD-M-YZ, 
U937 cells, were also used as controls (2.3.3.4). The results for several XTT proliferation 
assays are presented in Fig.  3-41. The IC50 value of ~ 20nM on L540 cells and of ~ 62nM on 
L1236 cells was in accordance to previous publications [121]. Only CD30+/DAPK2- cells were 
influenced by the fusion protein, the others being completely unaffected. Beside currently 
used immunotoxins which implement only antigen-specificity [72, 121] this drug requires 
double specificity (presence of CD30, absence of DAPK2) to induce cells into apoptosis, 
drugs based on this molecule would likely be very safe, with few side effects. To ensure that 
the fusion protein induced apoptosis rather than necrosis (which would lead to a massive 
inflammatory response) cells were stained with a mixture of AnnexinV and PI (2.3.3.5). Fig.  
3-42 shows that the active restoration of DAPK2 induces apoptosis in every cell lacking 
DAPK2 activity.  
Before in vivo experiments could be carried out, it was important to determine the stability of 
the fusion protein in mouse serum, as this would affect the longevity and activity of any drug 
based on the immunokinase. DAPK2∆73-CD30L was therefore incubated in 50% (v/v) 
mouse serum for different durations at 37°C to simulate the protein’s environment in vivo 
(2.3.3.6). The protein was found to be very stable (Fig.  3-43) with barely any degradation or 
loss of binding activity even 24 h later. The stability of the immunokinase could reflect the 
presence of five glycosylation sites on CD30L, some of which are probably occupied since 
the molecular weight of the fusion protein on western blots is 12.5 kDa higher than predicted. 
Glycoproteins are often more stable than aglycosylated counterparts in serum.  
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Having confirmed the stability of the immunokinase, functional in vivo experiments were 
carried out to determine the activity of the protein in a disseminated tumor model [162]. In 
this model, SCID mice were injected with L540 cells to simulate human Hodgkin lymphoma 
(2.3.4.1), and then filter-sterilized immunokinase was administered in escalating amounts to 
determine the maximum tolerable dose of 70 µg/mouse (2.3.4.1). Then, 30 mice were 
injected with L540 cells, 10 were left as controls, 10 were injected with DAPK2∆73-CD30L 
24h later, and the remaining 10 were injected at the same time with an unrelated 
immunokinase. The mice were monitored for 100 days as described in the literature [161, 
162]. Two mice from the group treated with DAPK2∆73-CD30L died several days after tumor 
injection (Fig.  3-44), but there were no signs of tumor growth and we concluded the deaths 
were not cancer-related. After 20 days, the first mice from the untreated and nonspecific 
immunokinase groups died and by 100 days all the control mice had died of cancer, while the 
eight survivors from the DAPK2∆73-CD30L group remained clear of tumor cells (Fig.  3-44). 
All the mice were dissected and tissues inspected for signs of tumor development - control 
mice showed signs of disseminated tumors in various tissues as well as an enlarged spleen 
(Fig.  3-45, Fig.  3-46). Enlarged spleens are a common hallmark for Hodgkin lymphoma. 
Additional immunohistochemical analysis confirmed the efficacy of DAPK2∆73-CD30L in 
vivo, as no tumors were detected in any tissue slide of the mice from the treated group. 
Instead of tissue slides from untreated mice which showed large CD30+ cell accumulations in 
nearly all analyzed organs. 
DAPK2∆73 is an attractive alternative to typical immunotoxin compounds, as its activity is 
restricted to cells that lack DAPK2 activity, making it ineffective against healthy cells. The 
fusion of CD30L allows the specific targeting of diseased cells. Combining both components, 
this protein represents a first step towards double-targeting as a strategy to ensure he 
specificity and safety of drugs. 
4.3 Immuno-RNA transcripts vs immunokinases 
This study aimed to develop novel targeted cancer therapeutics either by actively restoring a 
missing tumor suppressor gene activity or by silencing potential house-keeping or oncogenes 
in cancer cells. Specific gene silencing was implemented using RNA interference which 
relies on the use of small interfering RNA molecules to inhibit the expression of any 
homologous gene, thereby depleting the target protein. Using this technology combined with 
a RNA aptamer for cell-specific targeting, it was possible to develop novel immuno-RNA 
transcripts as alternatives to traditional protein-based immunotoxins. The advantages of 
these RNA transcripts include their specificity, their three-dimensional structure (which stops 
them being recognized as viral RNA), and the ease with which they can be synthesized. 
Their specificity is comparable with that of protein-based drugs, reflecting the precise manner 
in which linear RNA folds. The structure of each RNA molecule is essential for in vivo 
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stability, as it resists degradation by RNases. The size is also important for recognition by the 
adaptive immune system but could also increase the rate of blood clearance. RNAs or 
proteins that are smaller than 60kDa are easily cleared by the kidneys. A significant 
advantage compared to protein-based drugs produced in cultured cells is that the chemical 
production method for RNAs is highly reproducible, unlikely to become contaminated with 
pathogens and should be achievable on a large scale without excessive costs.  
The immunokinase approach was used to restore the function of a missing tumor suppressor 
gene product. Because the kinase domain used in this study was constitutively active it was 
easy to join it to the specific ligand CD30L, generating a fusion protein in which both 
components had a human origin. This makes an adverse immune response unlikely even 
after repeated intravenous administration, and increases the likelihood that the molecule will 
remain stable in the serum. It’s longevity is also ensured by its size, 70 kDa, which reduces 
the likelihood of it being removed from the blood in the kidneys.   
Functional comparison indicated that the protein-based immunokinase is more likely to 
succeed when applied as a cancer therapeutic than immuno-RNA-transcripts. 
Immunokinases were very stable in serum and highly effective in vivo. The results from 
McNamarra et al. showed xPSM-A10-3 to be efficient in vivo but only after several intrathecal 
injections [102]. There are no pharmacokinetic data or small RNA drugs in mice. RNA 
transcripts are promising tools for cell-specific gene silencing but more development is 
required before they are effective and convenient to use in vivo. Currently, large amount of 
RNA are required to achieve any effects on target cells, stability needs to be improved and 
the selection of appropriate aptamers is difficult since only the soluble, extracellular domain 
of a potential target protein needs to be recognized, and not the whole antigen. Prof. 
Famulok from the University of Bonn has developed a novel technology for aptamer 
screening on whole cells, which might offer new prospects in RNA-based drug development. 
Additionally most RNA selection libraries contain unmodified RNA sequences, but modified 
sequences are required for improved stability in vivo to avoid degradation by RNases.  
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5 Outlook 
5.1 Immuno-RNA-transcripts 
Two important aspects of siRNA based drugs must be taken into account: first, the 
identification of potent siRNA sequences that efficiently silence the expression of a disease-
causing or disease-related protein; and second, the efficient and safe delivery of functional 
siRNAs to specific organs, tissues or cell types.  
Our novel siRNAs targeting EEF2, SKIP5 and GRK4 selectively induced cell death in various 
cancer derived cell lines regardless of their genetic background or phenotype. More detailed 
analysis of the mechanism and kinetics of gene silencing might show how modifications to 
the application regimen, e.g. repeated administration, could improve the cytotoxic activity. 
Furthermore, comprehensive analysis of the siRNAs used will provide valuable information 
about the efficacy of these siRNA. Since these genes are expressed in every cancer cell, the 
siRNA could be developed into a universal ‘cancer-busting’ drug, suitable for the elimination 
of many different neoplastic cells. Therefore we aim to test the efficiency of this siRNA in 
combination with innovative delivery strategies in mouse tumor models. 
Dr. Ulrich Wüllner showed that aptamers are useful cell surface-specific ligands for the 
delivery of functional siRNAs and that increasing the valency of such ligands can enhance 
their efficacy. Very little is known about the exact mechanism by which aptamer-siRNAs are 
taken into the cell and processed within. More information about the translocation step from 
the endosome to the cytosol of target cells might facilitate the development of aptamer-
siRNAs with improved translocation characteristics. 
Since the final goal is the development of efficient siRNA-based cancer therapeutics any 
novel delivery agents need to be tested in vivo using animal models. A disseminated prostate 
tumor model will be established in order to test aptamer-siRNAs after systemic 
administration. It would also be straightforward to test chemical modifications such as 
cholesterol conjugation or PEGylation, which might improve the pharmacokinetic properties 
of siRNAs.  
In conclusion, the strategies for cell type specific delivery of functional siRNAs presented in 
this thesis could be developed into generic tools for research as well as forming the basis of 
a new generation of cancer drugs. The design principles for the aptamer-siRNA transcripts 
can be transferable to other cell surface-specific aptamers. Therefore, a board range of 
applications for the delivery of siRNAs can be envisaged.  
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5.2 Immunokinases 
The development of immunokinases for cancer therapy requires the identification of tumor 
suppressor genes whose restoration results in the induction of apoptosis.  
Although the efficacy of the immunokinase presented in this thesis is satisfactory (5.1 nM) 
compared to other immunotoxins the toxicity needs to be improved. Hetzel et al. [163] 
showed that release of the toxic component into the cytosol after uptake increases the 
toxicity dramatically. The use of an adaptor that facilitates cleavage of the immunokinase into 
its binding and cytotoxic components following internalization could therefore increase the 
cytotoxic efficacy of this protein.  
Another challenge is that it is currently not possible to produce this immunokinase by 
fermentation, so experiments need to be carried out to determine the best host cells and 
culture conditions for large-scale production. 
It would be also necessary to carry out hypermethylation analysis on patient material to 
ensure that the mechanisms evident in cell lines are also pertinent in vivo, and that the 
immunokinase is more likely to work on human patients. Therefore, we plan to carry out 
additional XTT proliferation assays using purified immunokinases applied to patient material.  
Although this study focused on DAPK2, DAPK1 could also be used in the same manner and 
preliminary experiments have been carried out to fuse different parts of DAPK1 to CD30L 
(i.e. the whole protein, the kinase domain, and the kinase domain lacking the regulatory CaM 
domain). The problem in this case is that DAPK1 is very large (120 kDa). DAPK1∆CaM-
CD30L has already been expressed and purified. It binds specifically to CD30 but no 
cytotoxicity was evident in L540 cells. Using the viable cell screening system from Genetix, 
we showed that DAPK1∆CaM-CD30L has no cytotoxic effects on CD30+ cells but inhibits 
their proliferation. Protein screens on CD30+ cells showed that all cells express DAPK1 at 
very low levels. CLL cells might be a better target for this approach, since in these cells the 
DAPK1 promoter is hypermethylated and the gene is silenced, analogous to the situation 
with DAPK2 in L540 cells.  
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6 Summary 
6.1 Immuno-RNA-transcripts 
A prerequisite for successful RNAi-based cancer therapy is the identification of potent siRNA 
sequences that selectively silence genes crucial for tumor cell survival. Most studies reported 
to date have focused on cancer-associated genes such as the anti-apoptotic genes Bcl-2, 
Mdm2 and IAP. Here the challenge was addressed by silencing key components of the 
translational machinery that are sensitive to apoptosis. This thesis has shown that the 
transfection of cytotoxic siRNAs into tumor-derived cell lines efficiently induces apoptosis. 
The EEF2-specific siRNA represents a novel addition to the repertoire of apoptosis-inducing 
siRNAs. Only the PLK1-1 and EEF2 siRNAs were able to induce apoptosis in every cell line 
used in this study. This sequence was effective in breast cancer, prostate cancer and in HL 
cells. At this stage, however, the potency of the EEF2 siRNA is difficult to compare to siRNAs 
targeting other common anti-apoptotic proteins because there are few studies reporting 
siRNA potencies in a dose-dependent manner. 
One of the major challenges in the development of siRNA-based drugs is the incorporation of 
effective strategies for cell type-specific siRNA delivery. We chose the well-established 
PSMA binding aptamer xPSM-A10-3 as a cell surface-specific ligand for the development of 
aptamer based siRNA-delivery vehicles. Furthermore, we also used A30, a novel RNA 
aptamer that binds to HER3 expressed on MCF-7 cells. This is the first study demonstrating 
the specific binding of A30 to HER3-expressing MCF-7, cells as well as its subsequent 
internalization. 
In agreement with the results obtained by McNamara et al., we demonstrate that it is 
possible to deliver functional siRNAs into PSMA and HER3 expressing cells. The monovalent 
aptamer-siRNA transcripts induced the siRNA sequence-specific knockdown of mRNA and 
protein expression. The administration of aptamer-siRNA transcripts specifically induced 
apoptosis and cell death only in antigen-expressing cells without activating the nonspecific 
type I Interferon response. As a global parameter for the overall efficacy of the aptamer 
siRNA transcripts, cell viability was evaluated in a dose-dependent manner.  
6.2 Immunokinases 
Over the past 10 years, many strategies for cancer therapy have been developed. The 
unique expression of surface markers on tumor cells make it possible to explore rational 
strategies for molecular targeting cancer cells without harming the surrounding normal cells. 
We developed a strategy to deliver a tumor suppressor protein specifically to Hodgkin 
lymphoma cells carrying the tumor-associated CD30 receptor. This was achieved by 
genetically fusing a constitutively active version of DAPK2 to the CD30 ligand, thus 
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decreasing the likelihood of systemic toxicity and providing proof-of-principle that compounds 
ineffective or unsuitable as systemic drugs can be developed as targeted therapeutic 
reagents.   
We have shown that DAPK2 protein is downregulated in different CD30+ Hodgkin lymphoma-
derived tumor cells and that receptor-specific targeting of those cells with a constitutively-
active version of DAPK2 fused to the CD30 ligand can restore this kinase activity and induce 
cell death in vitro and in vivo. For this purpose a fusion proteins was designed, expressed, 
purified and characterized concerning affinity, internalization activity, apoptosis induction and 
serum stability. These experiments were essential for the following in vivo experiments. In a 
disseminated mice model we could prove that the purified immunokinase was able to prevent 
tumor developement in SCID mice. Even after more than 100 days no cancer development 
could be observed in any tissue analyzed.  
In parallel we followed the same approach but containing the Death Associated Protein 
Kinase 1 instead of DAPK2. Due to the high potential observed by using DAPK2’-CD30L we 
fused different mutants of DAPK1 (1. only kinase domain, 2. kinase domain and death-
domain but without CaM domain, 3. full-length kinase) to CD30L. We could achieve inhibition 
of tumor growth in vitro but no induction of apoptosis. 
In this PhD thesis we showed that the corresponding gene of DAPK2 is downregulated by 
DNA promoter hypermethylation. Thus we present DAPK2 acting as a tumor suppressor in 
Hodgkin lymphoma and seving as a novel interesting tool for the elimination of DAPK2 
lacking cells. In conclusion, our data support the therapeutic potential of restoring the 
catalytic activity of kinases such as DAPK2 is an attractive alternative to commonly used 
toxins in combination with a specific ligand targeting diseased tumor cells in patients. 
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7 Appendix 
7.1 List of abbreviations 
5'-IAF  5’-Iodoacedamidofluoresceine 
Ab   antibody 
AC  acetate 
AEX   anion exchange chromatography 
AU   arbitary unit 
BSA   bovine serum albumin 
BV   bed volume 
cDNA   coding DNA 
DAPK1/2  death associated protein kinase 1/2 
DMF  dimethylformamide 
DMSO  dimethylsufoxide 
dNTP  deoxynucleotide triphosphate 
dsDNA  double stranded DNA 
dsRNA  double stranded RNA 
DTT   dithiothreitol 
E. coli   Escherichia coli 
EC50  evective concentration 50 
EDC 
 
1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide 
Hydrochloride 
eEF2  eucaryotic elongation factor 2 
ELISA   enzyme linked immunosorbent assay 
EtBr  ethidium bromide 
EtOH  ethanol 
FITC  fluoresceinethiosemicarbazide 
FSC  forward sideward scatter 
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GAPDH  glycerinaldehyd-3-phosphat-Dehydrogenase 
geo-MFI  geometric mean fluorescence intensity 
GFP  green fluorescent protein 
GMPS  guanosine-5’-O-monophosphothioate 
GRK-4  human G-protein coupled receptor kinase 4 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HER3  human epidermal growthfactor receptor 3 
HRPO   horse radish peroxidase 
IgG  immunglobulin G 
IPTG  isopropyl-beta-D-thiogalactopyranoside 
Kan  kanamycin 
Kb  kilobase 
kDa  kilo-Dalton 
l  liter(s) 
LB  Luria broth 
M   molarity (mol/l) 
MAPK-1  mitogen activated protein kinase-1 
MFI  mean fluorescence intensity 
min  minute(s) 
miRNA  microRNA 
mmol  millimol 
mRNA  messenger RNA 
MS   mass spectrometry 
MW  molecular weight 
NBT-BCIP  nitro blue tetrazolium chloride/5-bromo 4-chloroindol-3- 
NHS  N-hydroxysuccinimide 
nm  nanometer 
nt  nucleotides 
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NTP  nucleotide triphosphate 
o/n   over night 
OD  optical density 
PA   phosphatidic acid 
PAGE  polyacrylamid gel electrophoresis  
PBS  phosphate buffered saline 
PCR   polymerase chain reaction 
PEG  polyethylene-glycol 
PLK-1  polo-like kinase 1 
PI  phosphatidylinositol 
PI  propidium iodide 
pI   isoelectric point 
PSMA  prostate specific membrane antigen 
qPCR  quantitative real time RT-PCR 
RISC  RNA induced silencing complex 
RNAi   RNA interference 
rpm  rounds per per minute 
RT  reverse transcription 
rt  room temperature 
scFv  single chain Fv 
SDS  sodium dofecylsulfate 
SELEX  selective evolution of ligands by exponential enrichment 
shRNA  short hairpin RNA 
siRNA  short interfering RNA 
SKIP-5  SKIP 1 interacting partner 5 
SM  skim milk 
SPR  surface plasmon resonance 
ssDNA  single stranded DNA 
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Taq  Thermus aquaticus 
TCEP  Tris(2-carboxyethyl)phosphine hydrochloride 
UV   ultraviolet 
V   Volt 
v/v  volume per volume 
v/v  volume per volume 
w/v   weight per volume 
w/v   weight per volume 
XTT 
 
sodium 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-
methoxy-6-nitro)benzenesulfonic acid hydrate 
β-ME   β-mercaptoethanol 
µl  Microliter 
µm   Micrometer 
 
7.2 Synthetic oligonucleotides  
Synthetic oligonucleotides were provided by MWG-Biotech. Standard synthesis conditions 
were applied for oligonucleotides up to 50 nt. Oligonucleotides exceeding a length of 50 
nucleotides were further HPLC purified (HPSF). 
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Table  7-1 Names and sequences of synthetic oligonucleotides for RNA transcripts 
No. Name Sequence 
1 
PSMA Apt trunc 
5’-GGG AGG ACG ATG CGG ATC AGC CAT GTT 
TAC GTC ACT CCT TGT CAA TCC TCA TCG GC-3’ 
2 
5’PSMA 
5’-TAA TAC GAC TCA CTA TAG GGA GGA CGA 
TGC G-3’ 
3 3’ PSMA 5’-GCC GAT GAG GAT TGA C-3’ 
4 3’PSMA-GFP 5’-CGG CAA GCT GAC CCT G-3’ 
5 
PSMA-1GFP 
5’-GGG AGG ACG ATG CGG ATC AGC CAT GTT 
TAC GTC ACT C-3’ 
6 
PSMA-2GFP 
5’-GCT TGC GCC GAT GAG GAT TGA CAA GGA 
GTG ACG TAA ACA TGG CTG-3’ 
7 
PSMA-3GFP 
5’-CCT CAT CGG CGC AAG CTG ACC CTG AAG 
TTC ATG AAG CTT GGA ACT TC-3’ 
8 
PSMA-4GFP 
5’-CGG CAA GCT GAC CCT GAA GTT CCA AGC 
TTC ATG AAC TTC-3’ 
9 
PS-EEF2-2 
5’-GCG CTG CCG ATG AGG ATT GAC AAG GAG 
TGA CGT AAA CAT GGC TGA-3’ 
10 
PS-EEF2-3 
5’-ATC CTC ATC GGC AGC GCC ATC ATG GAC 
AAG AAT TGA AGC TTC TTC TTG-3’ 
11 
PS-EEF2-4 
5’ CCG CGC CAT CAT GGA CAA GAA GAA GCT 
TCA ATT CTT GTC CAT-3’ 
12 PS-EEF2-3’P 5’-CCG CGC CAT CAT GGA C-3’ 
13 
5’ A30 
5’-TAA TAC GAC TCA CTA TAG GGA ATT CCG 
CGT GTG CC -3’ 
14 3’ A30 5’-GAG GAT CCC GAA CGG ACC GCC -3’ 
15 A30-1 A30-1EEF2 
16 A30-2 A30-2EEF2 
17 A30-3 5’-CAT CTG GGC GGT CCG TTC GGG ATC CTC -3’ 
18 
A30-4 
Not necessary as aptamer sequence too short  
(Fig. 3-11) 
19 3’ A30-GFP 5’-CGG CAA GCT GAC CCT GAA GTT CCA AGC -3’ 
20 A30-1GFP * 
21 A30-2GFP * 
22 
A30-3GFP 
5’-CAT CTG GGC GGT CCG TTC GGG ATC CTC 
GGA AGC TTG CAA GCT GAC CCT G -3’ 
23 
A30-4GFP 
5’-CTG AAG TTC CAA GCT TCA TGA ACT TCA 
GGG TCA GCT TGC AAG C -3’ 
24 3’A30-EEF2 5’-CCG CGC CAT CAT GGA CAA GAA GAA GC -3’ 
25 
A30-1EEF2 
5’-GGG AAT TCC GCG TGT GCC AGC GAA AGT 
TGC GTA TGG GTC ACA-3’ 
26 
A30-2EEF2 
5’-ACG GAC CGC CCA GAT GAC ATG TGC CTG 
CGA TGT GAC CCA TAC GCA ACT T -3’ 
27 
A30-3EEF2. 
5’-CAT CTG GGC GGT CCG TTC GGG ATC CTC 
GAA GCT AGC GCC ATC ATG GAC A -3’ 
28 
A30-4EEF2 
5’-ATG GAC AAG AAG AAG CTT CAA TTC TTG 
TCC ATG ATG GCG CTA G -3’ 
29 3’ A30-GRK4-1 5’-CAG GAT GTT ACT CAC CAA GAA GAA GC -3’ 
30 A30-1GRK4-1 * 
31 A30-2GRK4-1 * 
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32 
A30-3GRK4-1 
5’-CAT CTG GGC GGT CCG TTC GGG ATC CTC 
GAA GCT AGG ATG TTA CTC ACC A -3’ 
33 
A30-4GRK4-1 
5’-CTC ACC AAG AAG AAG CTT CAA TTC TTG 
GTG AGT AAC ATC CTA G -3’ 
34 3’ A30-GRK4-2 5’-CCG GGT GTT TCA AAG ACA TCA GAA GC -3’ 
35 A30-1GRK4-2 * 
36 A30-2GRK4-2 * 
 
37 
A30-3GRK4-2 
5’-CAT CTG GGC GGT CCG TCC GGG ATC CTC 
GAA GCT AGG GTG TTT CAA AGA C -3’  
38 
A30-4GRK4-2 
5’-CAA AGA CAT CAG AGG CTT CAA TTC TTG 
GTG AGT ACC ATC CAT G -3’ 
39 3’ A30-PLK1-1 5’-CAC CAT ATG AAT TGT ACA GAA GAA GC -3’ 
40 A30-1PLK1-1 * 
41 A30-2PLK1-1 * 
42 
A30-3PLK1-1 
5’-CAT CTG GGC GGT CCG TTC GGG ATC CTC 
GAA GCT ACC ATA TGA ATT GTA C -3’ 
43 
A30-4PLK1-1 
5’-ATT GTA CAG AAG AAG CTT CAA TTC TGT ACA 
ATT CAT ATG GT G -3’ 
44 3’ A30-PLK1-2 5’-CCG GAT CAA GAA GAA TGA ATA GAA GC -3’ 
45 A30-1PLK1-2 * 
46 A30-2PLK1-2 * 
47 
A30-3PLK1-2 
5’-CAT CTG GGC GGT CCG TTC GGG ATC CTC 
GAA GCT AGG ATC AAG AAG AAT G -3’ 
48 
A30-4PLK1-2 
5’-AAG AAT GAA TAG AAG CTT CAA TAT TCA TTC 
TTC TTG ATC CTA G -3’ 
49 3’ A30-SKIP5 5’-AAC GTC TGG CTG CTG ATG GAA GAA GC -3’ 
50 A30-1SKIP5 * 
51 A30-2SKIP5 * 
52 
A30-3SKIP5 
5’-CAT CTG GGC GGT CCG TTC GGG ATC CTC 
GAA GCT ACG TCT GGC TGC TGA T -3’ 
53 GAPDH forward 5’-CTC ACT GGC ATG GCC TTC CGT G-3’ 
54 GAPDH reverse 5’-GTA CTC CAG GTG GTG GGA CAA CG-3’ 
55 EEF2 forward 5’- ATG GTG AAC TTC ACG GTA GAC-3’ 
56 
EEF2 reverse 
5’-GAC TTG ATG GTG ATG CAA CGG ACT TGA 
TGG TGA TGC AA CG-3’ 
 
* As presented in Fig. 3-11 first three primers (5’ forward primer, primer 1 and 2) contains the 
sequence for the aptamer portion. As the aptamer sequence was always the same the 5’ 
forward primer and primer 1 and 2 of A30-siEEF2 could be used for all transcripts. 
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Table  7-2 Names and sequences of synthetic oligonucleotides for DAPK2 constructs 
No. Name Sequence 
 For DAPK2’-
CD30L 
 
1 
5’ DK2XbaI 
5′- ACT GGT GAC TCT AGA ATG TTC CAG GCC 
TCA ATG AG-3′ 
2 
3’ DK2BlpI 
5′-ACC TTC GTG CTC AGC CCT GCG CAC CAT 
GGC TTG C-3′ 
 For DAPK2’  
3 5’ DK2XbaI s.o. 
4 
3’ DK2NotI 
5’-GGG GCC^CTG CGG CCG CCC TGC GCA CCA 
TGG CTT GC-3’ 
 For Ki4DK2’  
5 
5’ Ki4XbaI 
5’-GCA CTC GAG TCT AGA ATG TTC CAG GCC 
TCA ATG AG -3’ 
6 
3’ DK2’BlpI 
5’-AAA TCC GTG CTC AGC CCT GCG CAC CAT 
GGC TTG C -3’ 
 For DK2’Ki4  
7 5’ DK2XbaI s.o. 
8 
3’ Ki4BlpI 
5’-CAC CTT GCT CAG CCC TGC GCA CCA TGG 
CTT GC-3’ 
 For 
sequencing  
9 
5’ glyser DK2 
5’-CTC TGG GCC GGC TGG GCC GAA CCA CCA 
CCA CCC CTG CGC ACC ATG GC -3’ 
10 for DK2 seq 
KDK2 
5’-GGT GGC TCT GGC GTT GGC GG -3’ 
11 for DK2 seq 
prim 
5’-GGC CAC CAG CTT CAT TAA GC -3’ 
12 rev pMS seq In GenTSV 
 For MSP  
13 for DAPK2 
(unmethylated 
sequence) 
5′-GTA GGG TTG AGT TTA GTG TAT TTT-3′ 
14 rev DAPK2 
(unmethylated 
sequence) 
5′-AAA AAC TAA ACT ACC ACA ATC A-3′ 
15 for DAPK2 
(methylated 
sequence) 
5′-TAG GGT CGA GTT TAG CGT ATT TC-3′ 
16 rev DAPK2 
(methylated 
sequence) 
5′-AAA AAC TAA ACT ACC GCG ATC G-3′ 
 For RT-PCR  
17 for DAPK2 5′-CCA GAA ATT GTG AAC TAC GAG CC-3′ 
18 rev DAPK2 5′-GTG TTT CCT GCT TCG TGT CTC C-3′ 
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7.2.1 Synthetic siRNA sequences and targets  
Synthetic siRNA oligonucleotides were synthesised by Qiagen (Hilden) or by Dharmacon 
(Lafayette, USA). Prior to use single stranded siRNA oligonucleotides were deprotected and 
annealed according to manufactures recommendations. The following sequences were used: 
Table  7-3 siRNA sequences 
Name:   siEEF2 sequence 1 (Qiagen) 
Target: eukaryotic elongation factor 2 (eEF2) 
Accession number NC_000019.8 
Target DNA 
sequence: 
CAAGGCCTATCTGCCCGTCAA 
RNA sense: r(AGG CCUAUCUGCCCGUCAA)dTdT 
RNA antisense: r(UUGACGGGCAGAUAGGCCU)dTdG 
  
Name:   siEEF2 sequence 1 (Qiagen) 
Target: eukaryotic elongation factor 2 (eEF2) 
Acession number NC_000019.8 
Target DNA 
sequence: 
CCGCGCCATCATGGACAAGAA 
RNA sense: r(GCGCCAUCAUGGACAAGAA)dTdT 
RNA antisense: r(UUCUUGUCCAUGAUGGCGC)dGdG 
  
Name:   siEEF2 sen / siEEF2 as (Dharmacon) 
Target: eukaryotic elongation factor 2 (eEF2) 
Accession number NC_000019.8 
Target DNA 
sequence: 
CCGCGCCATCATGGACAAGAA 
RNA sense: G*C*GCCAUCAUGGACAAGAA*mU*mUT-N3-NH2 
RNA antisense: U*U*C UUG UCC AUG AUG GCG C*mG*mG 
 N*N =  phosphothioate phosphodiester backbone bond  
mN   = 2’-O-methyl modified nucleotide 
  
Name siGFP  
Target: enhanced green fluorescent protein (eGFP) 
Accession number --- 
Target DNA 
sequence: 
CGGCAAGCTGACCCTGAAGTTC  
RNA sense: GAACUUCAGGGUCAGCUUGCCG 
RNA antisense: GAACUUCAGGGUCAGCUUGCCG 
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Name:   siGFP sen/ siGFP as (Dharmacon) 
Target: enhanced green fluorescent protein (eGFP) 
Accession number -- 
Target DNA 
sequence: 
CGGCAAGCTGACCCTGAAGTTC 
RNA sense: G*A*ACUUCAGGGUCAGCUUGC*mC*mG-N3-NH2 
RNA antisense: G*A*ACUUCAGGGUCAGCUUGC*mC*mG 
 N*N =  phosphothioate phosphodiester backbone bond  
mN   = 2’-O-methyl modified nucleotide 
  
Name:   negative control siRNA (Qiagen) 
Target: no target (nonsilencing) 
Accession number no homolog DNA in human genome  
Target DNA 
sequence: 
--- 
RNA sense: UUCUCCGAACGUGUCACGUdTdT  
RNA antisense: ACGUGACACGUUCGGAGAAdTdT  
  
Name:   negative control siRNA  FITC (Qiagen) 
Target: no target (nonsilencing) 
Accession number no homolog DNA in human genome 
Target DNA 
sequence: 
--- 
RNA sense: sequence not provided by the  
RNA antisense: Manufacturer 
  
Name:   siMAPK1 
Target: mitogen-activated protein kinase 1 (MAPK1) 
Accession number NC_000022.9 
Target DNA 
sequence: 
AATGCTGACTCCAAAGCTCTG 
RNA sense: UGCUGACUCCAAAGCUCUGdTd 
RNA antisense: CAGAGCUUUGGAGUCAGCAdTdT 
  
Name:   Positive control siTOX (Promega) 
Target: multiple targets (high cytotoxicity) 
Accession number Different DNA in human genome  
Target DNA 
sequence: 
--- 
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RNA sense: -- 
RNA antisense: -- 
  
Name:   siGRK4 sequence 1 (Qiagen) 
Target: Human G-protein coupled receptor kinase 4 (GRK4) 
Accession number NC_003281.8 
Target DNA 
sequence: 
CAGGATGTTACTCACCAAGAA 
RNA sense: GGAUGUUACUCACCAAGAAUU 
RNA antisense: UUCUUGGUGAGUAACAUCCUG 
  
Name:   siGRK4 sequence 2 (Qiagen) 
Target: Human G-protein coupled receptor kinase 4 (GRK4) 
Accession number  NC_003281.8 
Target DNA 
sequence: 
CCGGGTGTTTCAAAGACATCA 
RNA sense: GGGUGUUUCAAAGACAUCAUU 
RNA antisense: UGAUGUCUUUGAAACACCCGG 
  
Name:   siPLK sequence 1 (Qiagen) 
Target: Polo-like Kinase 1 (PLK1) 
Accession number NC_000016.8 
Target DNA 
sequence: 
CACCATATGAATTGTACAGAA 
RNA sense: CCAUAUGAAUUGUACAGAAUU 
RNA antisense: UUCUGUACAAUUCAUAUGGUG 
  
Name:   siPLK sequence 2 (Qiagen) 
Target: Polo-like Kinase 1 (PLK1) 
Accession number  NC_000016.8 
Target DNA 
sequence: 
CCGGATCAAGAAGAATGAATA 
RNA sense: GGAUCAAGAAGAAUGAAUAUU 
RNA antisense: UAUUCAUUCUUCUUGAUCCGG 
  
Name:   siSKIP (Qiagen) 
Target: SKIP 1 interacting partner 5 
Accession number NC_000017.9 
Target DNA 
sequence: 
AACGTCTGGCTGCTGATGAA 
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RNA sense: CGUCUGGCUGCUGAUGGAAUU 
RNA antisense: UUCCAUCAGCAGCCAGACGUU 
  
7.2.2 Sequences 
All RNA aptamers were synthesised by in vitro transcription (2.2.4.7). As template either 
PCR products (2.2.4.3) or linearized plasmid DNA was used. Sequences of the final 
transcripts are provided in Table  7-4.: 
Table  7-4 Sequences of RNA aptamers used (5’- 3’) 
Aptamer Sequence 
xPSM-
A10-3 
GGGAGGACGAUGCGGAUCAGCCAUGUUUACGUCACUCCUUGUCAAUCC
UCAUCGGC 
xPSM-A3-
siGFP 
GGGAGGACGAUGCGGAUCAGCCAUGUUUACGUCACUCCUUGUCAAUCC
UCAUCGGCGCAAGCUGACCCUGAAGUUCAUGAAGCUUGGAACUUCAGG
GUCAGCUUGCCG 
xPSM-A3-
siEEF2 
GGGAGGACGATGCGGATCAGCCATGTTTACGTCACTCCTTGTCAATCCTC
ATCGGCAGCGCCATCATGGACAAGAATTGAAGCTTCTTCTTGTCCATGAT
GGCGCGG 
A30 GGGAAUUCCGCGUGUGCCAGCGAAAGUUGCGUAUGGGUCACAUCGCA
GGCACAUGUCAUCUGGGCGGUCCGUUCGGGAUCCUC 
A30-siGFP 
GGGAAUUCCGCGUGUGCCAGCGAAAGUUGCGUAUGGGUCACAUCGCA
GGCACAUGUCAUCUGGGCGGUCCGUUCGGGAUCCUCGGAAGCUUGCA
AGCUGACCCUGAAGUUCAUGAAGCUUGGAACUUCAGGGUCAGCUUGCC
G 
A30-
siEEF2 
GGGAAUUCCGCGUGUGCCAGCGAAAGUUGCGUAUGGGUCACAUCGCA
GGCACAUGUCAUCUGGGCGGUCCGUUCGGGAUCCUCGAAGCUAGCGC
CAUCAUGGACAAGAAUUGAAGCUUCUUCUUGUCCAUGAUGGCGCGG 
A30-
siGRK4-1 
GGGAAUUCCGCGUGUGCCAGCGAAAGUUGCGUAUGGGUCACAUCGCA
GGCACAUGUCAUCUGGGCGGUCCGUUCGGGAUCCUCGAAGCUAGGAU
GUUACUCACCAAGAAUUGAAGCUUCUUCUUGGUGAGUAACAUCCUG 
A30-
siGRK4-2 
GGGAAUUCCGCGUGUGCCAGCGAAAGUUGCGUAUGGGUCACAUCGCA
GGCACAUGUCAUCUGGGCGGUCCGUUCGGGAUCCUCGAAGCUAGGGU
GUUUCAAAGACAUCAUUGAAGCUUCUGAUGUCUUUGAAACACCCGG 
A30-
siPLK1-1 
GGGAAUUCCGCGUGUGCCAGCGAAAGUUGCGUAUGGGUCACAUCGCA
GGCACAUGUCAUCUGGGCGGUCCGUUCGGGAUCCUCGAAGCUAGGGU
GUUUCAAAGACAUCAUUGAAGCUUCUGAUGUCUUUGAAACACCCGG 
A30-
siPLK1-2 
GGGAAUUCCGCGUGUGCCAGCGAAAGUUGCGUAUGGGUCACAUCGCA
GGCACAUGUCAUCUGGGCGGUCCGUUCGGGAUCCUCGAAGCUAGGAU
CAAGAAGAAUGAAUAUUGAAGCUUCUAUUCAUUCUUCUUGAUCCGG 
A30-
siSKIP5 
GGGAAUUCCGCGUGUGCCAGCGAAAGUUGCGUAUGGGUCACAUCGCA
GGCACAUGUCAUCUGGGCGGUCCGUUCGGGAUCCUCGAAGCUACGUC
UGGCUGCUGAUGGAAUUGAAGCUUCUUCCAUCAGCAGCCAGACGUU 
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All DNA constructs for Immunokinase expression were cloned using a digested, purified PCR 
product and a digested plasmeid with corresponding cleavage sites (Cloning). Sequences of 
the final constructs are provided in Table  7-5: 
Table  7-5 ORF of DAPK2∆ 73 constructs used 
ORF Sequence 
pMS-
DAPK2∆
73 
Accession number: NM_014326.3 
pMS- 
SNAP-
CD30L 
Provided from Florian Kampmeier 
pMS- 
DAPK2∆
73-
CD30L 
Accession number: EU447259 
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